GB2028805A - Prostanoid compounds - Google Patents
Prostanoid compounds Download PDFInfo
- Publication number
- GB2028805A GB2028805A GB7924204A GB7924204A GB2028805A GB 2028805 A GB2028805 A GB 2028805A GB 7924204 A GB7924204 A GB 7924204A GB 7924204 A GB7924204 A GB 7924204A GB 2028805 A GB2028805 A GB 2028805A
- Authority
- GB
- United Kingdom
- Prior art keywords
- ether
- alpha
- compound
- preparation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Prostanoid compounds Chemical class 0.000 title claims abstract description 117
- 229940127293 prostanoid Drugs 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 346
- 238000002360 preparation method Methods 0.000 claims abstract description 204
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 45
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 130
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 32
- 230000000875 corresponding effect Effects 0.000 claims description 31
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000003277 amino group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 150000003814 prostanoids Chemical class 0.000 claims description 12
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000001589 carboacyl group Chemical group 0.000 claims description 7
- 150000002440 hydroxy compounds Chemical class 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000006189 4-phenyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 4
- 125000005518 carboxamido group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 150000003335 secondary amines Chemical class 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 claims 1
- 239000005922 Phosphane Substances 0.000 claims 1
- 101150113676 chr1 gene Proteins 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 229910000064 phosphane Inorganic materials 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract description 61
- 210000001772 blood platelet Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 5
- 229920006395 saturated elastomer Polymers 0.000 abstract description 2
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 769
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 342
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 332
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 325
- 239000000047 product Substances 0.000 description 241
- 239000000243 solution Substances 0.000 description 225
- 239000003921 oil Substances 0.000 description 202
- 235000019198 oils Nutrition 0.000 description 202
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 155
- 239000000377 silicon dioxide Substances 0.000 description 129
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 118
- 239000000203 mixture Substances 0.000 description 114
- 239000003208 petroleum Substances 0.000 description 114
- 238000004587 chromatography analysis Methods 0.000 description 112
- 238000004458 analytical method Methods 0.000 description 99
- 239000002904 solvent Substances 0.000 description 88
- 239000000284 extract Substances 0.000 description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 68
- 239000000741 silica gel Substances 0.000 description 67
- 229910002027 silica gel Inorganic materials 0.000 description 67
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 63
- 235000017557 sodium bicarbonate Nutrition 0.000 description 59
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 59
- 229960001407 sodium bicarbonate Drugs 0.000 description 57
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 55
- 229940093499 ethyl acetate Drugs 0.000 description 52
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
- 239000012267 brine Substances 0.000 description 45
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 239000003480 eluent Substances 0.000 description 44
- 239000007787 solid Substances 0.000 description 43
- 238000003756 stirring Methods 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 33
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 31
- 238000004440 column chromatography Methods 0.000 description 31
- 239000007858 starting material Substances 0.000 description 31
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 28
- 239000000725 suspension Substances 0.000 description 28
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 23
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 23
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 23
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 22
- 238000010828 elution Methods 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 20
- 150000004702 methyl esters Chemical class 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 235000011149 sulphuric acid Nutrition 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- 239000001117 sulphuric acid Substances 0.000 description 19
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 18
- 238000010992 reflux Methods 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 15
- 229940093956 potassium carbonate Drugs 0.000 description 15
- 235000011181 potassium carbonates Nutrition 0.000 description 15
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 15
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 14
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 14
- 229960004592 isopropanol Drugs 0.000 description 14
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 150000003180 prostaglandins Chemical class 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 11
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 11
- 235000019502 Orange oil Nutrition 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 235000010290 biphenyl Nutrition 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- PRLVHZDMICRVJF-UHFFFAOYSA-N cyclopentane;heptanoic acid Chemical compound C1CCCC1.CCCCCCC(O)=O PRLVHZDMICRVJF-UHFFFAOYSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000010502 orange oil Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- NRTYMEPCRDJMPZ-UHFFFAOYSA-N pyridine;2,2,2-trifluoroacetic acid Chemical compound C1=CC=NC=C1.OC(=O)C(F)(F)F NRTYMEPCRDJMPZ-UHFFFAOYSA-N 0.000 description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 10
- 239000003810 Jones reagent Substances 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003610 charcoal Substances 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 150000004820 halides Chemical class 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 7
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- ARLQDYZAXIPMJQ-UHFFFAOYSA-N methyl hept-5-enoate Chemical compound COC(=O)CCCC=CC ARLQDYZAXIPMJQ-UHFFFAOYSA-N 0.000 description 7
- 229940113083 morpholine Drugs 0.000 description 7
- 229910003445 palladium oxide Inorganic materials 0.000 description 7
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 6
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 6
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 6
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 6
- KPSZWAJWFMFMFF-UHFFFAOYSA-N delta-Hexylen-alpha-carbonsaeure Natural products CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 description 6
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical class CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 6
- 239000010902 straw Substances 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 5
- 230000002301 combined effect Effects 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 235000009518 sodium iodide Nutrition 0.000 description 5
- 239000012258 stirred mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910000091 aluminium hydride Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZEGXJLLXAKNJOU-UHFFFAOYSA-N 1-azido-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(N=[N+]=[N-])C=C1 ZEGXJLLXAKNJOU-UHFFFAOYSA-N 0.000 description 3
- 125000005976 1-phenylethyloxy group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- VLHDPVLJVMNOLT-UHFFFAOYSA-N C1(CCCC1)C(C(=O)O)CCC=CC Chemical compound C1(CCCC1)C(C(=O)O)CCC=CC VLHDPVLJVMNOLT-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 238000007239 Wittig reaction Methods 0.000 description 3
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- LNLLHUHPGPKRBM-UHFFFAOYSA-N bicyclo[3.2.0]hept-3-en-7-one Chemical compound C1=CCC2C(=O)CC21 LNLLHUHPGPKRBM-UHFFFAOYSA-N 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000000199 molecular distillation Methods 0.000 description 3
- QPNOPWWAMGQISP-UHFFFAOYSA-N n,n'-dicyclohexylmethanediimine;methylsulfinylmethane Chemical compound CS(C)=O.C1CCCCC1N=C=NC1CCCCC1 QPNOPWWAMGQISP-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- LJGBZZOJESPLJI-UHFFFAOYSA-N 1,1'-biphenyl;bromomethane Chemical compound BrC.C1=CC=CC=C1C1=CC=CC=C1 LJGBZZOJESPLJI-UHFFFAOYSA-N 0.000 description 2
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 2
- XWSRQWMZSWTDSV-UHFFFAOYSA-N 1-(methylamino)heptan-2-ol Chemical compound CCCCCC(O)CNC XWSRQWMZSWTDSV-UHFFFAOYSA-N 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical compound CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
- NMOFYYYCFRVWBK-UHFFFAOYSA-N 2-pentyloxirane Chemical compound CCCCCC1CO1 NMOFYYYCFRVWBK-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 238000006220 Baeyer-Villiger oxidation reaction Methods 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000020335 dealkylation Effects 0.000 description 2
- 238000006900 dealkylation reaction Methods 0.000 description 2
- RSJLWBUYLGJOBD-UHFFFAOYSA-M diphenyliodanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[I+]C1=CC=CC=C1 RSJLWBUYLGJOBD-UHFFFAOYSA-M 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- KPMKEVXVVHNIEY-UHFFFAOYSA-N norcamphor Chemical compound C1CC2C(=O)CC1C2 KPMKEVXVVHNIEY-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- AXCHZLOJGKSWLV-UHFFFAOYSA-N (4-phenylphenyl)methanol Chemical compound C1=CC(CO)=CC=C1C1=CC=CC=C1 AXCHZLOJGKSWLV-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 1
- WOLUYEFMPZAHNN-UHFFFAOYSA-N 1-(2-bromoethoxy)butane Chemical compound CCCCOCCBr WOLUYEFMPZAHNN-UHFFFAOYSA-N 0.000 description 1
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 1
- DNEPVPBJDHQGRK-UHFFFAOYSA-N 1-(chloromethyl)-4-cyclohexylbenzene Chemical compound C1=CC(CCl)=CC=C1C1CCCCC1 DNEPVPBJDHQGRK-UHFFFAOYSA-N 0.000 description 1
- XMWGTKZEDLCVIG-UHFFFAOYSA-N 1-(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1 XMWGTKZEDLCVIG-UHFFFAOYSA-N 0.000 description 1
- MDLKWDQMIZRIBY-UHFFFAOYSA-N 1-(dimethylamino)ethanol Chemical class CC(O)N(C)C MDLKWDQMIZRIBY-UHFFFAOYSA-N 0.000 description 1
- YVXDRCDGBCOJHX-UHFFFAOYSA-N 1-azido-4-methylbenzene Chemical compound CC1=CC=C(N=[N+]=[N-])C=C1 YVXDRCDGBCOJHX-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- LSXKDWGTSHCFPP-UHFFFAOYSA-N 1-bromoheptane Chemical compound CCCCCCCBr LSXKDWGTSHCFPP-UHFFFAOYSA-N 0.000 description 1
- BSNQVJYYACQGQW-UHFFFAOYSA-N 1-chloro-3-(2-chloroethoxy)propane Chemical compound ClCCCOCCCl BSNQVJYYACQGQW-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- NIBFJPXGNVPNHK-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-4-carbaldehyde Chemical group C1=CC(C=O)=C2OC(F)(F)OC2=C1 NIBFJPXGNVPNHK-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- NBXFAQFMTDGEQN-UHFFFAOYSA-N 2-[[3-(trifluoromethyl)phenoxy]methyl]oxirane Chemical compound FC(F)(F)C1=CC=CC(OCC2OC2)=C1 NBXFAQFMTDGEQN-UHFFFAOYSA-N 0.000 description 1
- WSZZGSWXNSKKNT-UNAAHQEJSA-N 2-[[3-[2-[(1s,5s,8ar)-5-methoxycarbonyl-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]furan-2-yl]methylamino]propanoic acid Chemical compound C([C@@H]1[C@@]2(C)CCC[C@](C2CCC1=C)(C)C(=O)OC)CC=1C=COC=1CNC(C)C(O)=O WSZZGSWXNSKKNT-UNAAHQEJSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UVRRJILIXQAAFK-UHFFFAOYSA-N 2-bromo-4-methylaniline Chemical compound CC1=CC=C(N)C(Br)=C1 UVRRJILIXQAAFK-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- VEBMWVXVMYSEMD-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1.OCCC1=CC=CC=C1 VEBMWVXVMYSEMD-UHFFFAOYSA-N 0.000 description 1
- 125000005975 2-phenylethyloxy group Chemical group 0.000 description 1
- XSDLSEOIVCVTQZ-UHFFFAOYSA-N 2h-cyclopenta[b]furan Chemical compound C1=CC2=CCOC2=C1 XSDLSEOIVCVTQZ-UHFFFAOYSA-N 0.000 description 1
- KZHCVXGCRMQOEP-UHFFFAOYSA-N 2h-cyclopenta[b]furan-2-ol Chemical class C1=CC2=CC(O)OC2=C1 KZHCVXGCRMQOEP-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- GJTMXOICTLOFHO-UHFFFAOYSA-N 3-oxatricyclo[4.2.0.0(2,4)]octan-7-one Chemical compound C1C2C(=O)CC2C2OC21 GJTMXOICTLOFHO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VORNGBNHDONIJP-UHFFFAOYSA-N 4-(chloromethyl)-n,n-dimethylaniline;hydrochloride Chemical compound Cl.CN(C)C1=CC=C(CCl)C=C1 VORNGBNHDONIJP-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- LBUCWUHBLCABKI-UHFFFAOYSA-N 4-bromo-3-(1-phenylethoxy)bicyclo[3.2.0]heptan-7-one Chemical compound C1C(C(C2)=O)C2C(Br)C1OC(C)C1=CC=CC=C1 LBUCWUHBLCABKI-UHFFFAOYSA-N 0.000 description 1
- PZDPQFNHGDOCGG-UHFFFAOYSA-N 4-bromo-3-hydroxybicyclo[3.2.0]heptan-7-one Chemical compound BrC1C(O)CC2C(=O)CC21 PZDPQFNHGDOCGG-UHFFFAOYSA-N 0.000 description 1
- CMSPKXNZPYYNBP-UHFFFAOYSA-N 4-oxabicyclo[3.2.1]octan-3-ol Chemical class O1C(O)CC2CCC1C2 CMSPKXNZPYYNBP-UHFFFAOYSA-N 0.000 description 1
- JCYLVLDCMAUAKJ-UHFFFAOYSA-N 4-oxabicyclo[3.2.1]octan-3-one Chemical compound O1C(=O)CC2CCC1C2 JCYLVLDCMAUAKJ-UHFFFAOYSA-N 0.000 description 1
- 125000006491 4-t-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QICUPOFVENZWSC-UHFFFAOYSA-N 5-bromopentylbenzene Chemical compound BrCCCCCC1=CC=CC=C1 QICUPOFVENZWSC-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- JRTAFMVODZGBGQ-UHFFFAOYSA-N BrN1C(CCC1=O)=O.Cl Chemical compound BrN1C(CCC1=O)=O.Cl JRTAFMVODZGBGQ-UHFFFAOYSA-N 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DUTSLDCJQZHQLM-UHFFFAOYSA-N C1CCC2C(=O)CC21OCC1=CC=CC=C1 Chemical compound C1CCC2C(=O)CC21OCC1=CC=CC=C1 DUTSLDCJQZHQLM-UHFFFAOYSA-N 0.000 description 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XNCNNDVCAUWAIT-UHFFFAOYSA-N Methyl heptanoate Chemical compound CCCCCCC(=O)OC XNCNNDVCAUWAIT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 102100026456 POU domain, class 3, transcription factor 3 Human genes 0.000 description 1
- 101710133393 POU domain, class 3, transcription factor 3 Proteins 0.000 description 1
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 description 1
- 101100391171 Schizosaccharomyces pombe (strain 972 / ATCC 24843) for3 gene Proteins 0.000 description 1
- AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IRTLGLYSFAKASM-UHFFFAOYSA-N acetic acid;propan-2-ol Chemical compound CC(C)O.CC(O)=O IRTLGLYSFAKASM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- XXJLQQRZZGAIGT-UHFFFAOYSA-N benzyl(methyl)azanium;bromide Chemical compound [Br-].C[NH2+]CC1=CC=CC=C1 XXJLQQRZZGAIGT-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- LNJNDNOHSVRMLG-UHFFFAOYSA-N bicyclo[3.2.0]heptan-4-one Chemical compound O=C1CCC2CCC12 LNJNDNOHSVRMLG-UHFFFAOYSA-N 0.000 description 1
- XADFSXKNPLLSDY-UHFFFAOYSA-N bicyclo[3.2.0]heptan-6-one Chemical compound C1CCC2C(=O)CC21 XADFSXKNPLLSDY-UHFFFAOYSA-N 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- XRAVYESZTUBEBU-UHFFFAOYSA-N cyclohexane;propan-2-ol Chemical compound CC(C)O.C1CCCCC1 XRAVYESZTUBEBU-UHFFFAOYSA-N 0.000 description 1
- 150000001940 cyclopentanes Chemical class 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- PMPYSSMGWFNAAQ-UHFFFAOYSA-N dichloromethane;n,n-diethylethanamine Chemical compound ClCCl.CCN(CC)CC PMPYSSMGWFNAAQ-UHFFFAOYSA-N 0.000 description 1
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 229940064471 heptanoic acid Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical compound ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000029860 luteolysis Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- DGEYTDCFMQMLTH-UHFFFAOYSA-N methanol;propan-2-ol Chemical compound OC.CC(C)O DGEYTDCFMQMLTH-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IQQDLHGWGKEQDS-UHFFFAOYSA-N methyl hept-2-enoate Chemical compound CCCCC=CC(=O)OC IQQDLHGWGKEQDS-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- CSYNQJPENMOLHR-UHFFFAOYSA-N n,n-diethylethanamine;ethyl acetate Chemical compound CCOC(C)=O.CCN(CC)CC CSYNQJPENMOLHR-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000328 pro-aggregatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 102200014657 rs121434437 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical class CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
- C07D317/04—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/16—Radicals substituted by halogen atoms or nitro radicals
Abstract
Prostanoid compounds are described having the formula: <IMAGE> where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is -CH=CH- or -(CH2)2-; R<1> is alkyl having a terminal -COOH or ester group; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.
Description
SPECIFICATION Prostanoid compounds
This invention relates to prostanoid compounds.
Prostaglandins are a class of naturally occurring cyclopentane derivatives which are biologically active in many physiological systems and they and substances which antagonise their effects are therefore of considerable interest in both human and veterinary medicine.
Prostaglandins can generally be regarded as formal derivatives of prostanoic acid, which has the structure:
The side chain at the 8-position is sometimes referred to as the a-side chain, and the side chain at the 12-position as the upside chain.
In the natural prostaglandins, the cyclopentane ring carries oxo and/or hydroxy substituents and it may also have a double bond, for example at the 10,11 - position. According to the substitution pattern in the ring the prostaglandins are defined as being of the A,
E, F etc. series (see for example "Prostaglandin
Synthesis", J. S. Bindra and R. Bindra, Academic
Press Inc. [New York], 1977). The two side chains may also be unsaturated, for example at the 5,6-or 13,14- positions, and the p-side chain frequently carries a hydroxy group at the 15- position.
The characteristic properties of natural prostaglandins include for example lowering or increasing blood pressure, stimulation or relaxation of smooth muscle, increase of blood flow, inhibition of lipolysis, inhibition of gastric secretion, inhibition of blood platelet aggregation and thrombus formation, stimulation of epidermal proliferation and keratinisation, induction of luteolysis in certain female mammals, and induction of parturition in mammais. Prostaglandins have been suggested for use in a variety of ways on account of these properties.
In view of the activity found in the natural prostaglandins, considerable effort has been directed towards the preparation of synthetic analogues.
Many such compounds have been described, and in general it has been reported that these compounds possess activity within the same spectrum as the natural compounds. The synthetic compounds can however have increased selectivity of action, longer duration of activity or different potency, and in some cases they can antagonise the activity of natural prostag landins.
In most of the synthetic prostanoids previously reported, the side chains have been attached to the cyclopentane ring via carbon atoms, as in the natural prostaglandin structure. We have now found a new class of prostanoid compounds in which the a-side chain has the same or similar structure to that of the natural compounds,whilethepside-chain is attached to the ring via a nitrogen atom. The /3-side chain in our compounds can be regarded as the residue of ammonia or a primary or secondary amine. Compounds in this class have shown prostanoid activity in our tests and in particular they inhibit blood platelet aggregation and have bronchodilatory action.
The invention provides prostanoids of the general formula (1)
in which
A represents
X is cis or trans -CH=CH- or-(CH2)2-; terminal substituent-COOR'0 where R10 is a hydrogen atom, Cia alkyl or C7-10 aralkyl;;
Y represents (i) -NR2R3 where R2 and R3 are the same or different and are each a hydrogen atom, aralkyl having a C17 alkyl portion or C1-10 alkyl, both alkyls being optionally substituted by one or more substituents-OR7 (where R7 is a hydrogen atom, C17 alkyl, aryl or aralkyl having a C,, alkyl portion) or -NR8R9 (where R8 and R9 are the same or different and are each a hydrogen atom or C14 alkyl, or where -NR8R9 is a saturated heterocyclic amine group as defined below for Y); any aryl group in R2 or R3 being optionally substituted by one or more C1-4 4 alkyl or trifluoromethyl groups; always provided that the total numbers of carbon atoms in the group -NR2R3 does not exceed 15;
or (ii) a saturated heterocyclic amino group which has 5-8 ring members and (a) optionally contains in the ring -O-, -S-, -SC2-, -NR14- (where R14 is a hyd rogen atom, C17 alkyl or aralkyl having a C1 4 alkyl portion), > C(OH)Ra (where R6 is a hydrogen atom, C17 alkyl, phenyl, or aralkyl having a C1 alkyl portion); and/or (b) is optionally substituted by one or more C1 4 alkyl groups; R4 is a hydrogen atom, C16 alkyl (optionally interrupted by one or two oxygen atoms), C3 5 alkenyl, C24 alkanoyl, aralkanoyl having a C2 4 alkanoyl por- tion, aryl or aralkyl having a C13 alkyl portion (the
aryl portion being optionally substituted by one or
more halogen, hydroxy, C1a alkyl, C16 alkoxy, C,, hydroxyalkoxy, trifluoromethyl, cyano, phenyl,
aryloxy, C,, cycloalkyl, aralkoxy,
dimethylaminomethyl, carboxamido (-CON H2), thiocarboxamido (-CSNH2), C1~4 -4 alkanoyl orNRaRa groups as defined above);; Ra is as defined above for R4, excluding aryl and
with the proviso that Ra is not hydrogen when A is the group (h);
and the physiologically acceptable salts thereof;
provided that when A is the group (a) in which both
R4 and RS are hydrogen atoms and Y is the group -NR2R3 in which R2 is a hydrogen atom or C14 alkyl,
R3 is not an alkyl group which is only substituted by a hydroxy group.
In the structural formulae herein, a broken line connected to a ring substituent means that, with the ring substantially in the plane of the page, the substituent lies below the plane of the ring; a wedge a connected to a ring substituent means that the sub stituentto which it is attached lies above the plane of the ring. A wavy line ~ connected to a ring substituent means that the substituent to which it is attached lies above and/or below the plane of the ring. Such formulae are to be understood to depict either or both optical isomers of each of the compounds concerned as well as mixtures of the isomers, including racemates, even though the precise structure as set out only relates to one optical isomer.
Generally, the cyclopentane ring preferably has the substitution/unsaturation pattern (a), (c) or (g) shown above. Compounds having the ring type (c) are particularly important.
In the group -CH2XRt, the R' alkyl group preferably contains 3 carbon atoms in a straight chain. Examples of suitable R10 groups are C12 alkyl and ben:ryl.
10 is preferably a hydrogen atom or methyl. R' is preferably-(CH2)3COOCH3 or-(CH2)2 COOH.
When R1 is terminally substituted by-COOH, the compounds are capable of salt formation with bases, examples of suitable salts being alkali metal (e.g.
sodium and potassium), ammonium and substituted ammonium (e.g. tromethamine or dimethylaminoethanol) salts.
X is preferably a-CH2CH2- group or a cis -CH=CH- group.
When one of R2 and R3 is alkyl or substituted alkyl, the alkyl group preferably contains no more than 7 (e.g. 2-7) carbon atoms and preferably has a straight chain. Examples of such groups are n-hexyl and n-heptyl. In such compounds, the other group of R2 or R3 is preferably hydrogen or methyl. When R2 or
R3 is an aralkyl group, it may for example be benzyl, phenethyl or phenpentyl.
In the optional substituent-OR7 in R2 or R3, examples of R7 are a hydrogen atom, methyl, n-butyl, phenyl, benzyl and phenethyl. The optional amino substituent -NR8R9 may for example be -N H2, -NHMe, -NHEt, -NMe2 or -NEt2. These optional substituents may for example be carried at the ss-position, as in ss-hydroxyalkyl groups. Two -OR7 groups may be present, particularly on an R2 or R3 alkyl group; for example, there may be a hydroxy group at the position and a second -OR7 group at the terminal position.
Aryl (e.g. phenyl) groups in R2 and R3 may themselves be substituted, e.g. by Ct , alkyl ortrif- luoromethyl.
Compounds in which Y is a saturated heterocyclic amino group are however preferred. The group may for example have a 5,6 or 7-membered ring, e.g.
pyrrolidino, piperidino, morpholino, piperazino, thiamorpholino, 1- dioxothiamorpholino, homomorpholino and hexamethyleneimino.
Examples of the optional substituents which may be present on a second nitrogen atom in the ring are methyl, ethyl and benzyl. The carbon atoms of the heterocyclic rings may for example be substituted by methyl or ethyl. The group > C(OH)R6 may for example be present in a piperidino ring and when R6 is other than hydrogen it may for example be methyl, ethyl, or butyl.
Compounds in which Y is a morpholino group are preferred, the group being either unsubstituted or substituted, e.g. by methyl at the 2- and/or 6-position.
The amino group in the /3-side chain enables the compounds to form salts with inorganic or organic acids, e.g. hydrochlorides, sulphates, acetates, maleates and succinates.
R4 may for example by a hydrogen atom, Ci-a alkyl (e.g. methyl, isopropyl or pentyl), C,, alkenyl (e.g.
allyl), alkyl having up to 6 carbon atoms interrupted by one or two oxygen atoms (e.g. methoxymethyl or methoxyethoxymethyl), C,, alkanoyl (e.g. acetyl), aryl (e.g. phenyl) or, preferably, aralkyl having a C13 alkyl portion. The alkyl portion may carry one or more aryl groups and the aryl group may be monoor bicyclic (e.g. phenyl). Examples of aralkyl groups are benzyl, phenethyl, a-methylbenzyl and benzhydryl.The aryl portions of the aralkyl groups may be substituted, preferably by halo, C1-a alkyl, C1a alkoxy, trifluoromethyl, cyano, phenyl, C57 cycloalkyl, amino,dialkylamino,-CONH2,-CSNH2, dimethylaminomethyl or formyl. Specific examples of these optional substituents are chloro, bromo, methyl, methoxy, butyloxy, cyclohexyl, amino, dialkylamino, and formyl. Substituted benzyl groups are particularly preferred, the substituent being for example in the para-position.
A particularly important group of compounds is those in which A is the group (c), X is cis -CH=CHor-CH2CH2-, R1 is-(CH2)3COOCH3 or-(CH2)3COOH, Y is a heterocyclic amino group (particularly morpholino) and R4 is alkyl, alkyl interrupted by one or two oxygen atoms, or substituted or unsubstituted aralkyl.
Compounds which are particularly preferred on account of the selective activity they have shown in our tests are those in which A is the group (c), X is cis -CH=CH-, R' is-(CH2)2COOCH3,Yis morpholino and
R4 is 4-phenyl-benzyl, 4-dimethylaminobenzyl, 4-cyclohexylbenzyl, 4-aminobenzyl or 4t-butylbenzyl; and those in which A is the group (c), X is cis-CH=CH-, R' is-(CH2)3COOH, Y is morpholino and R4 is4-phenylbenzyl or4-cyclohexylbenzyl; and those in which A is the group (c), X is-(CH2)2-, Y is morpholino, R4 is 4-phenylbenzyl and R1 is -(CH2)3COOCH3 or-(CH2)2COOH. These are the products of Examples 143, 144, 147, 175, 176, 177, 179, 199 and 208 below.
As indicated above, tests have shown that compounds offormula (1) inhibit blood platelet aggregation and/or have bronchodilatory activity. The test for potential bronchodilation is as described by K. M.
Lulich, eta/in British Journal of Pharmacology 58, 71-79, (1976) except guinea-pig lung is used instead of cat lung. The test for inhibition of platelet aggregation is as described by G.V. Born in Nature 194, 927-929 (1962) except collagen-is used instead of
ADP as the pro-aggregatory agent.
The compounds are thus of interest in the treatment of asthma and as antithrombotic agents for use in the treatment and prevention of cardiovascular diseases or conditions such as arteriosclerosis, atherosclerosis and myocardial infarcts. They may be formulated for use in conventional manner, with one or more pharmaceutical carriers. The compounds may also be used as additives for preventing aggregation of whole blood, e.g. for storage purposes.
For oral administration, the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups, or suspensions prepared by conventional means with acceptable excipients.
The compounds may be formulated for parenteral administration by bolus injections or continuous infusion. Formulations for injections may be presented in unit dosage form in ampoules, or in multi-dose containers, with an added preservative.
The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
Alternatively, the active ingredient may be in powder form for reconstitution before use with a suitable vehicle, e.g. sterile pyrogen-free water.
For administration by inhalation the compounds are conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, or as a cartridge from which the powdered composition may be inhaled with the aid of a suitable device. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
For use in antithrombotic agents, the compounds are preferably administered orally, for example in amounts of 0.1 to 10 mg/kg body weight, 1 to 4 times daily. For use in the treatment of asthma, the compounds may also be administered orally in amounts of0.1 to 10 mg/kg body weight,1 to 4 times daily; preferably however they are administered by inhalation in the form of aerosols or solutions for nebulisers, at doses varying from 0.3 to 30 mg, 1 to 4 times daily. The compounds may be used in combination with other antiasthmatic agents. It will be appreciated that the precise dose administered will always depend on the aquageous and condition of the patient.
The compounds offormula (1) may be prepared by selection and adaptation of methods known in prostanoid chemistry (see for example "Prostaglandin Synthesis", J.S. Bindra and R. Bindra, Academic Press Inc. [New York],1977) 1977) or by anaiogous methods. Methods (a) to (d) below are particularly important in forming certain prostanoids of the desired class, and these primary products (formulae 2,8, 12 and 17, below) can then be converted into other members of the class by conventionaltechni- ques.
(a) Thus for example one method of preparing compounds of formula (2)
(where Raa is as defined above for R1 where R1 bears a terminal -COOH group, Y and R4 are as defined above) is by reacting lactolsofformula (3) or their aldehyde isomers
(where Y is as defined above and -OR4a is as defined above for -OR4 or is a protected hydroxy group) with appropriate Wittig reagents, e.g. a phosphorane of formula Ra'I P=CHR1a or a salt thereof (where Rra is as defined above and R'1 is C1 alkyl or aryl, e.g.
monocyclic aryl such as phenyl), followed, where R4 is hydrogen, by removal of the protecting group -R4a. Suitable reaction solvents include hydrocarbons (e.g. benzene and toluene), ethers (e.g. tetrahydrofuran), dialkylsulphoxides (e.g. dimethylsulphoxide), alcohols and halogenated hydrocarbons.
The reaction may be carried out at any suitable temperature up to 50"C, preferably at room temperature.
The reaction is particularly suitable for the preparation of compounds in which R' is terminally substituted by -COOH (in salt form). If compounds in which OR4 represents a hydroxy group are required, the hydroxy group should preferably be in a protected state prior to the reaction. Any hydroxy group
in Y should preferably also be in a protected state
prior to this reaction. Suitable hydroxy protecting
groups are described below. Any -NH2 group pres
ent should also be protected, e.g. by t-butoxycarbonyl.
This reaction, as will be appreciated, is the last
step in a multi-stage sequence related to that desc
ribed in Belgian Patent Specification 84992 for the
introduction of carbon-attached /3-side chains, and
the intermediates required may be prepared by the
methods described therein, modified as necessary
for the introduction of the nitrogen-linked,8-side chain.
The intermediates offormula (3) may thus be pre
pared by the following sequence (where ya is as
defined for Y above, other than -NH2):
It should be noted that the tricyclic intermediates of formula (5) are not usually isolated; the norbornanones of formula (6) can be obtained directly by treating compounds of formula (4) with amines YaH in the presence of a non-nucleophilic base (e.g.
potassium t-butoxide, sodium hydride or sodium metal). It should also be noted that the significant difference in the method as compared with that of
Belgian Specification 848992 lies in the use of the amines Y"H to introduce the ya groups; these replace the organometallic reagents used in the method of the Belgian Specification to introduce /3-side chains attached via a carbon atom. In some circumstances (when YaH is sufficiently basic) no extra base needs to be added in the first stage, but in other respects the sequence leading to the lactols of formula (3) can be performed as described in the Belgian Specification.Thus, the Baeyer-Villiger oxidation of the norbornanones of formula (6) to lactones of formula (7) may for example be effected with peracetic acid at a low temperature, using aqueous acetic acid or
CH2CI2 as solvent: and lactones of formula (7) can be reduced to give the mixed epimers of lactols of formula (3) with di-isobutyl aluminium hydride in a hydrocarbon solvent, art a low temperature e.g.
about -700C.
When it is desired to isolate an intermediate of formula (5), it can be formed (as described in the
Belgian Specification) by treating a ketone of formula (4) with a non-nucleophilic base. A compound of formula (6) can then be prepared in a separate step, by treatment of a compound of formula (5) with an amine Y"H in the presence or absence of the base.
In the circumstances where ya contains an optional hydroxy substituent, this should preferably be protected in the preparation of compounds of formula (6).
Compounds of formula (4), particularly where R4 is aralkyl, may also be prepared by treating the compound of formula (4) in which R4 is hydrogen with a compound R40H in the presence of an acid catalyst.
Compounds of formula (2) in which Y is -NH2 may be prepared as follows. A compound of formula (4) is first treated with a phthalimide to give a compound of formula (6) in which ya is phthalimido.
After the Baeyer-Villiger oxidation, treatment with hydrazine gives a compound of formula (7) in which ya is -NH2. The amino group is then protected (e.g.
as (t-but)OCONH-) and the compound then reduced to give a lactol (3) and its aldehyde isomer. Protection of the free hydroxy group of the latter (e.g. as the tetrahydropyranly ether) allows the Wittig reaction to be performed. The hydroxy and amino protecting groups are then removed by acid hydrolysis e.g. with trifluoroacetic acid. This reaction sequence is particularly suitable for compounds in which R4 is aralkyl.
(b) An alternative method of forming the general prostanoid structure of compounds of formula (1) has as its last step the preparation of compounds of formula (8)
(where R1a R5 and ya are as defined above) by reaction of compounds of formula (9)
(where ya is as defined above and -OR5a is as defined above for-ORs or is a protected hydroxy group) with appropriate Wittig reagents, in the same manner as described above for the preparation of the compounds of formula (2) followed where R5 is hydrogen by removal of the protecting group -R5a. Any hydroxy group in R15 or ya should preferably be in a protected state prior to the Wittig reaction. Again, suitable protecting groups are as described below.
The intermediates of formula (9) may be prepared from compounds of formula (7) as shown in the following sequence:
In the compounds of formula (7) used in this reaction sequence, the group R4a should be capable of ready and selective removal, and thus generally R4a
O is a protected hydroxy group, e.g. a tetrahyd ropyranyloxy group or a carboxylic acyloxy, tri(hydrocarbyl) silyloxy or arylmethoxy group such as described below generally with reference to protected hydroxy groups. R4a is preferably a tetrahydropyranyl, acetal or benzyl group. The formation of the compounds of formula (10) can occur spontaneously on removal of the group R4a, e.g. by the methods described below. The rearrangement of the deprotected compound of formula (7) does not, however, always occur spontaneously, and in these cases the step of removing the R4a group may be followed by treatment with base (e.g. dilute sodium hydroxide) and then acid (e.g. dilute hydrochloric acid).
The hydroxy group of lactones of formula (10) may then be protected (e.g. as the tetrahydropyran-2-yl ether) to give lactones of formula (11) which are then reduced to give lactols of formula (9), e.g. with diisobutyl aluminium hydride in the same manner as described above for the reduction of formula (7).
(c) Compoundsofformula 12.
(where R16, R4, R6 and X are as defined above) may alternatively be prepared by reducing compounds of formula (13)
Compounds of formula (12) in which X is-(CH2)2- may be prepared by catalytic hydrogenation of the starting materials of formula (13) using for example platinum or palladium on carbon as the catalyst.
However, when compounds of formula (12) in which
X is-CH=CH-are required, selective reduction methods specific for the azide function should be used with compounds of formula (13). Examples of suitable reagents are zinc and sodium dihydrogen phosphate in a suitable solvent (e.g. tetrahydrofuran); zinc and methanol/sulphuric acid; or triphenylphosphine followed by methanol/sulphuric acid.
The starting materials of formula (13) may be prepared in the same manner as generally described above for the preparation of compounds offormulae (2) and (8), except that azide ion is used in the preparation of compounds of formula (6) instead of reagents rH. The norbornanone intermediates in this sequence thus have the formula (14)
and may be prepared by reacting ketones of formula (5) with azides (e.g. an alkali metal azide such as
NaN3), for example in a two phase reaction medium (e.g. water and a halogenated hydrocarbon, e.g.
CH2CI2) in the presence of a base e.g. sodium hydroxide. A phase transfer catalyst (e.g. benzyl triethylammonium chloride) is advantageously used. The compounds of formula (14) may then be converted into intermediates of formulae (15) or (16)
by the methods described above for reactions (1) and (2).
The compoundsofformulae (15) and (16) may be reduced directly to compounds of formula (12). The hydroxy groups, the group R'a or the configuration of X may be modified, or a double bond introduced into the ring, after the formation of the amino group.
The amino group may need to be protected in such transformations. The hydroxy groups may also be modified before the reduction of compounds of formula (13).
(d) Compounds of formula (17)
(where Rra and Y are as defined above) can also be prepared by treatment of compounds of formula (18)
with appropriate Wittig reagents, in the same manner as described above for the preparation of compounds of formulae (2) and (8). In this instance, the starting materials of formula (18) may be prepared by first treating a compound offormula (19)
with amines of formula YH (e.g. at room temperature in a suitable solvent, e.g. acetonitrile) to form compounds of formula (20)
and then reducing the latter, for example as described above for the reduction of the lactones of formula (7).
Some methods, which are generally conventional in prostanoid chemistry (see for example "Prostaglandin Synthesis" J.S. Bindra and R. Bindra, as above) will now be described briefly for the modification of prostanoids produced by methods (a) - (d) above or by other methods. It will be appreciated that the following reactions will frequently require the use of (or will conventionally be applied to) starting materials having protected functional groups (e.g. hydroxy). The protection and deprotection of the groups is discussed separately below, but it is to be understood that in the following methods references to the use of starting materials of corresponding structure to the desired product are intended to include starting materials having protected functional groups.It will also be appreciated that certain of the reactions described below are capable of affecting other groups in the starting material which are desired in the end product; care must therefore be taken, in accordance with conventional practice, to perform multi-stage reactions in a sequence which does not modify groups which are to be retained in the end products.
(e) Compounds in which R1 is terminally substituted by an esterified carboxyl group can be prepared by esterification of the corresponding carboxylic acid. Conventional esterification techniques may be used, reaction with a diazoalkane being preferred.
The alkyl esters may also be formed by reaction with an appropriate alcohol in the presence of a mineral acid, e.g. hydrochloric or sulphuric acid. Esterification (e.g. with methanol) is often useful in isolating compounds in which R' bears a terminal -COOH group, subsequent de-esterification liberating the acid if desired. Also, one ester may be converted into another, for example by treatment with the appropriate alcohol.
(f) Compounds in which R' is terminally substituted by a -COOH group can be prepared by saponifying a corresponding ester, e.g. using KOH or NaOH in methanol.
(g) Compounds in which X is trans -CH=CH- may be prepared by isomerising the corresponding cis compound. The isomerisation may for example be effected by treatment with azobisisobutyronitrile and thiophenol, using for example a hydrocarbon solvent and any suitable temperature up to reflux.
Where an oxo group is desired in the end product, it should be introduced after this reaction.
(h) Compounds in which X is -(CH2)2- may be prepared by catalytic hydrogenation of a corresponding compound in which X is-CH=CH-. Conventional catalysts may be used, preferably palladium or platinum on carbon, in a suitable solvent (e.g. an alcohol such as methanol) e.g. at room temperature.
(i) Compounds in which R4 or R5 is alkyl, alkenyl or aralkyl may be prepared by etherification of a corresponding hydroxy compound, for example by reaction with an appropriate halide, for example by reaction at room temperature in the presence of a suitable base (e.g. sodium hydride) in a suitable solvent (e.g. dimethylformamide).
(j) Compounds in which R4 or R6 is alkanoyl or aralkanoyl can be prepared by esterification of a corresponding hydroxy compound, for example with the appropriate acid or anhydride or halide thereof.
(k) Compounds in which R4 or R5 is a hydrogen atom can be prepared from the corresponding compounds in which the R4"0- or R5a0- group is a protected hydroxyl group, for example by reduction or acid or alkaline hydrolysis. The formation of hydroxy compounds in this way is discussed more fully below in connection with hydroxy group protection.
(l) Compounds having a 9-or 1 1-oxo group may be prepared by oxidising the corresponding hydroxy compound, for example with a Cr"' oxidising reagent, e.g. Jones reagent. Other conventional methods can also be used, for example using dimethylsul
phoxide and a suitable electrophilic reagent, such as
acetyl bromide, oxalyl chloride, thionyl chloride, or
dicyclohexylcarbodiimide. With the latter reagent, the reaction is preferably carried out in the presence
of trifluoroacetic acid or its pyridinium salt.
Any free hydroxy group present should be pro
tected in this reaction.
(m) Compounds in which A is the group (d) or (b)
may be prepared by elimination of R4aOH or R5aOH from a corresponding compound possessing the cyclopentanoid substitution pattern (c) or (h). The elimination may be effected in the presence of an acid (e.g. an organic acid such as acetic acid) at temperatures of 20-60"C, or by means of an acid anhydride in pyridine, e.g. at room temperature.
(n) Compounds in which A is the group (e) or (f) may be prepared by catalytic hydrogenation of a cor responding compound in which A is the group (d) or (g). Conventional catalysts may be used, particularly platinum or palladium on carbon.
(o) Compounds in which Y is a mono- or disubstituted amino group may be prepared by modifying a corresponding primary or secondary amino compound, with protection of hydroxyl groups where appropriate.
These reactions may be performed by reacting compounds of formula (1) in which for example Y represents NHR3 where R3 is as defined above with compounds of formu Ia R2X where RZ is as defined above other than hydrogen and where Xis a readily displaceable group such as halide (e.g. iodide) or a hydrocarbylsulphonyloxy group, e.g. a toluene-psulphonyloxy group. The reactions may be carried out in solvents (such as acetonitrile) in the presence of potassium carbonate.
When a primary amine is used as starting material [Y is -MH2 in formula (1)] the reaction can produce either N-mono or N,N-di-substituted products, and when a secondary amine offormula (1) is used as starting material the reaction can produce tertiary amines of the invention in which R2 and R3 are either the same of different. Compounds in which Y is a cyclic amino group may similarly be prepared by reaction of a compound in which Y is -NH2 with a compound XR'X, where R'5 is the appropriate divalent group. Alternatively, this process may be performed by reacting primary amino or secondary amino compounds of formula (1) with appropriate mono- or di-carbonyl compounds in the presence of a reducing agent in reductive arnination procedures.
For example with starting materials in which Y is -NH2, the use of aldehydes or ketones may give the corresponding N-mono or N,N-disubstituted compound (depending partly on the proportion of aldehyde or ketone used), whereas a dialdehyde or diketone may give compounds in which Y is a cyclic amino group (e.g. glutardialdehyde may be used to form a piperidino group). When secondary amines are used as starting materials, mono-carbonyl compounds only will be used. The reducing agents which may be used are those generally known for the reduction of imines, e.g. formic acid, or an alkali
metal borohydride or cyanoborohydride (e.g.
sodium borohydride or potassium cyanoborohyd
ride, using an alcohol such as ethanol as solvent, suitably at room temperature, preferably at pH 4-6), or hydrogen in the presence of a metal catalyst, e.g.
palladium.
Compounds in which R2 or R3 possesses a hydroxy substituent are conveniently prepared by
reacting appropriate compounds offormula (1) in
which Y is a mono- substituted amino group (par
ticularly -NHCH3) or a primary amino group with an
appropriate 1,2-epoxide.
Suitable primary amino starting materials may be
prepared by reaction (c) above. Secondary amino
starting materials may be prepared by reactions (a)
and (b) above, but in some instances they are more
conveniently prepared by dealkylation or de
aralkylation of a compound of formula (1) in which Y
is -NR'2R'3, where R'2 and R'3 are alkyl or aralkyl and
may be the same or different. The dealkylation or
dearalkylation may be effected by treating the dis
ubstituted amine with 2,2,2-trichloroethyl chloroformatetoform a carbamate in which Y is
-NCOOCH2CCl3
R13
which on treatment with zinc dust gives the required
starting material in which Y is -NHR'3.
(p) Compounds in which R4 is aralkyl substituted by I amino may be prepared by reduction of the corres
ponding azide, in the same manner as generally
described above for process (c).
(q) Compounds in which R4 is aralkyl substituted by
-CH2N(CH3)2 may be prepared by treatment of the
corresponding formyl compound with
dimethylamine in the presence of a reducing agent,
as generally described above for process (o).
(r) Compounds in which R4 is aralkyl substituted by -CO NH2 or-CSNH2 may be prepared from the cor
responding cyano compound by hydrolysis or hyd
rosulphidation, e.g. with sulphur in the presence of a
reducing agent.
Where salts of compounds of formula (1) are
desired such salts may be formed by conventional
methods, for example by treating acids of formula
(1) with appropriate bases such as dilute alkali-metal
hydroxides. Where the compound contains a basic
amino group, salts may also be formed with acids.
As indicated above, hydroxy groups will necessar
ily or conveniently be protected in the reactions
described above. The last step in the preparative
sequence is thus frequently the liberation of a free
hydroxy group from the protected form. Suitable
methods of protection and deprotection are
described below.
A protected hydroxyl group (ORh) may, for exam
ple, be a carboxylic acyloxy, tetrahydropyranyloxy,
tri(hydrocarbyl)silyloxy or arylmethoxy group.
Where ORh is acyloxy it may be alkanoyloxy, prefer
ably containing not more than 7 carbon atoms (e.g.
acetoxy). The protected group may also be a C27 alkoxycarbonyloxy group, which can be optionally sub
stituted (e.g. by halo), as in a trichloroethoxycar
bonyloxy group.
Where ORh is tri(hydrocarbyl)silyloxy the hyd
rocarbyl substituents may be the same of different,
e.g. Cut~6 alkyl, C26 alkenyl, C37 cycloalkyl, C7-20 aral
kyl and C620 aryl groups. Such groups include
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
t-butyl, allyl, phenyl and benzyl. Preferred hydrocar
byl groups are C1 alkyl, e.g. methyl and t-butyl.
Trimethylsilyl and t-butyldimethylsilyl ethers are
particularly preferred.
When ORh is an arylmethoxy group it may contain
up to 20 carbon atoms, e.g. benzyloxy, diphenylmethoxy ortriphenylmethoxy.
Particularly useful groups ORh includetri(hydrocar- byl)silyloxy groups, especially t-butyldimethylsilyloxy, and tetrahydropyranyloxy.
Deprotection of the protected hydroxy group will depend on the nature of Rh. Where appropriate, deprotection may be carried out in the presence of either an acid or a base or by reduction. Thus, for example, an acyl group may be removed by alkaline hydrolysis. A tri(hydrocarbyl)silyl group may, for example, be removed by acid hydrolysis, e.g. with dilute mineral acid ortrifluoroacetic acid or by treatment with fluoride ions (e.g. from a quaternary ammonium fluoride such as tetra-n-butyl ammonium fiuoride). Tetrahydropyranyl groups may for example be cleaved by acid hydrolysis, e.g.
with a dilute mineral acid ortrifluoroacetic acid.
Arylmethyl groups may be removed by reduction, e.g. with an alkali metal such as sodium dissolved in liquid ammonia or by hydrogenolysis, e.g. with a noble metal catalyst such as platinum or palladium.
Halogenated alkoxycarbonyl e.g. trichloroethoxycarbonyl groups may be removed by treatment with metallic zinc, e.g. in a suitable solvent such as tetrahydrofuran.
The following examples illustrate the invention.
The synthesis of the intermediates required is described in the Preparations. Temperatures are in "C. "Petroleum ether" refers to the fraction boiling at 40-60"; The following abbreviations are used:
DMSO -dimethylsulphoxide
DMF -dimethylformamide
THF -tetrahydrofuran
PyTFA -pyridinium trifluoroacetate
Py -pyridine
Ac2O -acetic anhydride
IPA -isopropanol
Dibal -diisobutyl aluminium hydride
Phos.salt -(4- carboxybutyl)triphenylphos
phonium bromide
TLC -thin layer chromatography
Preparations 1-17 5,7 - Disubstituted bicyclo [2.2. 1] heptan - 2 - ones
Table 1 summarises the preparation of the title compounds by the following methods: A.The appropriate amine was added to a stirred solution of the appropriate bicyclo [3.2.0] heptan - 6 - one in acetone at 0-10 . The solution was allowed to attain room-temperature and stirring was continued for the time specified. Ether was added and stirring was continued for 30 mins, whereupon the mixture was filtered and the filtrate evaporated in vacuo. The residue was dissolved in ether and extracted with water followed by 5N- hydrochloric acid. The acidic extract was cooled and made basic by the addition of 5N sodium hydroxide solution. The basic solution was extracted with dichloromethane and the combined extracts dried and evaporated.
B. A solution of the appropriate bicyclo [3.2.0g heptan - 6 - one in dichloromethane was added to a mixture of 5N sodium hydroxide, benzyl triethylammonium chloride and the appropriate amine in dichloromethane at room temperature and stirring continued for the time specified. The reac tion mixture was poured into water and extracted with dichloromethane. The combined extracts were washed, dried and evaporated. The material obtained was purified either by chromatography on silica gel or by crystallisation.
C.- To a stirred solution of potassium tert - butoxide in dry detrahydrofuran under nitrogen at -70" was added dropwise a solution of the appropriate bicyclo [3.2.0] heptan - - one in dry tetrahydrofuran.
Stirring was continued for 30 mins whereupon dry ether and charcoal were added. The mixture was filtered and the filtrate evaporated to a volume of about 150-200 ml. To the resulting solution of the 3 endo - substituted tricyclo [3.2.0.02.7] heptan - 6 - one at 0" was added the appropriate amine and the mixture was then stirred at room temperature for the time specified. The solvent was removed in vacuo and the residue purified by chromatography on silica gel.
TABLE I
Prep. Starting Amine Method Acetone CH2Cl2 Benzyl No. material vol. vol. THM triethyl KOtBu Chromato (ml) (ml) Total 5N NaOH ammounium wt Time graphy Yield IR C=0 Wt Wt vol. Vol. chloride (g) (hr) Solvent (g) cm-1 m.p.
R (g) Z (g) (ml) (ml) wt (g) 1 # 14.9 # 25 C - - 400 - - 8.2 18 ether 12.1 (Neat) 1755, 1740 2 # 118 # 139 A 1000 - - - - - 18 - 114.5 (CHBr3) 139-140.5 1744 from ethyl acetate cyclohexane 3 # 5.9 # 5 A 35 - - - - - 24 - 5.26 (CHB43) 106-7 from 1740 petroleum ether 4 # 8.85 # 9 A 100 - - - - - 18 - 9.3 (CHB43) 107-8 from 1740 petroleum ether 5 # 8.11 # 4 B - - - 25 0.65 - 48 9:1 CH2Cl2- 7.35 (CHB43) 136-40 from ether 1740 CH2Cl2 ehter 6 # 29.5 # 26.6 A 250 60 - - - - 3 - 18.71 (CHB43) 58-60 from 1743 isopropanol 7 -CH 43.8 # 100 A 150 - - - - - 5 1::1 ether- 39.8 (CHB43) 58-62 petroleum 1745 ether 8 # 44.4 # 41 C - - 800 - - 21.9 21 ether 40 (CHB43) 1740 9 # 5.9 # 5.43 B - - - 20 0.59 - 2 ether 6.6 (CHB43) 1748 Further Preparations for Table 1
Starting Material Amine THF 5N Benzyl Prep No. Acetone CH2Cl2 Total NaOH triethyl Method Vol Vol Vol Vol ammonium KOtBu Time Ir > C=0 R Wt(g) Z Wt (ml) (ml) (ml) (ml) chloride (wt) hr Chromato- Yield cm-1 m.p.
(g) wt(g) (g) graphy (g) (CHBr3) Solvent 10 -CH3 65.7 # 130.5 A 375 - - - - - 1.5 - 53.8 1745 86-7 from ptrol. ether 11 -CH2(CH3)2 5.0 # 8.81 A 30 - - - - - 4.5 - 3.8 1740 82-3 from petrol. ether 12 # 8.67 # 8.6 B - 60 - 30 0.87 - 20 ether 8.9 1740 b.p. 180 at 0.1mm Hg 13 # 11.8 # 9.4 B - 30 - 30 1.18 - 18 - 12.7 1742 126-7 from isopropanol 14 # 5.9 # 5.4 B - 40 - 20 0.59 - 2 ether 6.6 1743 35.5-7 15 # 3 # 2.02 B - 30 - 20 0.3 - 20 ether- 2.3 1740 from petroleum petroleum ether 2::3 ether 16 # 10 # 11.9 A 50 - - - - - 4.5 - 9.5 1740 108-8.5 from petroleum ether 17 -CH3(CH2) 5 # 4.3 A 80 - - - - - 18 ether 5.0 1742 54-5 from methanol water Preparation 18 (-H- 7-anti- (4-Morpho/iny/) - 5- endo - (2 phenylethoxy) bicyclo [2.2.1] heptan - 2 - one, hyd chloride N - Bromosuccinimide (26.6 g) was added in portions over 1.5 h to a cooled (-5 ) solution of bicyclo [3,2,0]hept - 2 - en - 6 - one (10.8 g)in 2
phenylethanol (54.9 g) and stirring continued for a
further 21 h. The mixture was diluted with dich
loromethane (150 ml) and then washed with water
(200 ml). The aqueous phase was extracted with
dichloromethane (2 x 80 ml). The combined organic phases were washed successively with sodium sulphite (80 ml), water 2 x 100 ml) and brine, then dried (MgSO4) and concentrated to afford a viscous oil.
This was dissolved in acetone (50 ml), cooled (0 ) and treated with morpholine(26.1 9) . After 3 hat room temperature the mixture was poured into 2N hydrochloric acid (60 ml) and extracted with ether (100 ml). The acidic layer was basified with 2N sodium hydroxide and extracted into ether (3 x 100 ml). The combined extracts were washed with brine, dried (MgSO4) and concentrated to afford a viscous oil. The product was dissolved in dry ether and treated with ethereal hydrogen chloride. The title compound was purified from isopropanol as an off-white solid (11.3 g) m.p. 156-158 .
Preparation 19 (+) - 2 - exo - Bromo - 3 - endo - (1- methylethoxy) bicyclo [3,2,0] heptan - 6- one N - Bromoacetamide (83 g) was added portionwise to a cold (0 ) solution of bicyclo [3,2,0] hept - 2 - en - 6 - one (54 g) in isopropanol (500 ml). The mixture was stirred overnight, poured into water (1 litre) and extracted into ether (2 x 500 ml). The combined extracts were washed with sodium sulphite solution, followed by brine, dried (over MgSO4) and filtered and evaporated to afford a viscous oil (111 g). The crude product was chromatographed on silica gel (3.5 kg) using 1:4 ether- petroleum ether (b.g.
40-60 ) as eluent. The title compound was obtained as a solid (33.8 g) which was further purified by crystallisation from petroleum ether (b.p. 60-80') giving m.p.36-37 .
Preparation 20 {+) - 5- endo - (2 - Phenylethoxy) - 7-anti- (1 - piperidinyl) - bicyclo [2,2,1] heptan -2- one The title compound (19.3 g) was prepared from bicyclo [3.2.0] hept - 2 - en - 6 - one (20 g) by the method described for Preparation 18. A sample was purified from petroleum ether as colourless microcrystals m.p. 72-74 .
Preparation 21 (j) - 1- (Methylamino) - 3 - phenoxy - 2 - propanol
To a solution of 1,2 - epoxy - 3 - phenoxypropane (15 g), in ethanol (50 ml) was added 25-30% methylamine in water (50 ml) and the mixture heated under reflux for 1 h. The ethanol was removed in vacuo and the residue acidified with 2N hydrochloric acid. The aqueous solution was extracted with ethyl acetate then made alkaline with
2N sodium hydroxide and extracted into ether. The combined ethereal extracts were dried (Na2SO4), filtered and evaporated to give a semi-solid (14.8 g).
The product was distilled in vacuo to give the title compound as white crystals b.p. 110 /0.07 mm, m.p.
74.77 (9 g).
Preparation 22 - 7 anti - Azido - 5 endo - (phenylmethoxy) bicyclo [2.2.1] heptan - 2 - one
2 - exo - Bromo - 3 - endo - (phenylmethoxy) bicyclo [3,2,0] heptan - 2 - one (25 g) in dichloromethane (85 ml) was added dropwise to a rapidly stirred mixture of sodium azide (6.9 g), benzyl triethylammonium chloride (2.5 g), 5N sodium hydroxide (85 ml) and dichloromethane (85 ml). The resultant mixture was stirred at room temperature for 18 h and then treated with water (700 ml). The separated aqueous phase was extracted with dichloromethane (2 x 600 ml) and the combined organic phases dried (MgSO4) and evaporated to afford an oil which crystallised on seeding (21.5 g). Trituration with petroleum ether gave the title compound as a white solid m.p. 37-39 (20.0 g).
Preparation 23 (#) - 2 - anti - (4 - Morpholinyl) - 5 endo - (1- phenylethoxy) bicyclo [2.2.1J heptan -2- one
A mixture of 2 - bromo - 3 - hydroxybicyclo [3.2.0J heptan - 6 - one (15 g), a-methylbenzyl alcohol (36 g) and p-toluenesulphonic acid (1 g) was heated at 90 for 6 h. The solution was poured into 8% sodium bicarbonate (300 mi) and extracted with ether (4 x 150 ml). The combined extracts were washed with brine (300 ml), dried (MgSO4) and evaporated to afford crude 2 - bromo - 3 - (1 - phenylethoxy) bicyclo [3.2.0] heptan - 6 - one as a pale yellow oil (29.1 g).
The crude product (28.1 g) was dissolved in acetone (50 ml) and treated with morpholine (19 ml). The mixture was stirred for3 h, poured into water (200 ml) and extracted with ether (4 x 150 ml). The combined extracts were washed with brine (200 ml), dried (MgSO4) and evaporated. The product was purified by chromatography on silica eluting with ether-petroleum ether (7:3) to give the title compound as a waxy solid (15.7 g). l.R. (CHBr3) 1745 cm-1.
Preparation 24 (t) - (5- endo, 7-anti) - N- [s- Phenylmethoxy) - 2 - oxobicyclo [2.2.1] hept - 7 - yl] phthalimide
To a stirred solution of 2 - exobromo - 3 - endo (phenylmethoxy) bicyclo [3.2.0] heptan - 6 - one (1 g) in dimethyl sulphoxide (10 ml) was added potassium phthalimide (2 g) and the suspension stirred for 3 days. The mixture was poured into water (100 ml) and extracted with ethyl acetate (4 x 30 ml). The combined organic phases were washed successively with 2N sodium hydroxide solution (2 x 30 ml) and brine, dried (MgSO4) and concentrated. The residual oil crystallised slowly on standing. Recrystallisation from iso-propanolmethanol gave the title compound as colourless needles (0.8 g) m.p. 130-31'.
Preparation 25 () -5 - endo [[( 1' - Biphenyl) -4 - yl] methoxy] - 7 - anti- (4 - morpholinyl) bicyclo [2.2.1] heptan -2- one The title compound (0.42 g) was prepared from 2
bromo - 3 - hydroxybicyclo [3.2.0] heptan - 6 - one
(0.5 g), 4 - phenylbenzyl alcohol (0.75 g) and mor
pholine (5 ml) according to the method of Prepara
tion 23. The oily product was purified using ether
petroleum ether 4:1 as eluent. l.R. (Neat) 1750 cm-1. Preparations 26-46 6, 8 - Disubstituted2 - oxabicyclo [3.2.1] octan - 3 ones
Table 2 summarises the preparation of the title compounds by the following methods:
A.To a stirred solution of the appropriate bicyclo [2.2.1] heptan - 2 - one in glacial acetic acid at 5 was added dropwise 6.12M peracetic acid.
B. As described in Method A with sodium acetate and water added.
The solutions obtained from methods A and B were slowly allowed to attain ambient temperature when stirring was continued for the time specified.
Excess peracid was destroyed by the addition of saturated sodium sulphite solution whilst maintaining the temperature below 20 . The acetic acid was removed in vacuo and the residue diluted with water, basified with 8% sodium bicarbonate solution and extracted with the solvent indicated. The combined organic extracts were washed, dried and evaporated. The product obtained was purified by crystallisation or by chromatography on silica gel. Table 2
Prep. Starting material Product Method Acetic Peracetic Sodium Water Time Extraction Chromatography Yield IR > C=0 m.p.
No. Z acid acid acetate vol. hr solvent solvent (g) cm-1 Z R Wt vol. vol. wt (ml) (g) (ml) (ml) (g) 26 # -COCH3 13.5 # A 70 40.5 - - 18 ethyl - 10.1 (CHBr3) 183-4 from acetate 1740 ethyl acetate -cyclohexane 27 # # 24 # A 200 50 - - 18 ethyl - 18.3 (CHBr3) 164-5 from acetate 1733 ethyl acetate -cyclohexane 28 # # 74.8 # B 460 204 102.5 187 24 ethyl ether 28 (CHBr3) 105.5-107 acetate 1728 29 # # 13.6 # B 160 51 24.9 16 30 ethyl - 5.7 (CHBr3) 104-5 from acetate 1730 119 iso propanol petroleum ether 30 # # 1 # B 10 4 1.3 1 20 dichloro- - 0.47 (CHBr3) 181-4 from methane 1738 ethyl acetate 31 # # 10 # B 40 28 12 16 21 ethyl 65::35 ether- 3.41 (CHBr3) 52 acetate petroleum 1730 ether 32 # CH3 5.2 # B 20 12.3 8.2 10 18 ethyl ether 2 (CHBr3) 48-9 from acetate 1730 ethanol 33 # # 2.4 # A 32 3.45 - - 24 ethyl - 0.95 (CHBr3) 82-3 from acetate 1730 chloroform petroleum ether 34 # # 9 # B 50 17.5 8.41 20 48 ethyl ether 3.21 (Neat) 3450, acetate 1740 36 # # 50 # B 750 140 60 60 48 ethyl - 22.3 (CHBr3) 111-112 from acetate 1780, methanol.
1736, 1710 purtner preparation for fapie 2
Prep Ketone No.
Acetic Peracetic IR Acid Acid Sodium Water > =0 Vol. Vol. Acetate Vol. Time Extraction Chromatography Yield cm-1 Z R Wt(g) Method (ml) (ml) Wt (g) (ml) hr Solvent Solvent (g) (CHBr3) m.p.
36 # -CH3 2.25 B 10 8.2 4.1 100 24 ethyl - 0.77 1730 122-4 acetate from ethyl acetate petrol ether 37 # # 14 B 100 59.1 25.5 40 25 ethyl 96::5 ether- 5.77 1730 82.5-83.5 acetate petroleum from ether petroleum ether 38 # -CH(CH3)2 3.3 B 26.7 12.4 5.3 10.7 24 ethyl - 1.28 1730 107-9 from acetate ethyl acetate petroleum ether 39 # # 5.0 A 25 11 - - 19 ethyl ether 1.45 1730 acetate 40 N3 # 40 B 200 59.1 31.9 100 67 ethyl - 11.4 1740 39-43 from acetate isopro panol 41 # # 10.5 B 50 26.9 11.6 20 24 ethyl ethyl acetate 2.4 1730 112 from acetate isopropanol 42 # # 10 B 64 24.2 13.1 26 20 ethyl 7:3 ether- 1.9 1730 74-5 from acetate petroleum ethyl acetate ether petroleum ether 43 # # 9.6 B 59 23.6 11.8 24 24 ether - 4.1 1738 93 from petroleum ether 44 # # 5.4 B 50 13.5 7.1 20 72 ether ether 2.4 1733 45 # # 5.64 B 40 9 9.2 17 24 ether 1: :1 ether- 1.0 1730 petroleum ether 46 # # 10 B 80 26.1 13.1 40 24 dichloro- 1:1 ether- 2.2 1740 methane petroleum ether Preparations 47-66 6, 8- Disubstituted -2- oxabicyclo [3.2.1] octan -3- ols
Table 3 summarises the preparation of the title compounds by the following procedure: Absolution of di-isobutyl aluminium hydride (2.02M in hexane) was added dropwise to a stirred
solution of the appropriate 2 - oxa - bicyclo [3.2.1] octan - 3 - one in the dry solvent specified at-78 under nitrogen. After the time specified methanol was carefully added and the mixture then allowed to attain room temperature.Filtration and evaporation in vacuo gave the product usually as an oil or foam.
Where necessary purification was effected by chromatography on silica gel.
Preparation 67 (+) - 3 - endo - Hydroxy - 2 - exo - (4 - morpholinyl) bicyclo [3.2.0] heptan -6- one
A mixture of (1α, 2α, 4α, 6α). 3 - oxatricyclo [4, 2, 0, 02,4] octan - 7 - one (5.3 g) and morpholine (20 g) was allowed to stand at room temperature for 3 days.
The morpholine was removed in vacuo and the residue was chromatographed on silica gel using ether-methanol (17:3) as eluent to give the title compound as a solid (5.58 g). Crystallisation from ethyl acetate gave material of m.p. 102-104.5 .
Table 3
Prep. Starting material Dibal Solvent Time Methanol Chromatography Yield IR No.
Z 8 (wt (ml) Vol. I (ml) ~ (g) ~ (ml) 47 u ethane ethyl aeetate 1715 48 CN CU2O 10 31.4 1 ,2-dimethoxy- 500 3 500 - 10.0 (Neat) u ethane 3400 (br) 49 CH3NN- -CH2 4.25 19.1 Dichloromethane 120 2 120 - 4.25 (CHBr,) 3540' 3174 i 50 oiCh CH2 0.5 1.4 Dichloromethane 20 0.5 20 - 0.45 (CHBr3) CH3 10;0 51 OCH;;D -CH2 5.86 17.1 1.2-Dimethoxy- 75 2 75 - 5.98 (CHBr3l - ethane 3420, CM),, 1720 52 ,,,"N- CH 4.13 22.3 t,2-Dimethoxy- 200 1.5 200 - 4.2 (Neat) u ethane 3400.
1720 53 O-CH2CH2/ CH2D 1.48 5.94 1,2-Dimethoxy- 100 2 100 - 1.42 (Neat) CiA%C112 ~ ethane 1720 54 BuOCONH- j Czar 2.27 8 Dichloromethane 80 1.2 100 - 2.3 Further Preparations for Table 3
Starting Material Dibal Solvent Prep Iwt VO' r Time Methanol Chromatography Yield IR(em-') No. Z R (sl (ml) Vol (hr) Vol (ml) Solvent (g) I(ml) 56 Or=N- -CM2Ci 3.0 9.0 dichloromethane 70 2 130 - 2.57 (CH8r,) 1715 In 0 CN -CH(CH,), 6.0 16.55 dichloromethane 12\0 0.75 130 N 57, -CH(CH,)2 6.0 16.55 dichioromethane 120 0.75 130 - 5.6 ICHBr,I 3520, 1716 58 5 CH2CH2 e 1.5 11.2 1,2 dimethoxyethane 75 2 75 - 13 3500(br), CII 1715 59 CFOCH2CHCH2 0 0 O 2.9 13.5 1,2 dimethoxyethane 75 2.5 150 - 2.7 1720 -C 3440, ocII2CHCN2 1720 60 Nr -CII 6.5 30 1.2 dimethoxyethane 300 1.5 300 - 6.0 (CHSr,l 3580, 2100.
HO 1720 61 H0 > C ~ CH2t 1.74 6.9 dichloromethane 40 2.5 60 - 1.65 (c3H5;) 1710 62 01 -CII 2.6 8A dichloromethane 50 1.0 50 - 2.6 (c3H58%r;l C)(( 1710 63 J1 -CH 3.9 as dichloromethane 60 2.5 165 - 4.1 (34Ne3a0t) 1720 In ,CN CH(CHE 2.2 6.5 dichloromethane 50 2.5 75 - 2.0 (Neat) 0 N - 3420.
1720 65 CN -CH(CH,L 1.34 6 dichloromethane 60 2 60 - 1.34 (CHBr3) 1715 66 G -CM2CH2 1.9 7 dichloromethane 70 2 70 - 1.62 (Neat) 1720 Preparation 68 (3a 4A, , 5α 6aα) - (t)-hlexahydro - 5- hydroxy-4- (4 - morpholinyl) - 2H - cyclopenta - (b) furan - 2 - one (a) A solution of the product from Preparation 26 (8
g) in methanol (100 ml) containing conc. sulphuric
acid (10 ml) was heated under reflux for 5 hr. The
solution was cooled and made alkaline by the addi
tion of solid sodium bicarbonate. The resulting sus
pension was filtered and the residue washed with
chloroform (100 ml).The filtrate was evaporated and
the residue taken up in chloroform (100 ml). Filtra
tion and evaporation gave the title compound as a
solid which was recrystallised from isopropanol
(4.85 g) m.p. 146-8 .
(b) A solution of the product of Preparation 67 (0.5 g)
in dichloromethane (8 ml) containing sodium acetate
(0.58 g) was cooled ito-10 with stirring and perace
tic acid (0.44 ml, 6.1 M) was added dropwise over
about 1 min. stirring at t 10 was continued for a
further 10 min. when an excess of saturated sodium
sulphite solution was added. Adjustment of the pH
to 8 by solid sodium bicarbonate followed by extrac
tion with dichloromethane, drying (MgSO4), filtration
and concentration gave the title compounds as a
solid (0.2 g).
Preparation 69 (3a α, , 4@ 4/3, 5 Osa) - (+) - Hexahydro - 5- hydroxy- [N- methyl-N-(2-hydroxy-3-phenoxy-propyl) amino]-2H- cyclopenta (b) furan - 2 - one
A rapidly stirred solution of the productfrom Preparation 34 (2.04 g) in ethanol (30 ml) and 2N hydrochloric acid (10 ml) was hydrogenated over prereduced 10% palladium oxide on charcoal (0.35 g) at atmospheric pressure. The catalyst was filtered off and the filtrate evaporated. The residue was diluted with brine, neutralised with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The combined extracts were dried and concentrated. The material obtained was chromatographed on silica gel using 10% methanol in ether as eluentto yield the title compound as an oil (1.11 g) IR (Neat) 3400, 1765 cm-'.
Preparation 70 (3aα, 4ss, 5α, 6aα)- (#) - Hexahydro - 4 - (4 - mor- pholinyl) - 5 - (tetrahydro-2H- pyran - 2 - yl) oxy - 2H - cyclopenta (b) furan - 2 - one To a solution of the product from Preparation 68 (10 g) and 2,3 - dihydropyran (25 ml) in dioxan (300 ml) at 0 was added p - toluene - sulphonic acid monohydrate (8.83 g). The solution was gradually allowed to attain ambient temperature when stirring was continued for 3 hr. The solvent was evaporated in vacuo and the residue treated with 8% sodium bicarbonate solution (250 ml). Extraction with dichloromethane, drying and evaporation gave an oil.
The material was purified by column chromatogra phy on silica gel using 7:3 ether-methanol as eluent.
The title compound crystallised on standing and was recrystallised from isopropanol - cyclohexane (8.63 g) m.p. 1034e.
Preparation 71 (3aα, 4ss, 5α, 6aα)-(#)-Hexahydro-4-[N-methyl- N-[3-phenoxy-2- [(tetrahydro - 2K- pyran - 2 - yl) oxy propyl] amino] -5 - (tetrahydro - 2K - pyran - 2 yl) oxy-2H- cyclopenta(b)furan - 2- one The title compound was prepared from the product of Preparation 69 according to the method of
Preparation 70. I.R. (Neat) 1770 cm-'.
Preparation 72 (3aα, 4ss, 5α, 6aα)-(#)-Hexahydro-4- (4 - morpholinyl) - 2K- cyclopenta(b)furan - 2
The title compound was prepared from the product of Preparation 26 (538 mg) in dry 1,2 dimethoxyethane (35 ml) by the method of Preparations 47-66. Purification by chromatography on silica gel using 4:1 ethyl acetate-methanol as eluent gave a solid (305 mg). Re-crystallisation from ethyl acetate-methanol gave the title compound, m.p.
136-7 .
Preparation 73 (3aα, 4ss, 5α, 6aα)-(#)-Hexahydro-4-(4-mor- pholinyl) - 5 - (tetrahydro - 2H- pyran - 2 - yl) oxy - 2H - cyclopenta(b)furan - 2 - ol
A solution of the product of Preparation 70 (6.3 g) in dry 1,2-dimethoxyethane (300 ml) was treated with a hexane solution of di-isobutylaluminium hydride and methanol according to the method of Preparations 47-66. Charcoal (2 g) was then added, the suspension allowed to attain room temperature and stirred for a further 1 hr. The mixture was filtered and the filtrate evaporated. The residue was treated with dichloromethane (250 ml), the solution dried, filtered and evaporated in vacuo to yield an oil (6.25 g), which slowly crystallised. Recrystallisation from ethyl acetate-petroleum ether gave the title compound m.p. 126-6 .
Preparation 74 3aα, 4/3, 54 6aa) - (H - Kexahydro - 4 - [N - methyl
N-[3-phenoxy-2-[(tetrahydro-2H-pyran-2-yl) oxy prop VI] amino]-5- (tetrahydro -2K - pyran -2- yl) oxy - 2K - cyclopenta(b)furan - 2 - ol
The title compound was prepared from the product of Preparation 71 according to the method of
Preparation 73. Purification was by chromatography on silica gel using 96:4 ether-methanol as eluent. IR (Neat)3410 cm-1.
Preparation 75 (+) - 1- (methylamino) - 2 - heptanol
To a stirred solution of m-chloroperbenzoic acid (100 g) in dichloromethane (900 ml) was added a solution of 1-heptene (44.8 g) in dichloromethane (50 ml) and the mixture stirred overnight at room temperature. The excess peracid was destroyed with 10% aqueous sodium sulphite solution, the organic layer separated, washed with 8% aqueous sodium bicar
bonate solution and dried. The solvent was evapo
rated in vacuo and the residue dissolved in ethanolic
methylamine (30% wlw, 340 ml), and stirred at room temperature for 48 hr. Evaporation of the solvent
gave an oil which was purified by distillation (b.p.
94-6 /2 mm) to give the title compound as a solid,
m.p. 40-3 .
Preparation 76 (3aα, 4ss, 5α, 6aα)-(#)-4-[N-(2-Hydroxyheptyl)-N- methylamino] - 3, 3a, 4, 6a - tetrahydro -2H- cyclopenta(b)furan - 2 - one
A mixture of (3aα, 6ss, 6aa) - 6 - bromo - 3, 3a, 6, 6a - tetrahydro - 2H - cyclopenta(b)furan - 2 - one (2.03
g) and 1 - methylamino - 2 - heptanol (3 g) in dry
acetonitrile (20 ml) was stirred at ambient temperature for 24 hr. The solvent was evaporated in vacuo and the residue chromatographed on silica gel. Elution with ether-methanol (19:1) increasing to (4:1) gave the title compound as an oil (1.95 g). IR (Neat) 3450, 1775 cm-1.
Preparation 77 (3aα, 4ss, 5α, 6aα)-(#)-4-[N-(2-Hydroxyheptyl)-N- methylamino] - 3, 3a, 4, 6a - tetrahydro - 2K- cyclopenta(b)furan - 2 - ol
To a stirred solution of the product of Preparation 76(1.95 g) in dry 1,2 - dimethoxyethane (50 ml) at 78 under nitrogen was added dropwise a hexane solution of di-isobutyl aluminium hydride (8.9 ml, 2.02 M). The solution was stirred for 1 hr and then treated with a further aliquot of di-isobutyl aluminium hydride (2.0 ml). After stirring for a further 1 hr methanol (150 ml) was carefully added and the mixture then allowed to attain room temperature. Filtration and evaporation gave the title compound as a gum (1.7 g). IR (Neat) 3400 cm-'.
Preparation 78 (3ao, 4ss, 5α, 6aα)-(#)-Hexahydro - 5- [[(1, 1 - dimethylethyl) dimethylsilyl] oxy] -4 - (4 - mor- pholinyl) - 2K- cyclopenta(b)furan - 2 - one
A mixture of Preparation 68 (454 mg), dimethyltertiary butyl silyl chloride (302 mg) and imidazole (340 mg) in dry dimethylformamide (3 ml) was stirred at room temperature for 20 h. Excess solvent was removed under high vacuum. The residual oil was treated with water (20 ml) and extracted with ether (3 x 50 ml). The organic phase was then dried (K2CO3) and evaporated to afford a solid (430 mg). The title compound was purified from petroleum ether (b.p.
60-80 ) as colourless platelets (320 mg) m.p.88-90 .
Preparation 79 (3aα, 4/3, 5α, 6aa) - (t) - Hexahydro - 5- [[(1, 1 - dimethylethyl) dimethylsilyl] oxy] -4- (4-morpholinyl) - 2H - cyclopenta(b)furan - 2
The title compound was prepared from the product of Preparation 78 (1.7 g) in dry dichloromethane (50 ml) by the method of Preparations 47-66. The product}1.61 g) was purified from isopropanol/cyclohexane as fine colourless platelets, m.p.88-89 .
Preparation 80 (3ao, 4α, 6aa) - (H - Tetrahydro - 4 - (4 - morpholinyl) - 2K - cyclopenta(b)furan - 2 - one
A solution of (3aa, 6a 6aa) - (+) - 6 - bromo tetrahydro - 2H - cyclopenta(b)furan - 2 - one (2.02 g)
in dry acetone (60 ml) containing morpholine (8 ml) was stirred at room temperature for 24 h. The hyd
robromide was filtered off and the solvent removed in vacuo. The residue was dissolved in dich
loromethane and the organic phase was extracted with water (3x) to remove the excess of morpholine.
The dichloromethane solution was washed with
brine, dried (MgSO4) and evaporated to give a solid.
The residue was triturated with ether to give an off
white solid which was purified from ethyl acetate
petroleum ether as tan microcrystals (1.43 g) m.p.
96-98 .
Preparation 81 (3aα, 4ss, 5α, 6aα)-(#)-Tetrahydro-4-(4-morpholinyl) -2H- cyclopenta(b)furan - 2- ol A solution of the product of Preparation 80 (3 g) in
dry dichloromethane (100 ml) was cooled to -70 under nitrogen. A solution of diisobutyl aluminium
hydride (Dibal) in hexane (1.0 molar, 30 ml) was
added dropwise with stirring. The reaction mixture was stirred at-70 for 1 h. Cold methanol (100 ml) was added cautiously at-70 and then the mixture was allowed to warm to room temperature, with further stirring for 1 h. The mixture was filtered (hyflo) and the solvents were removed in vacuo. The
residue was dissolved in dry dichloromethane and the solution was dried (MgSO4) and evaporated to give a solid (3.0 g).A portion (470 mg) was purified from ethyl acetate-petrol as a white solid (332 mg) m.p.100-103 .
Preparation 82 (3aα, 4α, 6aα)-(#)-Hexahydro-4-(4-morpholinyl) - 2H - cyclopenta(b)furan - 2 - one
A solution of the product of Preparation 80 (1 g) in ethyl acetate (30 ml) was hydrogenated over prereduced 5% rhodium on charcoal (250 mg) in ethyl acetate (20 ml), at atmospheric pressure for 30 min.
The catalyst and the solvent were removed and the residue in dichloromethane was washed with 8% sodium bicarbonate solution. The solvent was dried and evaporated to give a solid (583 mg, m.p. 59-61 ) which was purified from ether-light petroleum to give the title compound (380 mg) m.p. 65-67'.
Preparation 83 (3aα, 4α, 6aa) - (H - Nexahydro - 4 - (4 - morpholinyl) - 2H- cyclopenta(b)furan - 2 - ol
The title compound (2.2 g) was prepared from the product of Preparation 82 (2.11 g) in dichloromethane (75 ml) by the method of Preparations 47-66 I.R. (Neat) 3400 cm-'.
Preparation 84 (3aα, 4α, 5ss, 6aα)-(#)- Hexahydro-5-[(1,1'- biphenyl) - 4- yl] methoxy] -4 - (4 - morpholinyl) cyclopenta [b] furan -2- one
The product of Preparation 68 (1.85 g) was alky
lated with biphenylmethyl bromide (4.02 g) as
described for Examples 60-66 (Table 8) (Method B).
The title compound was obtained as a pale yellow
gum (1.87 g). A portion of the base was treated with
ethereal hydrogen chloride to give the salt which
was purified from ethyl acetate m.p. 231-2 .
Preparation 85 (3aα, 4α, 5ss, 6aα)-(#)- Hexahydro-5-[[(1,1'- biphenyl)-4-yl]methoxy]-4-(4-morpholinyl)
cyclopenta(b)furan-2-ol
The title compound (1.21 g) was prepared from the
product of Preparation 84 (1.47 g) in dich
loromethane (70 ml) by the method of Preparations 47-66 l.R. (CHBr3) 3580 cm-'.
Preparation 86 (l-8-anti-[N- Methyl-N-[3-phenoxy -2 [(tetrahydro - 2H - pyran -2- yl) oxy] propyl] amino] 6 - endo - (phenylmethoxy) -2- oxabicyclo [3,2,1] octan - 3 - one Dihydropyran (4.9 g) was added dropwise to a stir
red mixture of the product of Preparation 34 (Table
2) (2.4 g) and p-toluenesulphonic acid (1.11 g) in
dioxan (15 ml). After 1.5 hthe reaction mixture was
quenched with sodium bicarbonate solution,
extracted with ether (3 x 50 ml), dried (MgSO4) and
evaporated to give an oil. The product was
chromatographed on silica gel and elution with
ether: petroleum ether b.p. 40-60 4:1 gave the title compound as a yellow viscous oil (2.43 g). I.R.
(CHBr3) 1730 cm-1.
Preparation 87 (3aα, 4α, 6aα)-(#)- Tetrahydro - 4 - [N - methyl - N (phenylmethyl) amino] - 2H- cyclopenta [b] furan - 2 - one
A solution of (3aα, 6α, 6aα) - (+) - 6 - bromo tetrahydro - 2H - cyclopenta (b) furan - 2 - one (2.03 g) and N - methylbenzylamine (2.42 g) in acetone (40 ml) was stirred at ambient temperature for 3.5 days.
The reaction mixture was diluted with ether (50 ml) and filtered to remove the precipitated N - methyl- benzylamine hydrobromide. The solvent was removed and the residue in ether (60 ml) was washed with water (2 x 30 ml). The ethereal layer was extracted with 2N hydrochloric acid (2 x 30 ml) and the combined extracts washed with ether (2 x 30 ml). The aqueous acidic layer was cooled to 0 (icewater bath) and basified with concentrated ammonium hydroxide. The resultant aqueous mixture was extracted with ether (2 x 30 ml) and the organic phase washed with brine (30 ml). Drying (MgSO4) and removal of the solvent gave an oil (2.0 g). Chromatography on silica gel with ether as eluent gave the product as a pale yellow oil (1.65 g) which was purified from isopropanol to give the title compound as white crystals m.p. 52-52.5 .
Preparation 88 (3aα, 4α, 6aα)-(#)- Tetrahydro-4[N-methyl-N (phenylmethyl) amino] - 2H - cyclopenta (b) furan - 2 -ol
The title compound (10.25 g) was prepared from the product of Preparation 87 (10 g) in 1,2 dimethoxyethane (100 ml) by the method of Preparations 47-66.I.R. (CHBr3) 3580 cm-1.
Preparation 89 (3aα, 4α, 5ss 6aα)-(#)- Hexahydro-5-hydroxy-4- (1- piperidinylJ - 2H- cyclopenta (b) furan - 2 - one
The product of Preparation 28 (15.1 g) in water (60 ml), concentrated hydrochloric acid (60 ml) and ethanol (160 ml) was added to prehydrogenated 10% palladium oxide on charcoal (3.75 g) in ethanol (150 ml) and stirred under a hydrogen atmosphere until the theoretical volume of hydrogen had been taken up (1214 ml at 21 ). The mixture was filtered and the filtrate evaporated in vacuo. The residue was basified with 8% sodium bicarbonate solution and the solvent removed in vacuo. The residue was dried
by addition of anhydrous potassium carbonate and the resultant slurry washed with dichloromethane (6 x 100 ml). The combined washings were evaporated to give the title compound (9.64 g). A sample (223
mg) was purified from ethyl acetate:petroleum ether (b.p. 60-80') to give colourless prisms m.p.
106-106.5 (176 mg).
Preparation 90 (3aα, 4α, 5ss 6aα)-(#)- Hexahydro-4-(1- piperidinyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy] - 2H- cyclopenta (b) furan - 2 - one
Dihydropyran (15.1 g) was added to the product of
Preparation 89(10.1 g) and toluene - p - sulphonic
acid monohydrate (10.23 g) in dichloromethane (730
ml) at 0 and the mixture then stirred at 0 for 2.5 h.
The mixture was stirred at room temperature for 16
h, basified with 8% sodium bicarbonate solution (100
ml) and the basic layer extracted with dich
loromethane (2 x 100 ml). The combined organic
layers were dried (MgSO4) and evaporated in vacuo to give an oil (27.7 g). Chromatography on silica with methanol:ether3:17 as eluent gave the title compound as an orange oil (10.64 g). IR (CHBr3) 1760 cm1.
Preparation 91 (3aα, 4α, 5ss 6aα)-(#)- Hexahydro-4-(1 piperidinyl) - 5 - [(tetrahydro - 2K - pyran - 2 - yl) oxy] - 2K - cyclopenta (b) furan -2- ol The title compound (11.4 g) was prepared from the product of Preparation 90 (10.5 g) in dichloromethane (210 ml) by the method of Preparations 47-66, Table 3.IR (CHBr3) 3590,3380 cm-' Preparation 92 (-H -8 - anti - Amino -6 - endo - (phenylmethoxy) - 2 - oxabicyclo] 3, 2, 1] octan - 3 - one
Hydrazine hydrate (0.99 ml) was added dropwise to a stirred solution of the product of Preparation 35 (7 g) in ethanol (75 ml) and the mixture heated under reflux for 9 h. The mixture was concentrated and the residue chromatographed on silica gel using 4:1 ether-methanol as eluent to give the title compound as a viscous oil (3.8 g). I.R. (CHBr3) 3380 cm-1.
Preparation 93 (i)-6-endo-8-anti-N-[3-Oxo-6- (phenylmethoxy) - 2 - oxabicyclo [3, 2, 1] oct- 8 - yl] carbamic acid, (1, 1- dimethylethyl) ester 2-[1, 1 - Dimethylethoxy) carbonyloxyamino] -2- phenyl acetonitrile (0.142 g) was added dropwise to a stirred mixture of the product of Preparation 92 (0.13 g), dioxan (4 ml), water (2 ml) and triethylamine (0.08 g), and after the addition stirring was continued at room temperature for 22 h. The solution was treated with saturated ammonium chloride solution (50
ml) and extracted with dichloromethane (2 x 60 ml).
The combined organic extracts were dried (MgSO4) and concentrated, and the residue purified by chromatography on silica gel using 85:15 etherpetroleum ether as eluent to give the title compound as white needles (0.12 g), m.p. 102-3 .
Preparation 94 (1α, 2ss, 3ss, 5ss)-(#)-N-[2-(2-Oxoethyl)-3- (phenylmethoxyJ - 5- [(tetrahydro - 2K-pyran - 2 - ylJ oxy] cyclopentyl] carbamic acid, (1, 1dimethylethyl) ester
Dihydropyran (1.37 g) was added dropwise to a
solution of the product of Preparation 54 (1.9 g) and
pyridinium p-toluene sulphonate (2.05 g) in dry dich
loromethane (100 ml) and the solution stirred at
room temperature for 1 h. The mixture was treated
with 8% aqueous sodium bicarbonate solution (100
ml) and extracted with dichloromethane. The com
bined organic extracts were washed with brine, dried (MgSO4) and concentrated.The product was
purified by chromatography on silica gel using 3:2
ether-petroleum ether as eluent to give the title compound as a solid (1.7 g), m.p. 50-54
Preparations 95-98 7- (2, 3, 5- TrisubstitutedJ cyclopentyl - 5- heptenoic acid, methyl esters
Table 4 summarises the preparation of the title compounds from 2H-cyclopenta(b)furan - 2 - ols by the following method:
Dry (4-carboxybutyl)triphenyl phosphonium bromide was added to a stirred solution of potassium tert-butoxide in dry tetrahydrofuran at room temperature under nitrogen and stirring continued for 15-30 mins. A solution of the appropriate 2Hcyclopenta(b)furan - 2 - owl in drytetrahydrofuran was added dropwise and stirring continued at room temperature for the time specified. Ice was added to the reaction mixture followed by 2M NaHSO4 solution until pH 6 was attained.The mixture was then extracted with ethyl acetate or dichloromethane and the combined extracts washed and dried. The solution was treated with diazomethane in ether. The solvents were removed in vacuo and the product purified by chromatography on silica gel using ether as eluent.
Table 4
Starting Material Product Phos. THF Prep Salt KO1Bu Total Time Extraction Yield IR (Neat) No Z R Wit(9) R R' Wt (g) Wt (g) Vol (ml) (hr) Solvent Wt (g) cm~' 95 Ç0I rȯo t 2.27 t H 8.19 4.14 130 2 Ethyl acetate 2.2 3400,1735 a0CH2CNCN2 In 96 0WN- -SiMe::Bu 18.9 -SiMe,'Bu H 48.9 24.73 400 48 Dichloromethane 9.03 3505,1740 n 97 0WN- -5iMe,'Bu 18.9 H -SiMez'Bu 48.9 24.73 400 48 Dichloromethane 5.16 3460, 1740 N- t 10.63 H H 45A5 23 313 1.5 Dichlol=methlme 6 354 80, Preparation 99 [1α(Z), 2ss, 3α, 5α;]-(#)-7-[5-Acetoxy-2-(4- morpholinyl) - 3 - [(tetrahydro - 2K- pyran - 2 - ylJ oxy] cyclopentylg - 5- heptenoic acid, methyl ester 4-Carboxybutyltriphenyl phosphonium bromide (175.4 g) was added to potassium tert-butoxide (88.7 g) in dry tetrahydrofuran (500 ml). After 20 minutes the product of Preparation 73 (62 g) in dry tetrahydrofuran (200 ml) was added and stirring maintained for4 hr. Water (100 ml) was added and the solvents were removed in vacuo. The residue was treated with ice/water (200 ml) and carefully adjusted to pH 7 by adding sodium bisulphate solution. The mixture was extracted with dichloromethane. The aqueous phase was brought to pH 6 using sodium bisulphite and re-extracted with dichloromethane.This process was repeated twice more. The combined extracts were treated with excess ethereal diazomethane dried, and evaporated.
The residue was dissolved in acetic anhydride (200 ml) and pyridine (100 ml) and left at room temperature overnight. The solvents were removed in vacuo and the residue in dichloromethanewas washed with 8% sodium bicarbonate solution. The organic layer was dried (MgSO4) and evaporated. The residue was purified by chromatography on silica eluting with 9:1 ether-petroleum ether to give the title compound as a pale yellow oil (49.2 g).
T.L.C. Silica-ether Rf 0.36
I.R. (CHBr3) 1725 cm-1
Preparation 100 [1α(Z), 2ss, 3α, 5α]-(#)-7-[5-Acetoxy-2-(4- morpholinyl)-3- [(tetrahydro - 2H - pyran - 2 - vi) oxy] cyclopentyl] - 5- heptenoic acid, methyl ester
To a solution of sodium methoxide (404 mg) in dry methanol (50 ml) was added a solution of the product of Preparation 99 (2.3 g) in dry methanol (50 ml). The mixture was allowed to stand at room temperature for 4 hr then poured into saturated ammonium chloride and rapidly extracted with dichloromethane (4 x 50 ml). The combined organic phases were washed with brine, dried and evaporated under reduced pressure to afford an oil. The product was subjected to column chromatography on silica gel.Eluting with 95:5 ether-methanol gave the title compound as an oil (1.83 g). IR (Neat) 3530, 3460, 1740 cm-1.
Preparation 101 [1α(Z), 2ss, 3α, 5α]-(#)-7-[2-azido-3-hydroxy-5- (phenylmethoxy)cyclopentyl] - 5- heptenoic acid, methyl ester
4-Carboxybutyl triphenyl phosphonium bromide (21.1 g) was added to a solution of potassium tertbutoxide (10.66 g) in drytetrahydrofuran (300 ml) under dry nitrogen. The resultant deep orange suspension was stirred at room temperature for 30 min and then treated with a solution of the product of
Preparation 60 Table 3 (6.0 g) in dry tetrahydrofuran (50 ml) over 1 min. A slight exothermic reaction was noted at this stage.The reaction mixture was diluted with water (300 ml) after 10 min and the resultant red solution extracted with ether (2 x 150 ml). The ether
layers were extracted with 2N sodium hydroxide (150 ml) and the combined aqueous phases acidified with concentrated hydrochloric acid. The resultant aqueous mixture was extracted with ether (4 x 150
ml) and the combined ether layers washed with
brine (150 ml) and dried (MgSO4). Removal of the solvent gave the crude acid which was dissolved in
methanol (20 ml) and treated with ethereal
diazomethane to yield the crude methyl ester as an
oil (10.0 g). Purification by chromatography on silica
using ether: petroleum ether (40-60 ) 1:1 as eluent
gave the title compound as a pale yellow oil (3.0 g).
I.R. (Neat) 3450,2100, 1736cm-1.
Preparation 102 [1a(Z), 2ss, 3α, Sa] - (i) - 7-[2- [1, 1 -Dimethylethoxy) carbonylamino]-5-(phenylmethoxy)-3-[(tet rahydro - 2K- pyran - 2 - yl) oxy] cyclopentyl] - 5heptenoic acid, methyl ester.
4- Carboxybutyltriphenylphosphonium bromide
(2.58 g) was added to a solution of potassium tert
butoxide (1.3 g) in dry tetrahydrofuran (30 ml) under
nitrogen and stirring continued for 20 mins. A solution of the product of Preparation 94 (0.84 g) in tet
rahydrofuran (20 ml) was then added dropwise.
After 40 min. the mixture was treated with saturated
ammonium chloride solution until pH 6 and then
extracted with dichloromethane (3 x 100 ml). The combined organic extracts were treated with
ethereal diazomethane and then concentrated. The product was purified by column chromatography on silica gel using 3:2 ether-petroleum ether as eluent to give the title compound as a solid (0.59 g). m.p.
59-61 .
Preparation 103
1 - Azido - 4 - (bromomethyl)benzene
A mixture of p-azidotoluene (3.9 g),
N-bromosuccinimide (5.5 g) and azobisisobutyronitrile (1.0 g) in carbon tetrachloride (30 ml) was heated under reflux in the dark under nitrogen for 18 h. The reaction mixture was allowed to cool to room temperature and the solvent was removed in vacuo. The residue was dissolved in ether (50 ml) and filtered.
Evaporation of solvent gave an oil (6.5 g) which was chromatographed on silica gel (200 g, Merck 7734).
Elution with petroleum ether (b.p. 40-60 ) gave the title compound as an oil (2.37 g). I.R. (Neat) 2120 cm-' .
Preparation 104 2 - (4 - Bromomethyl)phenyl - 1,3 - dioxolane SBromomethyl benzaldehyde (1.0 g), ethylene glycol (0.42 ml) and p-toluenesulphonic acid (catalytic amount) in benzene (100 ml) were heated under reflux overnight. The mixture was poured into 8% sodium bicarbonate solution (200 ml) and extracted into ether (2 x 100 ml). The combined extracts were washed with sodium sulphite solution (200 ml), dried (MgSO4), filtered and evaporated to afford a solid. Purification from ether-petroleum ether gave the title compound as yellow needles (0.767 g) m.p.
41-42 .
Preparation 105 [1a(Z), 2/3, 3α, Sa] - (H - 7- [3 - [(1, 1 - Dimethylethyl) dimethylsilyl] oxy-5- methxymethoxy-2- {4- morpholinyl) cyclopentyl] - 5- heptenoic acid, methyl ester
The product of Preparation 96 (1.02 g) in N, N - di isopropylethylamine (2 ml) was treated dropwise with chloromethylmethyl ether (0.29 ml) and stirred for 10 hr. The reaction mixture was quenched with aqueous sodium bicarbonate (30 ml) and extracted with ethyl acetate (2 x 30 ml). The combined organic extracts were washed with brine, dried (MgSO4) and concentrated to afford a mobile liquid (1.06 g).The product was purified by chromatography on silica eluting with 30% petroleum ether in ethyl acetate to give the title compound as a pale yellow oil (0.9 g).
I.R. (CHBr3) 1730 cm-1.
Preparation 106 [1α(Z), 2ss, 3α, 5α] - (#) - 7 - [3 - [(1,1 - Dimethylethyl) dimethylsllyl) oxy] - 5- (2 - methoxyethoxy) methoxy - 2 - (4 - morpholinyl)cyclopentyl] - 5 - heptenoic acid, methyl ester
The title compound (1.33 g) was prepared from the product of Preparation 96(1.32 g) and methox- yethoxymethylchloride (1.02 ml) by the procedure described for Preparation 105. Chromatography on silica eluting with 4:1 ether-petroleum ether gave the title compound as a yellow oil. l.R. (CHBr3) 1728 cm-1.
Preparation 107 [1α(Z), 2ss, 3α, 5α]-(#)- 7-[(2-[N-Methyl-N- (phenylmethyl) amino] - 5- (phenylmethoxy) - 3 [[tetrahydro-2H-pyran-2-yl]oxy]cyclopentyl]-5heptenoic acid methyl ester
Dry p-toluenesulphonic acid (0.95 g) was added to a cold (-10") mixture of the product of ExampleS, Table 5(1.5 g) and dihydropyran (0.84 g) in dichloromethane (30 ml) which was then stirred for 3.5 h at-10 . A further quantity of dihydropyran (1 ml) was added and the mixture stirred for a further 0.5 h.It was then poured into 8% sodium bicarbonate (100 ml), extracted with dichloromethane (3 x 75 ml), dried (MgSO4) and evaporated, affording a dark oil (3.5 g). Chromatography on silica gel using ether and petroleum ether (b.p. 40-60 ) 1:1 as eluent gave the title compound (1.73 g). I.R. (CHBr3) 1725 cm-1
Preparation 108 (1α, 2ss, 3α, 5α)-(#)-2-(Methylamino)-5- (phenylmethoxy)-3- [(tetrahydro - - pyran -2- yl) oxy] cyclopentane heptanoic acid, methyl ester
The product of Preparation 107 (0.9 g) in ethyl acetate (60 ml) was hydrogenated over pre-reduced 10% palladium on charcoal (150 mg) for 20 h.The catalyst and the solvent were removed and the residue was purified by chromatography on silica eluting with ether-methanol 1:2 to give the title compound as a viscous oil (0.348 g). I.R. (CHBr3) 1728 cm-1
Preparation 109 [1α, 2ss, 3α, 5α]-(#)-2-[N-(2-Hydroxyethyl)-N- methylamino - S - (phenyl - methoxy) - 3 - [(tetrahydro - 2H - pyran -2- yl] oxy] cyclopentane heptanoic acid, methyl ester
A solution of the product of Preparation 108 (2.85 g) in toluene (30 ml) was treated with ethylene oxide
(25% in toluene, 70 ml).The mixture was heated (90 ) in an autoclave overnight and evaporated under
reduced pressure to afford an oil (3.5 g). Column
chromatography on silica gel with methanol as
eluent gave the title compound (2.5 g) as a colour
less oil. l.R. (Neat) 3460, 1740 cm-'.
Preparation 110 [1α, 2ss, 3α, 5α]-(#)-2-[N-(2-Chloroacetylox- yethyl)-N-methylamino]-5-(phenylmethoxy)-3 [[tetrahydro - 2H pyran - 2 - yl] oxy] cyclopentane heptanoic acid, methyl ester
Chloroacetyl chloride (0.55 ml) was added to a
cold (-10") stirred solution of the product of Prepara
tion 109(2.25 g) and pyridine (1.11 ml) in dich
loromethane (25 ml). After 45 min the mixture was
poured into 8% sodium bicarbonate solution (100
ml) and extracted into dichloromethane (3 x 50 ml).
The combined extracts were dried (MgSO4), filtered
and evaporated to afford an oil (3.05 g). Column
chromatography on silica gel with 20% petroleum
ether (40-60 ) in ether as eluent gave the title compound (2.03 g). I.R. (Neat) 1763, 1740 cm-'.
Preparation 111 [1α, 2ss(2#), 3α, 5α]-(#)-2-[N-(2-Hydroxyheptyl)- N - methylamino] - 5 - (phenylmethoxy) - 3 [[tetrahydro - 2K - pyran - 2 - yl] oxy] cyclopentane heptanoic acid, methyl ester
A mixture of the product of Preparation 108 (0.2 g) and 1,2 - epoxy- heptane (0.153 g) in dry methanol
(10 ml) was heated under reflux for 20 h. The solvent was evaporated to afford an oil. Column chromatography on silica eluting with petroleum ether@ether (2:3) gave the title compound as an oil (0.18 g). I.R.
(Neat) 3470, 1745 cm-1.
Preparation 112 [1α, 2ss (2#), 3α, 5α]-(#)-2-[N-(2- Chloroacetyloxyheptyl)-N-methylamino]-5 (phenylmethoxy) - 3 - [[tetrahydro - 2H - pyran - 2 - yl] oxy] cyclopentane heptanoic acid, methyl ester.
Chloroacetyl chloride (0.63 ml) was added dropwise to a cold (-10 ) solution of the product of Prep
aration 111 (3 g) and pyridine (1.26 g) in dry dich
loromethane (30 ml). The mixture was stirred for 1.5
h then poured into 8% sodium bicarbonate solution and extracted with dichloromethane (3 x 100 ml).
The combined extracts were washed with sodium acetate solution (100 ml), dried (MgSO4) and concentrated to afford a dark red oil. The product was purified by chromatography on silica. Elution with ether: petroleum 3:7 gave the title compound as a yellow oil (2.24 g). I.R. (Neat) 1760 (sh.), 1740 cm-1.
Preparation 113 [1a (Z), 2/3 3a] - (#) - 7- [[3-[1, 1-Dimethylethyl) dimethylsilyl]oxy]- 2 - (4 - morpholinyl)- 5 - oxocyclopenfryl] - 5- heptenoic acid, methyl ester.
To a stirred solution of the product of Preparation 97 (882 mg) and dicyclohexyl carbodiimide (1.648 g) in dimethylsulphoxide (20 ml) was added pyridinium trifluoroacetate (578 mg). Stirring was maintained for 1 h, the suspension poured into water (100 ml) and extracted into ether (3 x 50 ml). The combined ethereal layers were filtered (to remove dicyclohexyl urea), washed with water (2 x 50 ml), washed with brine (50 ml), dried (MgSO4) and evaporated. The residual solid was triturated with ether/petroleum ether 40-60 (25 ml, 1:1) and filtered. The filtrate was evaporated to afford the title compound as a colourless semi-soiid (0.81 g). T.l.c. (Silica) Rf. 0.37 (ether).
Preparation 114 [1α,(Z), 2ss, 3α, 5α]-(#)-7-[2-(N-methyl-N-(2,2, 2 - trichloroethoxycarbonyl) amino] - 5- (phenyl- methoxy) - 3 - [(tetrahydro - 2H- pyran - 2 - yl) oxy] cyclopentyl] - 5 - heptenoic acid, methyl ester
The title compound (2.4 g) was prepared from the
product of Preparation 107 (4.3 g) using the method
described for Example 39.Chromatography on
silica, eluting with ether-petroleum ether (1:1), gave
the product as an oil. l.R. (Neat) 1735 (sh.), 1720 cm-1
Preparation 115 [7a (Z), 2ss, 3α, Sa] -(H - 7 - [2 - Methylamino) - 5 (phenylmethoxy) -3- [(tetrahydro - 2H -pyran-2-yl)
oxy] cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (3.2 g) was prepared from the
product of Preparation 114(10.0 g) using the method described for Example 40. Chromatography on
silica, eluting with ether - methanol (4:1), gave the
product as an oil. l.R. (Neat) 1738 cm-1.
Preparation 116 [1α(Z), 2ss, 3α, 5α]-(#)-7-[2-[N-Methyl-N-[2- (phenylmethoxy) ethyl] amino] -5 - (phenylmethoxy) -3-[(tetrahydro-2H-pyran-2-yloxy]cyclopentyl - 5- heptenoic acid, methyl ester
A mixture of the product of Preparation 115(1 g), 2
- (phenylmethoxy) - 3 ethyl bromide (0.54 g), potas
sium carbonate (0.47 g) and sodium iodide (0.37 g) in
acetonitrile (30 ml) was heated under reflux for 20 hr.
The mixture was poured into saturated ammonium
chloride solution and extracted with dichloromethane. The combined extracts were dried and evaporated to give the title compound as a brown oil (1.48 g). T.l.c. (Silica) Rf. 0.72 and 0.64 (ether methanol, 9:1).
Preparation 117 [1α(Z), 2ss, 3α, 5α]-(#)-7-[2-(N-Methyl-N-(4 - phenoxybutyl)amino]-5-(phenylmethoxy)-3 [(tetrahydro - 2K-pyran - 2 - yl) oxy] cyclopentyl]-5- heptenoic acid, methyl ester
The title compound (1.37 g) was prepared from the product of Preparation 115(1 g) and4-phenoxybutyl bromide (0.57 g) using the procedure described for
Preparation 116.T.l.c. (Silica) Rf. 0.69 (ethermethanol, 9:1)
Preparation 118 [1α(Z), 2ss, 3α, 5α]-(#)-7-[2-[N-Methyl-N-(5- phenylpentyl)amino]-5-(phenylmethoxy)-3-[(tetrahydro - 2H - pyran -2-yl) oxy] cyclopentyl] - 5 - heptenoic acid, methyl ester
The title compound (1.5 g) was prepared from the product of Preparation 115 (1 g) and 5-phenylpentyl bromide (0.61 g) using the procedure described for
Preparation 116.T.l.c. (Silica) Rf. 0.47 (ethermethanol, 95:5)
Preparation 119 (3aα, 4α, 6aα)-(#)-Tetrahydro-4-[N-methyl-N-[2 - [(tetrahydro - 2H - pyran -2- yl) oxy] heptyl] amino] - 2H- cyclopenta [b] furan - 2 - one
The title compound (1.0 g) was prepared from the product of Preparation 76 (2.2 g) using the method of
Preparation 107. Chromatography on silica, eluting with ether-petroleum ether (4:1), gave the product as an oil. I.R. (Neat) 1775 cm-'.
Preparation 120 (3aα,4α,6aα)-(#)-Tetrahydro-4-[N-methyl-N-[2 -[(tetrahydro-2H-pyran-2-yl)oxy]heptyl]amino] -2H-cyclopenta[b]furan-2-ol.
The title compound (2.1 g) was prepared from the product of Preparation 119(2.1 g) in dry dichloromethane (50 ml) by the method of Preparations 47-66. I.R. (Neat) 3420 cm-1.
Preparation 121 [1α(Z),2,3,5α]-(#)-7-[5-Hydroxy-2-[N-methyl- N - [2 - [(tetrahydro - 2H-pyran-2-yl) oxy] heptylamino)-3-cyclopenten-1-yl]-5-heptenoic acid, methyl ester.
The title compound (10.83 g) was prepared from the product of Preparation 120 (18 g) using the procedure described for Examples 95-98 Table 4.
Chromatography on silica, eluting with etherpetroleum ether (9:1),then ether, gave the product as an oil. I.R. (Neat) 3540, 1740 cm-1.
Examples 1-15 (-H - 7 - (2,3,5 - TrisubstitutedJ cyclopentyl - 5- heptenoic acid, methyl esters
Table 5 summarises the preparation of the title compounds from 2 - oxabicyclo [3,2,1] octan - 3 - ols by the method of Preparations 95-98. The reaction mixture was then worked up by one of the following methods:
A. The reaction mixture was treated with methanol followed by concentrated sulphuric acid until acidic and left to stir at room temperature for the time specified. After removal of solvents in vacuo the residue was basified by the addition of 8% aqueous sodium bicarbonate solution and/or solid sodium bicarbonate. Extraction with ethyl acetate, followed by washing of the combined extracts, drying and evaporation gave an oil. Purification was by chromatography on silica gel or alumina.
B. Isolation of the crude ester was as described in
Method A. The resulting oil was treated with acetic anhydride and pyridine and stirred at room temperature for the time specified. The solvent was removed in vacuo and the product purified by chromatography on silica gel.
C. Ice was added to the reaction mixture followed by the careful addition of 2N hydrochloric acid until neutral. The mixture was then poured into water, extracted with ethyl acetate, washed with brine, dried and concentrated. The crude material was dissolved in dichloromethane and treated with freshly distilled diazomethane in ether. The solution was concentrated and the product purified by chromatography on silica gel.
Table 5(i)
Ex. Starting Material Product No.
Phos THF salt KOtBu Total Method MeOH cH2SO4 Ac2O Py. Chromatography wt (Wt) vol. Time of Vol. Vol. Time Vol. Vol. Time System Yield I.R. (CHBr3) Tic (silica Z R Wt(g) R' (g) (g) (ml) hr work-up (ml) (ml) hr (ml) (ml) hr Silica (g) cm-1 Rf(solvent) 1 # # 5 -COCH3 28.53 14.04 170 20 B 300 20 72 120 50 3 9::1 ether 3.1 (Neat) 1736 0.46 ether petroleum ether 2 # # 10.9 -COCH3 21.08 10.65 250 3 B 300 25 18 50 50 16 ether 9.95 1750 (sh) 0.57 ether 1720 3 # # 1.8 H 6 3 40 1.5 A 150 20 16 - - - 94:6 ether- 1.05 3520, 1728 0.3 (94::6 methanol ether (Alumina) petroleum ether) (Alumina) 4 # # 3 H 7.3 3.68 175 2 A 150 25 90 - - - ethyl 3.11 3600, 1730 0.35 (ethyl acetate acetate) 5 # # 6.44 H 11.52 5.9 150 3 A 200 6 18 - - - ether 5 3580 (sh), 0.48 (ether) 3520, 1729 6 # -CH3 4.2 H 26.6 13.4 250 2 A 200 25 24 - - - ether 3.7 3580-3500 0.3 (ether) 1725 Table (ii)
Ex. Starting Material Product No.
Phos THF salt KOtBu Total Method MeOH cH2SO4 Ac2O Py. Chromatography wt (Wt) vol. Time of Vol. Vol. Time Vol. Vol. Time System Yield I.R. (CHBr3) Tic (silica Z R Wt(g) R' (g) (g) (ml) hr work-up (ml) (ml) hr (ml) (ml) hr Silica (g) cm-1 Rf(solvent) 7 # # 2.3 H 11.16 5.62 120 2 C - - - - - - ether 1.42 (Neat)3540, 0.3(ether) 3450, 1733 8 # -CH3 5.03 -COCH3 37.6 18.54 300 3 B 300 20 18 30 30 18 ether 5.95 0.63(ether) 9 # # 2.57 H 7.98 4.04 120 3 A 100 15 18 - - - 97::3 ethyl 0.94 3540, 1728 0.37(94:6 acetate- ether methanol methanol) 10 # -CH(CH3)2 5.2 -COCH3 17 8.6 130 1.2 B 100 20 18 24 40 3 ether 3.23 1725 0.39(ether) 11 # # 6.3 -COCH3 16.8 8.5 210 3 B 200 40 18 50 100 3 3:2 ethyl] 5.65 1725 0.48(3:2 ethyl acetate- acetate petroleum petroleum ether ether 12 # # 2.8 -COCH3 9.5 4.74 80 1.5 B 100 10 20 25 50 3 3::2 ether- 2.2 1723 0.74(ether) petroleum ether 13 # # 3.96 H 12.6 6.4 100 1 A 75 15 16 - - - 4:1 ether- 1.97 3580, 3540, 0.5 (95.5 ether petroleum- 1730 methanol) ether 14 # -CH(CH3)2 1.34 H 6.6 3.34 110 0.5 A 36 4 18 - - - 5:1 ether- 0.84 3520, 1728 0.44(5:1 methanol ether methanol15 # # 1.6 H 6.4 3.24 150 0.5 A 36 4 18 - - - 5: ether- 1.03 3540, 1730 0.55(5:1 methanol ether methanol) EXAMPLES 16-19
Deacetylation of 7 - (3 or 5 - acetoxy - 2,5 or 2,3 disubstituted cyclopentyl) - 5 - heptenoic acid, methy esters
Table 6 summarises the deacetylation of the title compounds by the following method.
To a solution of the appropriate acetate in methanol at room temperature was added either sodium methoxide or potassium carbonate. The mixture was stirred for the time specified then poured into saturated ammonium chloride solution and extracted with dichloromethane. The combined extracts were dried (MgSO4), filtered and concentrated, and the product purified by short path column chromatography on silica gel.
Table 6
Starting Material Et No. MeOH NaOMe iGCO, Time Chromatog Yield IR Tlcsilics Z R Wt(g) Vol. Wt Wt(g) (hr) raphySystem (g) (CHBJ Rf (ml) (g) cm (solvent) 16 r\ 152 200 3.4 93:7ether- 15.68 3520. 0.63 (9:1 CLN- -CH, 4.7 10 0.66 4.5 methanol 1725 ethyl acetate 17 0 No -cH 4.7 10 0.66 - 4.5 acetone 3.95 3520. 0.11 1725 (ether) 1 a CH(cH3), 6.8 140 - 3A2 4 95:5 ether- 52 (Neat) OA5 methanol 3450. (95:5 1730 ether methanol) 19 - -C1' 2.1 40 0.72 - 5 95:5 ether- 1.2 3600. 0.43 methanol 3500, (95:5 1725 ether methanol) Example 20 [1α(Z),2ss,3α,5α]-(#)-7-[3,5-Dihydroxy-2-(4- morpholinylJ cyclopentylg - 5- heptenoic acid, methyl ester
The product of Preparation 72 (2.3 g) was treated with (4 - carboxybutyl) triphenyl phosphonium bromide (17.7 g) according to the method of Preparations 95-98.The reaction mixture was then worked up as follows:
The reaction mixture was treated with methanol (100 mt) followed by saturated ethereal HCI (75 ml) and the suspension allowed to stand at 5 for 2 days.
Water was added and the mixture carefully made alkaline by the addition of solid NaHCO3. Extraction with ethyl acetate, followed by washing of the combined extracts drying and evaporation gave an oil which was purified by chromatography on silica gel, using 85:15 ethyl acetate - methanol as eluent, to yield the title compound (1.82 g), IR (Neat) 3420, 1735 cm-1.
Analysis Found: C, 62.1; H, 9.3; N, 4.2; C17H29NOs requires: C, 62.4; H, 8.9; N, 4.3%.
Example 21 [1α(E),2ss,3α,5α]-(#)-7-[3-HYdroxy-2-(4-mor- pholinyl) - 5- lphenylmethoxyJ cyclopentyl] - 5- heptenoic acid, methyl ester
A solution of the product of Example 16 (2.5 g), thiophenol (7.5 ml) and azobisisobutyronitrile (1.5 g) in benzene (10 ml) was heated at 70 for 6 hr. The reaction mixture was applied directly to a silica gel column and eluted with diethyl ether to remove the thiophenol. Elution with 30% methanol in diethyl ether gave the crude trans ester (2.46 g). The product was further subjected to column chromatography on silica gel whereupon elution with 3% methanol in ethergave the title compound as an oil (1.48 g). IR (Neat) 3450, 1730cm-1.
Analysis Found: C, 68.4; H, 8.3; N, 3.3; C24H3sNOs requires: C, 69.0; H, 8.5; N, 3.4%.
Example 22 [1α(Z),2ss,3α,5α]-(#)-7-[5-Acetoxy-3-hydroxy-2 - (4- morpholinylJ cyclopentyl] - 5- heptenoic acid, methy ester
A solution of the product from Preparation 99 (2.51 g) in acetone (100 ml) containing 2N hydrochloric acid (25 ml) was allowed to stand at room temperature for 5 hr. The mixture was poured into 8% aqueous sodium bicarbonate (200 ml) and extracted into dichloromethane (4 x 50 ml). The combined extracts were washed with brine, dried and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with 3% methanol in ether to give the title compound as an oil (1.95g). IR (Neat) 3450, 1738 cm-1.
Analysis Found: C, 62.09; H, 8.93; N, 3.76; C,9H31NO6 requires: C, 61.76; H, 8.46; N, 3.79%.
Example 23 [1a(Z), 2ss, 3α,5α] - H)- 7-[3-Kydroxy-S- (phenylmethoxy)-2-(1-piperidinyl)cyclopentyl]5- heptenoic acid, methyl ester
Sodium methoxide (0.889 g) was added to the product of Example 2 (7.56 g) in dry methanol (25 ml) at - 10 . The reaction mixture was stirred at room temperature for 20 hr. Sodium methoxide (0.889 g) was added and the stirring continued for a further 6 hr. The mixture was poured into 8% aqueous sodium bicarbonate solution (100 ml) and water (50 ml) and extracted with ether (3 x 135 ml). The dried organiclayers were evaporated in vacuo.Silica gel chromatography on the residue with acetone as eluent gave the title compound as an oil (5.1 g), IR (Neat) 3500,3440,1738 cm-t.
Analysis Found: C, 71.83; H, 8.82; N, 3.41; C2sH37NO4 requires: C, 72.25; H, 8.98; N, 3.37%.
Example 24 [1α(Z),2ss,3α,5α]-(#)-7-[3-Acetoxy-2-(N-benzyl - N- methylamino) - 5- methoxy - cyclopentyl - 5- heptenoic acid, methyl ester
The product of Example 6 (25.25 g) was dissolved in a mixture of dry pyridine (20 ml) and Az2O (20 ml) and the resultant solution allowed to stand at room temperature for 18 hr. Removal of the solventin vacuo and chromatography of the residue on silica gel using ether as eluent gave the title compound as an oil (5.7 g). IR (Neat) 1737 cm-1.
Analysis Found: C, 69.07; H, 8.38; N, 3.30; C24H3sNOs requires: C, 69.03; H, 8.45; N, 3.35% Example 25 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3-Hydroxy-2-[N- methyl-N-(2-phenylethyl)amino]-5-(phenylmethoxy)cyclopentyl] - 5 - heptenoic acid, monohydrate
The product from Example 7 (1.0 g) was dissolved in a solution of potassium hydroxide (360 mg) and methanol (30 ml) and the solution allowed to stand at room temperature for 2 days. The methanol was then removed in vacuo and the residue dissolved in water (20 ml). The resultant solution was neutralised carefully with 2N hydrochloric acid and then extracted with ethyl acetate (3 x40 ml). The combined organic phases were washed with brine (20 ml), dried and the solvent removed to yield a viscous oil.Chromatography on silica gel using 4:1 ethyl acetate-methanol as eluent gave the title compound as an oil (513 mg). IR (Neat) 1720 cm-'.
Analysis Found: C, 71.94; H, 8.57; N, 2.87;
C28H37NO4H2O requires: C, 71.61; H, 8.37; N, 2.98% Example 26 [lalZ 2a 3s 50 -( - 7- C3, 5- Dihydroxy-2 - [N - methyl - N - (2 - hydroxy - 3 - phenoxy - propyl) amino]cyclopentyl] - 5- heptenoic acid, methyl ester
2N Hydrochloric acid (15 ml) was added dropwise to a solution of the product of Preparation 95 (2.01 g) in acetone (15 ml) at room temperature. After 20 mins the solution was neutralised with aqueous sodium bicarbonate, diluted with brine, extracted with ethyl acetate, dried and concentrated to give a viscous liquid. The crude material was purified by column chromatography on silica gel eluting with 5% methanol in ether to yield the title compound as a viscous oil (0.81 g), IR (Neat) 3400, 1736cm-1.
Analysis Found: C 65.41; H, 8.87; N, 3.32; C23H3sNO6 requires: C,65.53; H, 8.37; N, 3.32%
Example 27 [lalZI, 2W 50;1-(rl- 7- [5- Hydroxy-2- [N- (2 - hydroxyheptyl) - N - methylamino]-3- cyclopenten
1- yl] - 5 - heptenoic acid, methyl ester
Dry (4-carboxybutyl) triphenyl phosphonium
bromide (8.4 g) was added to a stirred solution of potassium tertbutoxide (4.23 g) in dry tetrahydrofuran (50 ml) at room temperature under nitrogen and stirring continued for 30 mins. A solution of the product of Preparation 77 (1.7 g) in dry tetrahydrofuran (20 ml) wad added dropwise and stirring continued at room temperature for 30 mins. The reaction mixture was treated with methanol (150 ml) followed by concentrated sulphuric acid until acidic and then stirred at room temperature for 18 hr.The mixture was concentrated in vacuo and the residue treated with water (100 ml) and extracted into ether (3 x 50 ml).
The acidic aqueous layer was basified with 8% aqueous sodium bicarbonate solution and extracted with ethyl acetate (3 x 60 ml). The combined organic extracts were dried, filtered and evaporated.
The crude product was treated with acetic anhydride (10 ml) and left to stand at ambient temperature for 18 hr. Evaporation in vacuo gave a residue which was chromatographed on silica gel using ether as eluent. The diacetate, isolated as an oil (1.6 g), was dissolved in dry methanol (25 ml) and treated with anydrous potassium carbonate (1 g). After stirring for 18 hr. at room temperature the reaction mixture was diluted with water (50 ml) and extracted with ether (3 x 50 ml). The combined extracts were washed, dried and evaporated and the residue chromatographed on silica gel. Elution with 9:1 ether-methanol gave the title compound as an oil (1.13 g). IR (Neat) 3420, 1740 cm-1.
Analysis Found: C, 68.37; H, 10.27; N, 3.82; C2,H37NO4 requires: C, 68.63: H, 10.15: N,3.81%
Example 28 [1α(Z), 2ss, 3α, 5α]-(#)-7-[2-Amino-3-hydroxy-5 - (phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
a) The product of Preparation 101(1 g) in tetrahydrofuran (10 ml) was treated sequentially with zinc dust (2.0 g) and 1 M potassium dihydrogen phosphate (2.0 ml) and the resultant slurry stirred rapidly for 1 hr. A second aliquot of 1 M potassium dihydrogen phosphate (2.0 ml) was then added and the reaction stirred for a further 2 hr and then filtered.
The filtrate was diluted with ether (25 ml) and extracted with 2N hydrochloric acid (3 x 15 ml). The combined acidic layers were washed with ether (20 ml) and then basified with concentrated ammonia solution at 0 . The resultant basic solution was extracted with dichioromethane (3 x 20 ml) and the combined organic phases washed with brine (2 x 15 ml) and dried (MgSO4). Removal of the solvent gave the product as a colourless oil (300 mg). IR (CHBr3) 3680,3500, 1728 cm-1.
Analysis Found: C, 68.4; H, 9.0; N, 4.2 C2tH31 NO4 requires: C, 68.7; H, 8.9; N, 4.O'/o b) Trifluoro acetic acid (1 ml) was added dropwise to the product of Preparation 102 (0.323 g) stirred at -5 . After 10 min. the mixture was treated with 8%
sodium bicarbonate solution until pH 7, followed by
extracted with dichloromethane (2 x 50 ml). The
combined organic extracts were washed (8%.
NaHCO3), dried (MgSOi) and concentrated. The pro
duct was purified by chromatography on silica gel
using 1:1 ether-petroleum ether as eluent to give the
title compound as a viscous oil (0.122 g).
Example 29 [1α(Z), 2ss, 3α, 5α]-(#)-7-[2-(Hexahydro-1,4- oxazepin -4- yl) -3- hydroxy - S - (phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
The product of Example 28 (1.0 g), 1 - chloro - 3 - (2 - chloroethoxy) propane (452 mg) and sodium bicarbonate (484 mg) in dry methanol (5 ml) were heated in an autoclave at 125 for 18 hr. The mixture was filtered and the solvent removed in vacuo to give an oil (1.44 g), which was chromatographed on silica.
Elution with methanol/ether 1:9 gave the title compound as a straw coloured oil (400 mg).
Analysis Found: C, 69.7; H, 8.4; N, 3.45;
C25H37NO5 requires: C, 69.6; H, 8.6; N, 3.25%
IR (CHBr3) 3550, 1730 cm-1.
Example 30 [la(ZI 28 3p 5n] -(-tl- 7- [3- Hydroxy-2- (4 - morpholinyl)-5-(phenylmethoxy)cyclopentyl]-5heptenoic acid
To a stirred solution of potassium hydroxide (1.25 g) in methanol (10 ml) was added a solution of the product of Example 16 (766 mg) in methanol (10 mg). The resultant solution was stirred for 1 hr. then allowed to stand overnight. The solvent was removed by evaporation under reduced pressure and the residue dissolved in water (7 ml).
Hydrochloric acid (5N) was added until the solution attained pH 7. The solution was extracted with dichloromethane (5 x 10 ml). The combined organic extracts were washed with brine, dried (sodium sulphate) and evaporated under reduced pressure to afford a foam (625 mg). The product was subjected to short path column chromatography on silica gel
(50 g). Eluting with 12% methanol in ether gave the title compound as a glass (383 mg). IR (CHBr3) 3600, 1720 cm-1.
Analysis Found: C, 67.8; H, 8.3; N, 3.2; C23H33NOs requires: C, 68.5; H, 8.2; N, 3.5%
Example 31 [1α(Z), 2ss, 3α, 5α]-(#)-7-[1-(4-Butyl-4-hydroxy) piperidinyl] - 3 - hydroxy - 5- (phenylmethoxy) cyc @opentyl] - 5- heptenoic acid, methyl ester, hydrochloride
The title compound base (0.98 g) was prepared from the product of Preparation 61 (Table 3) (1.65 g) by the method described for Examples 1-15, Table 5.
A sample of the base was dissolved in ether and treated with ethereal hydrogen chloride. The resulting oil was purified from ethyl acedtate to give the title compound as a white solid m.p. 132-132.5 .
Analysis Found: C, 66.3; H, 9.1; N, 2.7; C2aH45NO,HCl requires: C, 66.45; H, 8.85; N, 2.7%
Example 32 [1α(Z), 2ss, 3α, 5α]-(#)-7-[5-Hydroxy-2-[N- methyl - N-(phenylmethyl) amino] - 3 - cyclopentenyl] - 5 - heptenoic acid, methyl ester
The title compound (8.0 g) was prepared from the
product of Preparation 88 (10.2 g) by the method
described for Examples 1-15 (Method A). The reaction mixture was chromatographed on silica eluting with ether. A portion was subjected to molecular dis
tillation b.p.148 at 0.05 mm Hg.
Analysis Found: C, 73.05; H, 8.6; N,4.1; C21H2aNO2 requires: C, 73.4; H, 8.5; N,4.1% Example 33 [1α(Z), 2α, 5ss]-(#)-7-[2-Hydroxy-5-(4-mor- pholinylJ - 3 - cyclopenten - 1- yl] - 5- heptenoic acid,
methyl ester
The title compound (4.55 g) was prepared from the product of Preparation 81(4.6 g) the method described for Examples 1-15. Method A. The reaction mixture was chromatographed on silica eluting initially with ethyl acetate and then 9:1 ethyl acetatemethanol m.p. 37-40 .
Analysis Found: C, 66.6; H, 9.0; N, 4.6;
C17H27NO4 requires: C, 66.0; H, 8.8; N, 4.5%
Example 34 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3-[[(1.1'-Biphenyl)-4- yl] methoxy] - 5- hydroxy - 2 - (4 - morpholinyl) cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (1.04 g) was prepared from the product of Preparation 85(1.16 g) by the method described for Examples 1-15. Method A. The reaction mixture was chromatographed on silica eluting with ethyl acetate. A portion was purified from ether as needles m.p. 91-91.5 .
Analysis Found: C, 73.25; H, 8.05; N, 2.8; C2tH,eNO, requires: C, 73.0; H, 8.0; N, 2.85%
Example 35 [1α(Z), 2α, 5ss]-(#)-7-[2-Hydroxy-5-(4-mor- pholinyl) cyclopentyl] - 5- heptenoic acid, methyl ester, hydrochloride
The title compound base was prepared from the product of Preparation 83 (2.13 g) by the method described for Examples 1-15, Method A. After removal of the solvents in vacuo the residue in water (150 ml) was extracted with ethyl acetate (2 x 100 ml). The combined organic extracts were back- extracted with 2N sulphuric acid. The combined acidic aqueous layers were basified with solid sodium bicarbonate and extracted with ethyl acetate (3 x 100 ml).The combined organic extracts were dried and evaporated to give an oil which was purified by chromatography on silica, eluting initially with ethyl acetate and then 19:1 ethyl acetate-methanol (2.06 g). A portion (800 mg) was converted into the hydrochloride salt (800 mg) which was purified from methanol-ethyl acetate to give the title compound (695 mg) m.p. 141-143 .
Analysis Found: C, 58.55; H, 9.1; N, 4.0; Ct,H29NO4HCI requires: C, 58.7; H, 8.7; N, 4.0%
Example 36 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3,5-Dihydroxy-2-[N- methyl - N - (2- phenylethyl) amino] cyclopentyl] -5 - heptenoic acid, methyl ester
The title compound (385 mg) was prepared from the product of Preparation 58 (Table 3) (1.2 g) by the
method of Preparations 95-98. The reaction mixture was treated with methanolic hydrogen chloride (50
ml) and the resultant suspension stirred for 19 hr. at
ambient temperature. The methanolic mixture was
neutralised with 8% sodium bicarbonate solution
and treated with ethyl acetate (100 ml) and brine (100
ml). The phases were separated and the aqueous
solution extracted with ethyl acetate (2 x 50 ml). The
combined organic extracts were washed with brine
(100 ml), dried (MgSO4) and the solvent removed to
yield an oil (6.25 g). Chromatography on silica elut
ing with methanol-ethyl acetate 3:17 gave the title
compound as a pale yellow oil.
Analysis Found: C, 70.3; H, 8.7; N, 3.7;
C22H33NO4 requires: C, 70.4; H, 8.6; N, 3.7%
IR(CHBr3) 3590,3530, 1725cm-1.
Example 37 [1α[Z), 2ss, 3α, 5α]-(#)-7-[3-Hydroxy-2-[N- methyl - N- (2 - hydroxy - 3 - phenoxypropyl) amino] - 5- (phenylmethoxy) - cyclopentyl] - 5- heptenoic acid, methyl ester
The product of Preparation 59 (Table 3) (2.6 g) was subjected to a Wittig reaction as described for Preparations 95-98 (Table 4)
2N Hydrochloric acid (10 ml) was added to a solution of the product (2.17 g) in acetone (15 ml) at room temperature. After 3 hr the solution was neutralised with aqueous sodium bicarbonate, extracted with ether, dried (Na2SO4) and concentrated to give a gum (2.1 g). The crude material was purified by chromatography on silica gel eluting with 4% methanol in either to yield the title compound a pale yellow viscous oil (1.07 g). IR (CHBr3) 3590, 1725 cm-' .
Analysis Found: C, 70.07; H, 8.27; N, 2.63;
C30H41NO6 requires: C, 70.42; H, 8.08; N, 2.74%
Example 38 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3-Acetoxy-2-[N- methyl - N- (phenylmethyl) amino] -S - (phenyl- methoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
The product of Example 5 (Table 5) (8.04 g) was treated with acetic anhydride (35 ml) and pyridine (35 ml). The resulting solution was stirred for 24 hr at ambient temperature. The solvent was removed to yield an oil. This crude product was chromatographed on silica gel (500 g) with ether as eluent giving the title compound as a yellow oil (7.01 g). Distillation at 1800/0.1 mm Hg gave the title compound. IR (CHBr3) 1723cm-1.
Example 39 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3-Acetoxy-2-[N- methyl - N- 2,2,2- trichloroethoxycarbonyl) amino] - 5- (phenyimethoxy) cyciopentyl] -5- heptenoic acid, methyl ester
The product of Example 38 (6.2 g) was added to trichloroethylchloroformate (2.2 ml). The reaction mixture was heated with stirring at 90 for 1.25 hr after which time potassium carbonate (2.5 g) was added and the stirring continued for a further 1 hr.
The excess trichloroethylchloroformate was removed by distillation (80 /1 mm Hg). The product was diluted with ether (50 ml) and filtered. Removal of the solvent gave the crude product which was chromatographed on silica gel (850 g) with etherpetroleum ether 2:1 as eluent. The product was recovered as a yellow oil (6.47 g). Distillation at 1700/0.05 mm Hg gave the title compound. IR (Neat) 1733, cm-'.
Example 40 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3-Acetoxy-2- (methylamino)-5-(phenyl-methoxy)cyclopentyl] 5 - heptenoic acid, methyl ester
Potassium dihydrogen phosphate solution (1 M, 30 ml) was added dropwise to a cold (0 ) stirred mixture of the product of Example 39 (4.0 g) and activated zinc dust (15.0 g) in tetrahydrofuran (50 ml). The mixture was stirred at room temperature for 7 hr. then poured into 8% sodium bicarbonate solution (400 ml), filtered and extracted into ethyl acetate (3 x 200 ml). The combined extracts were dried (MgSO4), filtered and evaporated to afford an oil (2.7 g).
Chromatography on silica gel (50 g) with 20% methanol in ether as the eluent gave the title compound (2.05 g). IR (CHBr3) 1725 cm-'.
Analysis Found: C, 68.2; H, 8.3; N, 3.5; C23H33NOs requires; C, 68.5; H, 8.2; N, 3.5%
Example 41 [lalZJ, 2P, 3s 501] -(-)-7 -[3- Hyd/oxy-2- (methylamino) -S - (phenylmethoxy) cyclopentyl] - 5 - heptenoic acid, methyl ester
Potassium carbonate (1.74 g) was added to a stirred solution of the product of Example 40 (4.24 g) in dry methanol (50 ml). The mixture was stirred for 4.5 hr, poured into ammonium chloride solution (125 ml) and extracted dichloromethane (3 x 60 ml). The combined extracts were dried (MgSO4), filtered and evaporated to afford the title compound as a viscous oil (4.0 g). IR(CHBr3) 3680, 3510, 1730 cm-1.
TIc (Silica) Rf 0.16 (4:1 Ether-methanol).
Example 42 [1α(Z), 2ss, 3α,5α]-(#)-7-[2-(N-Heptyl-N- methylamino) - 3 - hydroxy -5 - (phenylmethoxy) cyclopentylg - 5 - heptenoic acid, methyl ester
A mixture of bromoheptane (0.605 g), potassium carbonate (0.627 g), sodium iodide (0.55 g) and the product of Example 41 (1.1 g) in acetonitrile (55 ml) was heated under reflux for 24 hr. The suspension was diluted with ethyl acetate (50 ml), filtered and evaporated to afford a viscous oil (1.73 g).
Chromatography on silica gel (50 g) with 10% methanol in ether as the eluent gave the title compound (0.73 g). IR (CHBr3) 3540, 1730 cm-1.
Analysis Found: C, 73.3; H, 10.0; N, 3.1; C2aH4tNO4 requires: C, 73.2; H, 9.9; N, 3.1%
Example 43 [1α(Z),2ss,3α,5α]-(#)-7-[2-N-(2-butoxyethyl)-N -methylamino]-3-hydroxy-5-(phenylmethoxy cyclopentyl] - 5- heptenoic acid, methyl ester
A mixture of 2 - bromoethylbutyl ether (0.48 g!, potassium carbonate (0.5 g), sodium iodide (0.4 g) and the product of Example 41 (0.87 g) in acetonitrile (30 ml) was heated under refluxfor 20 hr. The mixture was poured into a saturated solution of ammonium chloride (75 ml) and extracted into dichloromethane (3 x 50 ml). The combined extracts were dried (MgSO4), filtered and evaporated to afford a viscous oil (1.2 g). Chromatography on silica gel with 1:9 methanol - ether as the eluent gave the title compound (0.74 g).IR (CHBr3) 3540-3360, 1730 cm-'.
Analysis Found: C, 70.0; H, 9.8; N, 3.2; C27H43NOs requires: C, 70.2; H, 9.4; N, 3.00/0 Example 44 [1α(E),2ss,3α,5α] - (H -7- [3 - Hydroxy 5- (phenylmethoxy) - 2 - (1- piperidinyl) cyclopentyl]-5- heptenoic acid, methyl ester
A solution of thiophenol (2 ml), azobisisobutyronitrile (0.4 g) and the product of Example 23 (1.27 g) in benzene (6 ml) was maintained at 65 . for 4 hr. The benzene was removed and the product was isolated directly by chromatography on silica eluting firstly with ether and then with acetone containing triethylamine (1%).The crude product was purified by chromatography on silica eluting with acetone containing triethylamine (1%) to give the title com pound as a yellow oil (0.9 g). IR (CHBr3) 3520, 1724 cm-1.
Analysis Found: C, 71.9; H, 9.3; N, 3.4;
C25H37NO4 requires: C, 72.2; H, 9.0; N, 3.35% Example 45 [1α(Z),2ss,3α,5α]-(#)-7-[3-Acetoxy-2-(4-mor- pholinyl) - 5- {1- phenylethoxy) cyclopentyl] - 5
heptenoic acid, methyl ester
To a stirred solution of potassium t - butoxide (4.0
g) in dry tetrahydrofuran (50 ml) under nitrogen was
added 4 - carboxybutyl triphenyl phosphonium
bromide (7.98 g). The dark red suspension was stir
red for 30 min whereupon a solution of the product
of Preparation 56, Table 3 (2 g) in dry tetrahydrofu
ran (20 ml) was added. After 2 hr excess ethereal
hydrogen chloride (100 ml) was added and the mix
ture evaporated under reduced pressure (finally at 2
mm).The residue was dissolved in dichloromethane
(200 ml) and treated with excess ethereal
diazomethane. Acetic acid was added cautiously to
decompose unreacted diazoalkane. The solution was
washed with 8% sodium bicarbonate (100 ml) and
the phases separated. The aqueous layer was
washed with dichloromethane (150 ml). The com
bined organic extracts were dried (MgSO4) and
evaporated. The residue was taken up in acetic
anhydride (25 ml) and pyridine (50 ml), left over
night and then evaporated in vacuo (2 mm). The
crude product was treated with 8% sodium bicarbo
nate (100 ml) and extracted into dichloromethane (4
x 75 ml). The combined organic layers were dried (MgSO4) and evaporated. The residual oil was
purified by chromatography on silica. Eluting with
ether/petroleum ether 4:1 gave the title compound
as a colourless oil (2.34 g).IR (CHBr3) 1726 cm-'.
Analysis Found: C, 68.1; H, 8.3; N, 3.0; C27H39NO6 requires: C, 68.5; H, 8.3; N, 3.00/0 Example 46 [1α(Z),2ss,3α,5]α-(#)-7-[3-Hydroxy-2-(4-morpholinyl) - S - (1- phenylethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
To a stirred solution of the product of Example 45
(2.2 g) in anhydrous methanol (25 ml) was added dry
potassium carbonate (770 mg). After 4 h the suspen
sion was poured into saturated ammonium chloride
(100 ml) and extracted with dichloromethane (4 x 50
ml). The combined extracts were dried (MgSO4) and
evaporated. The residual oil was purified by
chromatography on silica. Eluting with 4% methanol
in ether gave the title compound (1.6 g) as a straw
coloured oil.
Analysis Found: C, 69.0; H, 8.5; N, 3.2; C2sH37NOs requires: C, 69.6; H, 8.6; N, 3.3% I.R. (CHBr3) 3520, 1730cm-1.
Example 47 [1α(Z),2ss,3α,5α] - (t)- 7-[2- (2,6- trans - Dimethyl - 4 - morphollnyl) -3- hydroxy - 5 - (phenylmethoxy)
cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound was isolated from the experi
ment described in Example 13 Table 5. Chromatog
raphy of the crude reaction product on silica as
described gave the title compound as a brown oil
(135 mg). l.R. (CHBr3) 3540, cm-'.
TIc (Silica) Rf 0.59 (95:5 Ether- methanol)
Examples 48-73 7 - (3- Kydroxy -2,5 - disubstituted) cyclopentyl - 5- heptenoic acid, methyl ester
Tables 7-9 summarise the preparation of the title compounds from 7 - (5 - hydroxy - 2,3 - disubstituted) - cyclopentyl - 5 - heptenoic acid, methyl esters by the following methods:
A. Withoutcharacterisation ofthe 7- (2,3,5- trisubstituted) cyclopentyl - 5 - heptenoic acid, methy esters
1. To a cold (0") stirred solution of the appropriate alcohol and halide* in dry dimethylformamide under nitrogen was added sodium hydride (80%) dispersion in oil). After2-2 h the mixture was poured into saturated ammonium chloride solution and extracted with ether. The combined extracts were dried, filtered and evaporated.The residual oil was dissolved in methanol and conc. sulphuric acid carefully added. The solution was allowed to stand for 1 h at room temperature, poured in 8% sodium bicarbonate solution and extracted into ether. The combined ethereal layers were washed with brine, dried (over MgSO4) and concentrated. The product was purified by short path column chromatography on silica gel.
2. The procedure is essentally as described under Al except that the crude reaction mixture is poured into methanol and conc. sulphuric acid carefully added.
3. The procedure is essentially as described under A.2 except that 5N HCI is used instead of c.
H2SO4.
4. The procedure is essentially as described under A.1 except that methanolic HCI is used.
*Where a more reactive halide than the one com
mercially available is required it is synthesised i.e.
RX + NaY # RY. This is indicated in the Table.
B. With isolation ofthe 7- (2,3,5- trisubstituted) cyclopentyl - 5- heptenoic acid, methyl ester
To a cold (0") stirred solutation of the appropriate alcohol and halide in dry dimethylformamide under
nitrogen was added either sodium hydride (80% dis
persion in oil) or potassium tert - butoxide. After 1 h
at 0" and 0.5-1.5 h at room temperature the mixture
was poured into saturated ammonium chloride solu
tion and extracted with ether. The combined extracts
were dried, filtered and evaporated. The residual oil
was purified by column chromatography on silica
gel.
C. Deprotection ofthe 7- (2,3,5- trisubstituted)
cyclopentyl - 5- heptenoic acid, methyl esters
The prostanoids are then deprotected by one of the following methods:
1. A solution of the prostanoid in methanol at room temperature was treated with ethereal HCI. After 0.5
h h the solvent was removed in vacuo and the residue
dissolved in dichloromethane and washed with 8%
aqueous sodium bicarbonate solution. The com
bined organic extracts were dried, filtered and con
centrated. The residue was purified by column
chromatography on silica gel.
2. A solution of the prostanoid in methanol at
room temperature was treated with methanolic sul
phuric acid. After 0.5-1 h the solution was poured
into 8% aqueous sodium bicarbonate solution with
the remaining work-up as described in procedure C.l. Table 7 (i)
Halide DMF NaH MeOH cH2SO4 Chromatography Yield I.R. (CHBr3) Tlc (silica) Ex. Alcohol Method Total Wt Vol. Vol. System (g) Rf (solvent) ** No. Wt (g) Vol. (g) (ml) (ml) (ether-methanol) cm-1 R X Wt(g) (ml) 48 2.46 # Br* 4.49 A3 55 0.9 100 100 96:4 1.10 1725 0.27 (5NHCl) 49 1.64 # Br 5.92 A2 15 0.72 100 10 96:4 0.87 3540, 1728 0.27 50 2.5 # Br 5.9 A1 30 0.73 67.5 7.5 95:5 2.0# 359-3520, 0.23 1730, 1700 51 2.47 # Br 5.83 A1 20 0.72 22.5 2.5 97:3 1.6 3530, 1728 0.37 52 0.5 # Br 0.3 A1 7 0.146 13.5 1.5 97::3 0.175 1730 0.37 53 2.47 # Br 6.31 A1 20 0.72 22.5 2.5 97:3 1.69 3540,1729 0.35 Table 7 (ii)
Halide DMF NaH MeOH cH2SO4 Chromatography Yield I.R. (CHBr3) Tlc (silica) Ex. Alcohol Method Total Wt Vol. Vol. System (g) Rf (solvent) ** No. Wt (g) Vol. (g) (ml) (ml) (ether-methanol) cm-1 R X Wt(g) (ml) 54 2.47 # Br 6.31 A1 20 0.72 22.5 2.5 97:3 1.61 3530, 1730 0.42 55 2.47 # Br 4.8 A1 20 0.72 22.5 2.5 97:3 1.66 3540(br), 0.36 1730 56 2.47 # Br 6.31 A1 20 0.72 22.5 2.5 97:3 1.55 3570, 3540, 0.31 1728 57 2.46 -(CH2)4CH3 I 5.91 A4 20 0.72 20 - 95:5 0.91 3520, 1730 0.36 58 2.46 # Br 3.84 A1 20 0.72 30 1.5 95::5 1.87 3600, 3540, 0.33 1730 59 2.47 # Br 5.93 A1 20 0.72 22.5 2.5 97:3 0.97 3590, 3500, 0.46 1730 * Sodium iodide (2-7g) was first added to the bromide in D.M.F.
# The isolated product is the aldehyde
** Rf values were determined in the solvent system used for column chromatography Table 8
Alcohol Halide NaY DMF Ex. Wt. (g) Wt Total NaH Chromatography Yield (g) I.R.(CHBr3) Tlc (silcia) Rf (ether) No. (g) Vol. Wt System R X Wt(g) (ml.) (g) 60 2.47 # Cl 5.61 Y=Br 25 0.9 1:1 ether- 2.01 1730 0.52 3.72 petroleum ether 61 2.2 # Br 7.84 - 20 0.9 9:1 ether- 1.2 2250, 1730 0.35 methanol 62 2.46 # Cl 5.6 Y=I 30 0.72 Ether 2.0 1730 0.39 3.6 63 2.46 # Br 4.82 - 30 0.72 Ether 2.2 1730 0.39 64 2.46 # Cl 5.87 Y=I 30 1 Ether 3.0 1730 0.36 4.5 65 2.46 -CH2-CH=CH2 Br 2.9 - 20 0::72 Ether 2.1 1740 0.33 66 2.46 -CH2CH2CH2Ph I 5.9 - 20 0.72 Ether 1.12 1740 0.38 Table 9
Starting Material Method MeOH Ether/HCl cH2SO4 Chromatography System Yield I.R. (CHBr3) Tlc silica Ex. Vol. Vol. (ml) Vol. (ml) (ether-methanol) (g) Rf 5% methanol in No. (ml) cm-1 ether R Wt(g) 67 # 2.6 C2 50 - 5 95:5 1.27 3450, 1730 0.26 68 # 2.1 C2 50 - 5 94:6 1.53 3500, 2250, 0.35 1730 69 # 2.0 C2 95 - 5 95:4 0.84 3520, 1725 0.35 70 # 2.2 C2 95 - 5 95:4 1.25 3530, 1728 0.32 71 # 3.0 C2 95 - 5 96:4 1.76 3540, 1728 0.3 72 -CH2-CH=CH2 2.1 C1 15 - 5 95:5 1.27 3540, 1728 0.26 73 # 1.1 C1 15 15 - 95::5 0.7 3520, 1728 0.31 Example 74 [1a(Z), 2/3, 3α Sa] - (#) 7- [5- [4 (Aminothiox
omethyl) phenylmethoxy] - 3 - hydroxy - 2 - (4 - morpholinyl) cyclopentylt - 5- heptenoic acid, methyl
ester
Dry tetrahydrofuran (10ml) was added dropwise to
a stirred mixture of sodium borohydride (0.623 g)
and sulphur (1.56 g). After 20 min the product of
Example 68 (1.8 g) in dry tetrahydrofuran (5 ml) was
added. The mixture was heated under reflux with
stirring for 4.5 h then poured into water (250 ml) and
extracted into dichloromethane (3 x 100 ml).The
combined extracts were dried (MgSO4) and evaporated to afford an oil (2.8 g). Column chromatogra
phy on silica gel with 1 oO/o methanol in ether as the eluent gave the title compound as a yellow oil (1.02 g). I.R. (CHBr3) 3580, 3490, 3375, 1730, 1600 cm-1.
Analysis Found: C, 62.3; H, 7.9; N, 5.8; C25H36N2SOs requires: C, 62.9; H, 7.6; N, 5.9 /O Example 75 [1α(Z), 2ss, 3α,5α]-(#)-7-[5-[4-Aminocarbonyl (pheny/methoxy) - 3 - hydroxy - 2 - (4 - morpholinyl) cyclopentyl] - 5 - heptenoic acid, methyl ester
A mixture of the product of Example 68 (1.0 g), potassium hydroxide (1.0 g) and tertiary butanol (20 ml) was heated under reflux for 45 min. The mixture was treated with excess methanolic hydrogen chloride at room temperature for 4h then evaporated. The residue was neutralised with 8% sodium bicarbonate solution and extracted into dichloromethane (3 x 50 ml).The combined extracts were dried (MgSO4) and filtered and evaporated to afford the title compound (0.9 g). I.R. (CHBr3) 3530, 3410,1730,1675,1620 cm-1.
Analysis Found: C, 64.7; H, 8.2; N, 5.6; C2tH26N2Oe requires C, 65.2; H, 7.9; N, 6.1%
Example 76 [1α(Z),2ss,3α,5α]-(#)-7-[5-[[1,1'-Biphenyl)-4- yl]methoxy]-3-hydroxy-2-(4-morpholinyl) cyclopentyl] - 5- heptenoic acid, methyl ester hydrochloride
To a cold (0 ) solution of the product of Preparation 100 (39) and biphenyl methyl bromide (5.419) in dry dimethylformamide (15 ml) was added potassium tertiary butoxide (2.65 g). The cooling bath was removed and the solution stirred for 2 hr during which time a fine white suspension developed. The mixture was poured into saturated ammonium chloride (100 ml) and extracted with ether (4 x 75 ml).
The combined organic extracts were washed successively with water (100 ml) and brine (100 ml), dried (MgSO4) and evaporated. The residue was purified by chromatography on silica eluting with ether to give the product as an oil (2.91 g). The oil was dissolved in 5% sulphuric acid in MeOH (100 ml) and was allowed to stand at room temperature for 1 hr. The solution was poured into 8% sodium bicarbonate (200 ml) and extracted with dichloromethane (4 x 75 ml). The combined extracts were dried (MgSO4) and evaporated. The residue (2.4 g) was purified by chromatography on silica eluting with 5% methanol in ether to give the title compound base as an oil (1.72 9).
A portion of the product (0.6 g) in ether (20 ml) was treated with an excess of ethereal hydrogen chloride. The oily product was purified from ethyl acetate-methanol to give the title compound as fine platelets (0.47 g) m.p. 127-128 .
Analysis Found: C, 67.7; H, 7.6; N, 2.7.
C30H39NOs . HCI requires: C, 68.0; H, 7.6; N, 2.6%
Example 77 [la(ZJ, 2P, 3ac 501] -()- 7-[5-[[ 1, 1'-B/phenyl)-4- ylg methoxy - 3 - hydroxy - 2 - (4 - morpholinyl) cyclopentyl - 5- heptenoic acid, hydrochloride
To a solution of the product of Example 76 in methanol (30 ml) was added aqueous potassium hydroxide solution (340 mg. in 10 ml). The mixture was allowed to stand at room temperature for 7 hr then evaporated in vacuo (0.5 mm). The residual oil was treated with water (20 ml), carefully acidified (to pH 7) with 2M sodium bisulphite and extracted with dichloromethane (2 x 30 ml). The pH of the aqueous layer was adjusted to pH 6 by dropwise addition of bisulphite. Several extractions with dichloromethane (4 x 50 ml) were made during this operation.The combined organic layers were dried (MgSO4) and evaporated to afford a pale pink foam (2.2 g). A small sample (ca. 200 mg) was taken up in dichloromethane (5 ml) and treated with excess ethereal hydrogen chloride. The solvent was removed and the oily residue was purified from isopropanol-petroleum ether to give the title compound m.p. 122-124 .
Analysis Found: C, 67.0; H, 7.3; N, 2.6 C29H37NO5. HCl requires: C, 67.5; H, 7.4; N, 2.7%
Example 78 [1α(Z), 2ss, 3α, 5alpha;]-(#)-7-[5-(4-Cyclohexylohenyl- methoxy)-3-hydroxy-2-(4-morpholinyl)cyclopentyl] - 5 - heptenoic acid, methyl ester p-Cyclohexylbenzyl chloride (4.99 g) was added to a solution of sodium iodide (4.2 g) in analaracetone (50 ml). The mixture was stirred for4 hr at room temperature and then evaporated under reduced pressure. The residue was treated with ether (100 ml) and filtrate was washed with brine (50 ml), dried (MgSO4) and evaporated to afford an orange oil. This iodide was contaminated with some (10%) of the ortho isomer.
The above benzyl iodide in dry dimethylformamide (20 ml) was added to a cold (-20 ) solution of the product of Preparation 100 (2.46 g) in dry dimethylformamide ( < 10 ml). Sodium hydride (900 mg, 80% dispersion) was introduced, the cooling
bath removed and stirring was continued for 12 hr. The mixture was poured into saturated ammonium chloride (100 ml) and extracted with ether (4 x 70 ml). The combined organic extracts were washed with water (100 ml) and brine (100 ml), dried (MgSO4) and evaporated. The residue oil was immediately purified by chromatography on silica.
Eluting with ether gave a mixture (2.56 g) of two closely running components.
T.L.C. Rf 0.46 and 0.51, silica/ether.
The mixture (2.5 g) was dissolved in 5% sulphuric acid in methanol (100 ml) and allowed to stand at room temperature for 1 hr. The solution was poured into 8% sodium bicarbonate (150 ml) and extracted with dichloromethane (3 x 75 ml). The combined extracts were dried (MgSO4) and evaporated to afford an oil (2.1 g). The product was purified by chromatography on silica, eluting with 95:5 ethermethanol gave the title compound as a colourless oil (1.17 g) I.R. (CHBr3) 3520 (br.), 1728 cm-1.
Analysis found: C, 71.9; H, 9.4; N, 3.0 C30H45NO5 requires: C, 72.1; H, 8.1; N, 2.8%
Example 79 [1α(z) ss, 3α, 5α]-(#)-7-[5-(2-Cyclohexyl- phenylmethoxy) - 3 - hydroxy - 2 - (4 - morpholinyl) cyclopentyl] - 5- heptenoic acid, Methyl ester
The title compound (0.18 g) was also isolated during the experiment described in Example 78.I.R. (CHBr3) 3520(br). 1728 cm-1.
Analysis Found: C, 72.0; H, 9.4; N, 2.7; C30H4sNOs requires: C, 72.1; H, 9.1; N, 2.8%.
Example 80 [1a (Z), 2ss, 3α, Sa] -(#) - 7- [5(4- Cyclohexyl pheny/methoxy) - 3 - hydroxy - 2 - (4 - morpholinyl) cyclopentyl] - 5- heptenoic acid, hydrochloride
The product of Example 78 (2 g) in methanol (15 ml) was added to aqueous potassium hydroxide solution (5 ml, 0.008016 mole). The mixture was stirred overnight then evaporated in vacuo. The residue was treated with water (25 ml) and the pH adjusted to pH 6-6.5 with 2M sodium bisulphate solution. The suspension was extracted with dichloromethane (5 x 50 ml). The combined extracts were dried (MgSO4) and evaporated to give an off-white foam (1.89 g).
A small portion (ca. 200 mg) was taken up in ether (5 ml) and treated with excess ethereal hydrogen chloride. The oily product was triturated with fresh
ether to give the title compound. m.p. 162-163".
Analysis found: C, 66.5; H, 8.4; N, 2.6; C29H43NOs HCI requires: C, 66.7; H, 8.4; N, 2.7%
Example 81 [1α(Z),2ss,3α,5α]-(#)-7-[5-[4-Dimethlamino (phenylmethoxy]-3-hydroxy-2-(4-morpholinyl) cyclopentylJ - 5- heptenoic acid, methyl ester
To a stirred, cold (10") solution of Preparation 100
(2.46 g) and p-dimethylaminobenzyl chloride hydrochloride (8.65 g) in dry dimethylformamide (30 ml) was added portionwise sodium hydride (1.8 g, 80% dispersion in oil). After 30 mins the suspension was
poured into saturated ammonium chloride (250 ml)
and extracted with ether (4 x 400 ml). The combined
extracts were washed with water (2 x 100 ml) fol
lowed by brine (100 ml), dried (MgSO4) and evapo
rated to afford a brown oil.
The above reaction was repeated twice more and the
combined products were chromatographed on silica
gel. Eluting with ether: petroleum ether (9:1) gave
the product (920 mg) as a colourless oil.
A solution of the oil (900 mg) in 5% methanolic sul
phuric acid (30 ml) was allowed to stand at room
temperature for 30 mins. The solution was poured
into 8% sodium bicarbonate (100 ml) and extracted
with dichloromethane (3 x 50 ml). The combined
extracts were dried (MgSO-4) and evaporated to
afford an oil (870 mg). The product was purified by
chromatography on silica, elution with
ether:methanol (96:4) gave the title compound (541
mg) as a colourless oil. l.R. (Neat) 3440 (br.), 1735 cm-1.
Analysis found: C, 67.7; H, 8.7; N, 6.3;
C20H40N2O5 requires: C, 67.8; H, 8.8; N, 6.1%
Example 82 [1a (Z), 2ss, 3α, 5a] - (H - 7- [S- [4-Azido (phenyl meth ox V)] - 3 - hydroxy - 2 - (4 - morpolinyl) cyclopentyl] - 5- heptenoic acid, methyl ester
A solution of the product of Preparation 100 (2.5 g) and p-azido benzyl bromide (5.16 g) in dry dimethylformamide (16 ml) was treated with sodium hydride (0.73 g., 80% dispersion in oil) under nitrogen and the mixture was stirred at room temperature for 2 hr.
Ammonium chloride solution (20 ml) was added with cooling and the mixture extracted with dichloromethane (3 x 20 ml). The combined organic layers were washed with water (50 ml) then dried (MgSO4). Solvent removal in vacuo afforded an oil which was chromatographed on silica. Elution with ethyl acetate-petroleum ether (3:1) gave the product as an oil (2.2 g). A sample of the oil (0.45 g) was treated with sulphuric acid/methanol 1:9 (3 ml) at 0" and stirred at room temperature for 30 mins. The reaction mixture was poured into sodium bicarbonate (10 ml) and was extracted with dichloromethane (3 x15 ml). The combined organic layers were washed with water (20 ml), brine (20 ml), and dried (MgSO4) Solvent removal in vacuo yielded a light brown oil (360 mg) which was chromatographed on silica.Elution with methanol/ether 1:9 gave the title compound as a light brown oil (0.22 g).
I.R. (CHBr3) 3540 (br.), 2110,2060 (sh), 1730 cm-1
Analysis Found: C, 62.7; H, 7.4; N, 12.0 C24H34N4Os requires: C, 62.9; H, 7.4; N, 12.2%
Example 83 [1α(Z), 2ss, 3α, 5α]-(#)-7-[5-(4-(1,1- Dimethylethyl) phenylmethoxy - 3 - hydroxy - 2 - 64 morpholinylJ cyclopentyl] - 5- heptenoic acid, methyl ester
Sodium hydride 0.15 g 80% dispersion in oil) was added to a cold (0") stirred solution of the product of Preparation 100 (0.5 g) and p-tertbutylbenzyl- bromide (0.28 g) in dry dimethylformamide (7 ml).
After 2 hr the suspension was poured into saturated ammonium chloride solution (75 ml) and extracted into ether (3 x 50 ml). The combined extracts were dried (MgSO4) filtered and evaporated to afford an oil (0.9 g). The product was treated with a 10% conc.
sulphuric acid in methanol solution (15 ml) and left standing for 10 min. The solution was neutralised with 8% sodium bicarbonate and extracted into dichloromethane (3 x 30 ml). The combined extracts were dried (MgSO4), filtered and evaporated to afford a yellow oil (1.0 g). Chromatography on silica with 7% methanol in ether as eluent gave the title compound as a colourless oil (0.302 g). I.R. (CHBr3) 3540, 1730 cm-1
Analysis Found: C, 70.8; H, 9.4; N, 2.9
C28H43NO5 requires: C, 71.0; H, 9.2; N, 3.0%
Example 84 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3-Hydroxy-2-(4- morpholinyl) - S - phenoxycyclopentyl] - S - heptenoic acid, methyl ester
To a cold solution (0") if the product of Preparation
100 (1 g) in dry dimethylformamide (10 m(s) was
added NaH (292 mg, 80% dispersion in oil). After 5
mins diphenyliodonium chloride (1.549) was added, the cooling bath removed and stirring continued for
a further 30 mins. A further quantity of diphenyliodonium chloride (1.54 g) was added after
45 mins, the mixture was poured into saturated
ammonium chloride (50 mls) and extracted with
ether (5 x 50 mls). The combined organic extracts
were washed successively with water (100 mls) and
brine (100 mls), dried (MgSO4) was evaporated. The
residue was purified by chromatography on silica
and eluting with ether gave the product (170 mg).
The above experiment was repeated to give a further
150 mgs of the product.
The intermediate (320 mg) in 10% methanolic sul
phuric acid (5 ml) was allowed to stand at room temperature for 30 mins. The solution was poured
into saturated bicarbonate (50 mls) and extracted with dichloromethane (5 x 30 mls). The combined extracts were dried (MgSO4) and evaporated. The residue (310 mg) was purified by chromatography on silica. Eluting with 3% methanol in ether gave the title compound (220 mg) as a colourless oil.
I.R.(CHBr3)3590, 1730cm-1
Tlc (Silica) Rf 0.29 (97:3 Ether-methanol)
Example 85 [1a rZl 2/3, 3u, Sa] - (#)-7-[5- (Diphenylmethoxy)- 3-hydroxy-2-(4-morpholinyl)cyclopentyl]-5heptenoic acid, methyl ester, hydrochloride salt
A solution of the product of Preparation 100 (4.0 g) and diphenyl diazomethane (6.5 g) in acetonitrile was heated at 85 for 5 h. The solvent was removed
under reduced pressure to give a semi-solid. The residue was dissolved in 5% methanolic sulphuric acid (100 ml) and left at room temperature for 1 h.
The solution was poured into 8% sodium bicarbonate (200 ml) and extracted into dichloromethane (4 x 100 ml). The combined extracts were dried (MgSO4) and evaporated and the residue purified by column chromatography on silica gel (Merck7734, 180 g). Eluting first with ether and then with 95:5 ether-methanol gave the product as an oil (3.81 g). A sample (500 mg) was dissolved in ether (25 ml) and treated with excess ethereal hydrogen chloride. The title compound crystallised from ethyl acetatemethanol as colourless platelets, m.p. 174-175 .
Analysis Found: C, 67.6; H, 7.7; N, 2.7; C3tH3aNOa.HCl requires: C, 68.0; H, 7.6; N, 2.6%
Example 86 [1α(Z), 2ss, 3α, 5α]-(#)-7-[5-[4- (Dimethylaminomethyl)phenylmethoxy]-3-hyd
roxy- 2 - {4 - morpholinyl) cyclopentyl]-5- hep
tenoic acid, methyl ester
To a solution of the product of Example 50 (0.6 g) in
methanol (5 ml) was added ethanolic dimethylamine
(33% w/w, 1.45 ml) followed by hydrochloric acid (5N, 0.81 ml) and sodium cyanoborohydride (0.48 g).
The resultant mixture was stirred for 3 days then
poured into 8% sodium bicarbonate solution (100
ml) and extracted into ether (2 x 100 ml). The com
bined extracts were dried (MgSO4), filtered and
evaporated to afford a viscous oil (0.9 g). Short path column chromatography on silica gel (25 g) with
methanol as the eluent gave the title compound as a colourless oil (0.396 g).
Analysis Found: C, 68.2; H, 9.0; N, 5.8; C27H42N2Os requires: C, 68.3; H, 8.9; N, 5.9% I.R. (CHBr,.) 3540 (br), 1733 cm-1
Example 87 [la IZJ, 2P, 3r 50i] -(+1- 7- [3- Hydroxy-5- methox- ymethoxy - 2 - (4 - morph olin yl) cyclopentyl]-5- heptenoic acid, methyl ester
Tetrabutyl ammonium fluoride (0.86 g) was added to
a solution of the product of Preparation 105 (0.8 g) in
dry tetrahydrofuran (20 ml) and the reaction stirred
at 45 for 3 hr. The mixture was quenched with
aqueous sodium bicarbonate (50 ml) and extracted
with dichloromethane (3 x 40 ml). The combined
organic extracts were washed with brine, dried
(MgSO4) and concentrated to afford an oil (0.8 g).
The product was purified by chromatography on
silica eluting with 4% methanol in ether to yield title compound as a colourless oil (0.41 g).
I.R. (Neat) 3440, 1738 cm-'
T.L.C. (Silica) Rf 0.18 (95:5 ether-methanol)
Example 88 [1α(Z),2ss,3α,5α]-(#)-[3-(Hydroxy-5-(2- methoxyethoxy) methoxy -2- (4- morpholinylJ cyclopentyl] - 5 - heptenoic acid, methyl ester
The title compound (0.85 g) was prepared from the product of Preparation 106 (1.53 g) by the procedure described for Example 87. Chromatography in silica eluting with 93:7 ether-methanol gave the title compound as a yellow oil. l.R. (Neat) 3450, 1735 cm-'.
Analysis Found: C, 60.4; H, 9.3; N, 3.3
C21H37NO7 requires: C, 60.7; H, 9.0; N, 3.4%
Example 89 1α(Z), 2ss, 5α]-(#)-7-[2-(4-Morpholinyl)-5- [1,1'-biphenyl)-4-yl]methoxy]cyclopentyl]-5heptenoic acid, methyl ester, hydrochloride
The product of Example 35 (1.35 g) was alklated with biphenyl methyl bromide (3.6 g) as described for Examples 48-59. The title compound was purified from ethyl acetate-ether (520 mg) (m.p. 99-100 ).
Analysis Found: C, 70.2; H, 8.2; N, 2.7; C2tHs9NO4.HCl requires: C, 70.1; H, 7.8; N, 2.7%
Example 90 [1α(Z), 2ss, 5α]-(#)-[2-(4-Morpholinyl)-5- (pheny/methoxy/) cyclopentyl] - 5 - heptenoic acid, methyl ester, hydrochloride
The product of Example 35 (2.6 g) was alkylated with phenyl methyl bromide (5.7 g) as described for
Examples 48-59. The title compound was purified from ethyl acetate-light petroleum (500 g) m.p.
94-96 .
Analysis Found: C, 65.9; H, 8.4; N, 3.2; C24H32NO4.HCl requires: C, 65.8; H, 8.3; N, 3.2%
Example 91 [1a(Z), 2ss, 5ss] - {+J - 7- [5- (4- MorpholinylJ -2 (phenylmethoxy)-3-cyclopenten-1-yl]-5-hetenoic acid, methyl ester
A solution of the product of Example 33 (1.42 g) in dry dimethylformamide (22 ml) containing benzyl bromide (3.15 g) was stirred at 0 whilst potassium tertiary butoxide (1.03 g) was added. The cooling bath was removed after ca. 5 min and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was poured into an excess of ammonium chloride solution and extracted with ethyl acetate. The combined extracts were dried (MgSO4) and evaporated to give an oil which was filtered through a short silica column in ether to remove the excess of benzyl bromide. The residual oil (1.2 g) was chromatographed on silica in ethyl acetate to give the title compound as a colourless oil (0.43 g). I.R. (CHBr3) 1723 cm-t Analysis Found: C, 72.1; H, 8.4; N, 3.6;
C24H33NO4 requires: C, 72.15, H, 8.3; N, 3.5%
Example 92 [1α(Z),2ss, 3α, 5α]-(#)-7-[5-[[(1,1'-Biphenyl)-4- yl] methoxy] - 3 - hydroxy - 2 - (1 -piperidinyl) cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (0.79 g) was prepared from the product of Preparation 98 Table 4 (29) by the procedure described for Examples 48-59 Table 7 Method
A.1.Chromatography on silica eluting with ethermenthanol 19:1 increasing to 17:3 gave the title compound as an orange oil. l.R. (CHBr3) 3540, 1730 cm-t T.L.C. silica 95:5 ether-methanol Rf. 0.32.
Examples 93- 102 (1u, 2,B, 3hx, Sa)- (#)-2,3,5- Trisubstituted cyclopen- taneheptanoic acid, methyl esters
Table 10 summarises the preparation of the title compounds by the following method:
A solution of the appropriate alkene in the solvent specified was hydrogenated over pre-reduced 100/o palladium on charcoal at atmospheric pressure.
When necessary an acid catalyst was used and this specified in the Table. When the hydrogen uptake ceased the mixture was filtered through hyflo and evaporated. The residue when necessary as either chromatographed on silica gel with the solvent specified or crystallised from the solvent specified to give the title compound.
Starting Mateial Product Chromato- I.R.
Ex, where Z is Pd. O/C raphy Yield (CHBr3) Tlc (silica) No. R Z Wt (g) different Solvent Vol. (ml) Wt. (g) System m.p. (g) cm-1 Rf(solvent) 93 -CH2Ph # 1.85 -- ethanol 75 0.35 -- -- 1.91 (Neat) 3520, 3440, 1740 94 -CH2Ph # 1.0 -NHCH ethyl 35 0.5 -- 45-8 from 0.4 3520, 0.23 (1::2 acetate EtoAc 1730 ethyl acetate petroleum methanol ether 95 -CH3 # 1.0 -NHCH methanol 20 0.2 -- 106-8 0.63 3500 0.2 (orthanol) from 1728 ethyl acetate 96 -CH3 # 0.37 -- methanol + 20 0.073 ether -- 0.25 2580, 5N HCl 3500, 0.3 (ether) (0.25 ml) 1728 97 -CH2Ph # 0.42 -- methanol 20 0.05 3:17 -- 0.3 3580, 0.45 (98::4 methanol- 1728 ether ethylacetate methanol) 98 -CH2Ph # 0.8 -- methanol 50 0.15 -- 100-10 from 0.61 3530. 0.32 (95:5 EtoAc- 1725 ether petroleum methanol) ether 99 -CH3 # 1.66 -- ethanol 60 0.3 -- 33-34.5 1.63 3520, 0.11 (ether) 3280 100 -CH2Ph -N3 13.5 -NH2 methanol 50 1.4 -- 88-9 from 5.8 3320, 0.31 (1:
:1 EtoAc- 3280, ether Petroleum 3200, methanol ether 1723 101 -CH2Ph # 3.5 -- methanol 90 0.3 94:6 -- 2.6 3590, 0.17 (95:5 ether- 3520, ether methanol 1728 methanol 102 -CH2Ph # 0.36 -- ethanol 25 0.9 4:1 ether- -- 0.26 3540, 0.49 (95::5 patroleum 1730 ether ether methanol) Example 103 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-2-[N-(2- methoxyethyl)-N-methylamino]-5-(phenylmethoxy) cyclopentane heptanoic acid, methyl ester
A mixture of the product of Example 94 (1.1 g), 2-bromoethylmethyl ether (2.1 g), anhydrous potassium carbonate (1.1 g) and dry acetonitrile (20 ml) was heated under reflux for 4 1/2 hr. The reaction mixture was filtered and the filtrate concentrated in vacuo to yield an oil. Column chromatography on silica gel using (10:1) ether-methanol as eluent gave the title compound as an oil (0.9 g), IR (Neat) 3450, 1735 cm-1.
T.l.c. (Silica) Rf 0.4 (acetone).
Example 104 (1α, 2ss, 3α, 5α) - (#) - 3 - Hydroxy - 2 - [N - (2- hydroxyheptyl) - N - methylamino] - 5 - methoxycyclopentaneheptanoic acid, methyl ester
A solution of the product of Example 95 (0.59 g) and 1,2-epoxyheptane (0.68 g) in methanol (10 ml) was heated under reflux for 12 hr. Evaporation of the solvent gave an oil which was chromatographed on silica gel using 100:1 ethyl acetate-triethylamine as eluent. Epimer A of the title compound was isolated as the least popular material (0.34 g) and Epimer B as the most popular (0.27 g).
EpimerA IR (Neat) 3420, 1740 cm-1
Analysis Found: C, 65.23; H, 10.22; N, 3.53; C22H4NO5 requires: C, 65.80; H, 10.79; N, 3.490/c EpimerB IR (Neat) 3420, 1740 cm-1
Analysis Found: C, 65.01; H, 10.67; N, 3,47%
Example 105 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-2-[N-(2- hydroxy - 2 - phenylethyl) - N - methylamino] - 5 - methoxycyclopentaneheptanoic acid, methyl ester
The process of Example 104 was repeated using the product of Example 95 (574 mg) and styrene oxide (480 mg), heating under reflux for 5 hr, to yield the title compound as an oil (530 mg). IR (Neat) 3400, 1740cm-1.
Analysis Found: C, 67.48; H, 9.21; N, 3.50% C23H37NOs, requires: C, 67.78; H, 9.15; N, 3.44%
Example 106 %(1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-2-[N-methyl-N [2 - hydroxy -3- [3 - (trffluoromethyi) phenoxy] propyl] amino] - 5- methoxycyciopentaneheptanoic acid, methyl ester
The process of Example 104 was repeated using a
solution of the product of Example 95 (287 mg) and
1,2 - epoxy - 3 - (3 - trifluoromethyl) phenoxyp
ropane (325 mg) in methanol (3 ml), heating under
reflux for 3 hr, to yield the title compound as an oil
(371.3 mg).
IR (Neat) 3420, 1740cm-1.
Analysis Found: C, 59.01; H, 7.65; N, 2.77; C2sH38F3NO6 requires: C, 59.39; H, 7.58; N, 2.77%
Example 107 (1α, 2ss, 3α, 5α)-(#)-3,5-Dihydroxy-2-(4- morpholinyl) - cyclopentaneheptanoic acid, methyl ester
A solution of the product of Example 16 (0.75 g) in
methanol (110 ml) containing 60% perchloric acid (2
ml) was hydrogenated at atmospheric pressure and
room temperature over 10% palladium on charcoal
(400 mg). After 4 h the catalyst was removed by filtration through hyflo. The filtrate was poured into ammoniacal sodium chloride solution 150 ml) and extracted with dichloromethane (2 x 50 ml). The combined organic extracts were washed with brine (100 ml), dried (sodium sulphate) and evaporated to afford an oil (987 mg). The product was purified by short path column chromatography on silica gel (50 g).Elution with 10% methanol/ethyl acetate gave the title compound which was further purified by molecular distillation (0.37 g) I.R. (Neat) 3400, 1735 cm-t Analysis Found: C, 61.7; H, 9.5; N, 4.1; C17H31NOsrequires: C, 62.0; H, 9.5; N, 4.3%
Example 108 (1α, 2ss, 3α, 5α)-(#)-3,5-Dihydroxy-2-(N-methyl - N - (2- phenylethyl) amino] cyclopentaneheptanoic acid, methyl ester
The product of Example 5 (Table 5) (0.74 g) was converted into the title compound (0.208 g) by the method of Example 107.
Analysis Found: C, 70.4; H, 9.3; N, 3.7; C22H3sNO4 requires: C, 70.0; H, 9.35; N, 3.7%
I.R. (CHBr3) 3590, 3520(sh), 1725 cm-'
Example 109 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-2-[N-methyl-N- (2. phenylethylJ amino] - S - (phenylmethoxy) - cyclopentaneheptanoic acid, methyl ester
The title compound (1.38 g) was prepared from the product of Example 5 (Table 5) (1.5 g) in ethanol (20 ml) by the method of Examples 93-102 (Table 10). A portion (0.86 g) was distilled at 180 /0.1 mm Hg to give the title compound (0.62 g) as a pale yellow oil.
Analysis Found: C, 74.4; H, 8.9; N, 3.0 C29H41NO4 requires: C, 74.5; H, 8.8; N, 3.00/0 Example 110 (1α, 2ss, 3α, 5α)-(#)-5-Acetoxy-3-hydroxy-2-(4- morpholinyl) - cyclopentane heptanoic acid, methyl ester
The product from Example 22 (0.9 g) was converted into the title compound (0.71 g) by the method described for Examples 93-102. Crystallisation from ether-petroleum ether gave white needles m.p.
50.5-51.5 .
Analysis Found: C, 60.5; H, 8.8; N, 3.9; C19H33NO6 requires: C, 61.4; H, 9.0; N, 3.8%
Example 111 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-5-(1- methylethoxy) -2- (4 morpholinylJ - cyclopentaneheptanoic acid, methyl ester hydrochloride
The title compound base was prepared from the
product of Example 18 (1 g) in methanol (50 ml) by
the method of Examples 93-102 (Table 10). The base
in ether was treated with an excess of ethereal hyd
rogen chloride. Purification from ethyl acetate gave
the title compound (0.54 g) m.p. 131-132 C.
Analysis Found: C, 59.2; H, 9.3; N, 3.4; C20H37NOs.HCI requires:
C, 58.9; H, 9.3; N, 3.4%
Example 112 (1α, 2α, 5ss)-(#)-2-Hydroxy-5-(4-morpholinyl) cyclopentane heptanoic acid, methyl ester, hydroch
loride
The title compound base was prepared from the
product of Example 33 (1.9 g) in methanol (100 ml)
by the method of Examples 93-102 (Table 10). The
base in ether was treated with an excess of ethereal
hydrogen chloride. Purification from methanol-ethyl
acetate gave the title compound (1.6 g) m.p.
160-163 .
Analysis Found: C, 58.3; H, 9.6; N, 4.0;
C17H31NO4.HCI requires: C, 58.4; H, 9.2; N, 4.0%
Example 113 (1α, 2α, 5ss) -(#)-5-(4-Morpholinyl)-2-(phenyl- methoxy) - cyclopentane - heptanoic acid, methyl ester, hydrochloride, hemihydrate
A solution of the product of Example 112 (1.55 g) in sodium bicarbonate solution was extracted with dichloromethane. The free base in dimethylformamide (20 ml) containing benzyl bromide (3.03 g) was stirred at 0e while potassium tertiary butoxide (0.993 g) was added. The cooling bath was removed after ca. 5 min and the reaction was stirred at room temperature for 1 h. The reaction mixture was
poured into an excess of ammonium chloride solution and extracted with ethyl acetate.The combined extracts were dried and evaporated to give a yellow oil which was filtered through a short silica column in ether to remove the excess of benzyl bromide. The residual oil was chromatographed on silica in ethyl acetate to give a colourless oil (400 mg). The oil was dissolved in dry ether and treated with an excess of ethereal hydrogen chloride to give a tan solid (400
mg). Purification from ethyl acetate-methanol gave the title compound as an off-white solid (260 mg) m.p.118-120 .
Analysis Found: C, 64.2; H, 8.5; N, 3.2; C24H37NO4.HCI.2H2O requires: C, 64.2; H, 8.75; N, 3.1%
Example 114 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-2-[N-methyl-N- [2 ydroxy-3-(3- trifluoromethylphenoxy) propyl]amino]-5-methoxy-cyclopentaneheptanoic acid, methyl ester
A solution of the product of Example 95 (287 mg) and 1,2 - epoxy - 3 - (3- trifluoromethylphenoxy) propane (325 mg) in methanol (325 mg) in methanol (3 ml) was heated under reflux for 3 h. Removal of the solvent gave an oil which was purified by chromatography on silica. Eluting with ether gave the title compound as a colourless oil (371 mg).
Analysis Found: C, 59.0; H, 7.65; N, 2.8; C2sH38F3NO6 requires: C, 59.4; H, 7.6; N,2.8%
I.R. (Neat) 3420, 1740 cm-1
Example 115 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-5-methoxy[N- (2- methoxyethyl) - N - methylamino] cyclopentaneheptanoic acid, methyl ester
A mixture of the product of Example 95 (Table 10) (1.5 g), 2-bromoethyl methyl ester (3.0 g), anhydrous potassium carbonate (1.5 g) and dry acetonitrile (10 ml) was refluxed for 5 h. The solvent was removed in vacuo and the residue treated with ether (50 ml) and filtered. Removal of the solvent from the filtrate gave
a pale orange oil (1.75 g).Molecular distillation (1600/0.01 mm) gave the title compound as a colour
less oil (1.164 g). l.R. (Neat) 3600-3200, 1739 cm
Analysis Found: C, 61.4; H, 10.1; N, 3.9; C18H3sNOs requires: C, 62.6; H, 10.2; N, 4.1%
Example 116 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-2-(methylamino)- 5- (phenylmethoxy) cyclopentane heptanoic acid, methyl ester
The product of Example 5 (Table 5) (1.0 g) in ethyl acetate (20 ml) was added to a pre-hydrogenated
suspension of 10% palladium oxide on charcoal (0.5 g) in ethyl acetate (15 ml). The reaction was stirred for 3 h. The reaction mixture was filtered and the solvent removed to give a solid (0.64 g).Purification from petroleum ether-ethyl acetate 10:1 gave the title compound as pink needles (0.41 g) m.p. 45-c0.
Analysis Found: C, 69.7; H, 9.2; N, 3.8; C21H33NO4 requires: C, 69.4; H, 9.1 5; N,3,85%
Example 117 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-2-[N-hydroxy- yethyl)-N-(methylamino)] -5-(phenylmethoxy) cyclopentane heptanoic acid, methyl ester
A mixture of the product of Example 116(1 g) and 25% ethylene oxide in toluene solution (20 ml) was heated (90 ) in an autoclave for 3 days. Excessive solvent was evaporated under reduced pressure to afford a viscous brown oil (1.2 g). Column chromatography on silica gel with methanol as the eluent gave the title compound as a yellow oil (0.86 g). l.R. (Neat) 3400, 1735cm-1.
Analysis Found: C, 67.4; H, 9.1; N, 3.4; C23H37NOs requires: C, 67.8; H, 9.2; N, 3.4%
Example 118 (1α, 2ss, 3α, 5α)-(#)-3-Hydroxy-5-(phenyl methoxy) - 2- (4 - thiomorpholinyl) cyclopentaneheptanoic acid, methyl ester, S-dioxide, maleate
A solution of the product of Example 4 (Table 5) (1 g) in methanol (40 ml) was hydrogenated over prereduced 10% palladium oxide on charcoal (250 mg) for 15 min. The catalyst and the solvent were removed giving a gum (1.0 g). The product was purified by chromatography on silica eluting with etherto give a colourless oil. The oil was dissolved in ether and treated with an excess of an ethereal solution of maleic acid. The precipitated gum was triturated with ether to give the title compound (590 mg) m.p.95-97 .
Analysis Found: C, 57.25; H,7.1; N 2.5; C24H3,SNO6. C4H4O4 requres: C, 57.6; H, 7.0; N, 2.4%
Example 119 (1α, 2ss, 3α, 5α)-(#)-2-(Hexahydro-1H-azepinyl)- 3- hydroxy - 5- (phenylmethoxy) cyclopentane heptanoic acid, methyl ester hydrochloride
Anhydrous potassium carbonate (2.76 g) was added to a solution of the product of Example 100 (3.5 g) and 1,6-dibromohexane (2.93 g) in dry acetonitrile (30 ml) and the mixture heated under reflux for 8 h. The suspension was filtered and the filtrate evaporated. The residue was purified by chromatography on silica eluting with 4% methanol in ether to give the product (2 g) as a pale orange oil.
A sample (600 mg) in ether (15 ml) was treated with an excess of ethereal hydrogen chloride. The product was purified from ethyl acetate-petroleum ether to give the title compound as colourless platelets m.p. 75-6 .
Analysis Found: C, 66.6; H, 9.1; N, 3.0; C2eH41NO4. HCI requires: C, 66.7; H, 9.0; N,3.0%
Example 120 , 2/3, 3α, 5α) - +) - 3 - Hydroxy S- (phenyl methoxy)-2- (1 -pyrro/idinyl) cyclopentane hep- tanoic acid, methyl ester, hydrochloride
Anhydrous potassium carbonate (2.4 g) was added to a solution of the product of Example 100 (4 g) and 1,4-dibromobutane (2.98 g) in dry acetonitrile (30 ml) and the mixture heated under reflux for 18 h.
The suspension was filtered and the filtrate was diluted with ether (100 ml) and washed with 8% sodium bicarbonate (50 ml). The aqueous phase was back-extracted with ether (2 x 30 ml). The combined organic phases were washed with brine, dried (MgSO4) and evaporated. The residual oil was purified by chromatography on silica eluting with 10% methanol in etherto give the product (2.51 g) as a pale orange oil which slowly solidified on standing (m.p. 34-35 ). A sample (800 mg) in ether (20 ml) was treated with an excess of ethereal hydrogen chloride. The product was purified from ethyl acetate-petroleum ether to give the title compound as off-white platelets m.p. 88-89'.
Analysis Found: C, 65.6; H, 8.9; N, 3.2; C24H37NO4 . HCI requires: C, 65.5; H, 8.6; N, 3.2%
Example 121 [(1α, 2ss (2#), 3α, 5α) -(#)-2-[N-(2-Chloroacetylox yphenyl) - N - methylamino] - 3 - hydroxyl - 5 - (phenylmethoxy- cyclopentane heptanoic acid, methyl ester
The product of Preparation 112(1.8g) in methanol (5 ml) was treated with 5% concentrated sulphuric acid in methanol (25 ml) at-10 . After stirring for 2.5 h the solution was neutralised with 8% sodium bicarbonate solution and extracted with dichloromethane (3 x 100 ml). The combined organic extracts were washed with brine, dried (MgSo4) and concentrated to afford an orange viscous oil. The product was purified by chromatography on silica.
Elution with petroleum ether in ether 2:3 gave the title compound as a yellow oil (1.2 g). l.R. (Neat) 3540,3460, 1765 (sh), 1740 cm-'
Analysis Found: C, 64.55; H, 8.7; N, 2.5; C30H48CINO6 requires: C, 65.0; H, 8.7; N, 2.5%.
Example 122 1 1α, 2ss, 3α, 50E] -(#) - 2 - ran - (2 - Chloroacetylox- yethyl)-N-methylamino]-3-hydroxy-5 (phenylmethoxy)cyclopentane heptanoic acid, methyl ester.
A cold (0 ) solution of the product of Preparation 110(1.87 g) in methanol (10 ml) was acidified with
ethereal hydrogen chloride and left stirring for 45
min. The solution was diluted with ether (100 ml) and washed with 8% sodium bicarbonate solution
(100 ml). The aqueous phase was re-extracted with
ether (50 ml). The combined organic extracts were
dried (MgSO4), filtered and evaporated to afford an
oil (1.6 g). Column chromatography on silica gel with
ether as eluent gave the title compound (0.60 g) as a pale yellow oil.T.l.c. (Silica) Rf 0.3 (Ether).
Analysis Found: C, 61.6; H, 7.8; N, 2.8; C25H38CINO requires: C, 62.0; H, 7.9; N, 2.9%
Examples 123-137
7 - (2,5- Disubstituted -3- oxocyclopentyl) heptanoic
acid, methyl esters
Table 11 summarises the preparation of the title
compounds by the following methods:
A. Jones reagent[chromlum trioxide (26.7 g) and concentrated sulphuric acid (23 ml) made up to 100 ml with water] was added dropwise to the appropriate alcohol in acetone at -5 to 0 and stirred for 0.5-5 h. The mixture was poured into cold (0 ) 8% aqueous sodium bicarbonate solution and extracted with ether. The combined organic extracts were dried (MgSO4), filtered and concentrated. The material obtained was purified by chromatography on silica gel.
B. The method is as described in Method A except that isopropanol is added to destroy the excess of
Jones reagent and the chromium residues are removed by filtration. The product is isolated from the filtrate as described in Method A.
Table 11 (i)
Starting Material Jones Time I.P.A. Chromatography Yield I.R. Tlc (silica) Ex. Method Acetone Reagent hr Vol. System (g) (CHBr3) Rf (solvent) No. Z R X Wt Vol (ml) Vol. (ml) (ml) ether-petrol. cm-1 (g) ether 123 # CH2Ph CH=CH(cis) 1.2 A 35 2.7 2.7 1:1 0.59 1730 0.54 (ether) 124 # CH2Ph CH2CH2 1.116 A 35 2.5 2 - 1:1 0.735 1730 0.58 (ether) 125 # CH2Ph CH2CH2 0.6 B 15 1.0 2 2 1:1 0.242 1730 0.45 (ether) 126 # CH3 CH=CH(cis) 1.5 A 50 2.3 4.5 - 3:1 0.96 1735 0.33 (ether) 127 # CH2Ph CH=CH(cis) 1.0 A 50 1.6 1 - 4::6 0.58 1730 0.7 (ether) 128 # CH2Ph CH2CH2 0.8 A 25 1.4 1.5 - 3:7 0.26 1730 0.7 (ether) 129 # CH3 CH=CH(cis) 0.7 A 25 1.05 2 - 1:2 0.39 1730 0.55 (ether) Table 11 (ii)
Starting Material Jones Time I.P.A. Chromatography Yield I.R. Tlc (silica) Ex. Method Acetone Reagent hr Vol. System (g) (CHBr3) Rf (solvent) No. Z R X Wt Vol (ml) Vol. (ml) (ml) ether-petrol. cm-1 (g) ether 130 # CH3 CH2CH2 0.57 B 10 2.0 3 2 2:1 0.47 1730 0.4 (ether) 131 # - CH2Ph CH=CH(cis) 1.2 B 50 1.16 0.5 10 7:3 0.63 1730 0.47 (7:3 ether petroleum ether) 132 # CH3 CH2CH2 1 A 30 2.73 3 - 3:1 0.85 1730 0.42 (ether) 0.27 (3:2 ether133 # -CH2Ph CH2CH2 1.4 B 100 1.9 2 10 3:2 0.36 1730 petroleum ether) 134 # -CH2Ph CH2CH2 1.5 B 100 2.32 2 10 3:7 0.265 1730 0.23 (3: :7 ether petroleum ether) 135 # -CH2Ph CH=CH(cis) 0.92 A 10 1.26 1 - 4:1 0.42 3595, 0.54 (ether) 1730 m.p. 32-34 136 # -CH2Ph CH2CH2 1.37 B 40 1.87 0.7 10 4::1 0.81 3590, 0.46 (ether) 1730 137 # # CH=CH(cis) 0.72 B 15 0.97 2.5 1 ether 0.32 1740 0.5 (ether) Example 138 [7alZJ, 2P]-lfl-7-[2- 14 -Morpholinyll-3- oxocyclopent- 4 - en - 1- y/| - 5 - heptenoic acid, methyl ester
To a stirred solution of the product of Example 22 (3.0 g) in acetone (100 ml) at 0 was added Jones reagent (4.0 ml). The mixture was stirred at 0.5 for 3 hr whereupon isopropanol (5 ml) was added. After a further 15 min, 8% aqueous sodium bicarbonate solution (100 ml) was added. The mixture was extracted into dichloromethane (3 x 50 ml) and the combined organic phases dried and evaporated.The residual oil was dissolved in pyridine (10 ml) and stood for
18 hr. Excess pyridine was removed in vacuo and the residue chromatographed on silica gel using ether
as eluent, to give the title compound as an oil (1.3 g).
IR (Neat) 1735, 1710cm1.
Analysis Found: C, 66.0; H, 8.4; N, 4.5; Ct7H2sNO4 requires: C, 66.4; H, 8.2; N, 4.6%
Example 139 (1α, 2ss) - (#) - 2 - [4 - (Morpholinyl)]3 - oxocyclopentaneheptanoic acid, methyl ester
A solution of the productfrom Example 138 (600 mg) in ethyl acetate (100 ml) was hydrogenated at atmospheric pressure over prereduced 10% palladium oxide on charcoal (50 mg). The catalyst was filtered off and the solution evaporated under reduced pressure to afford an oil which was purified
by column chromatography on silica gel using ether
as eluentto yield the title compound as an oil (502 mg) which slowly solidified, m.p. 31-2 IR (CHBr3)
1730 cm-'.
Analysis Found: C, 66.1; H, 9.6; N, 4.6; C17H29NO4 requires: C, 65.6; H, 9.3; N,4.5%
Example 140 p1α(Z),2ss]-7- [2-[N-(2-Hydroxyheptyl)-N- methylamino]-5- oxo - 3 - cyclopenten - 1- yl] - 5- heptenoic acid, methyl ester
Jones reagent (3M, 0.43 ml) was added dropwise to a stirred solution of the product of Example 27 (0.69 g) in acetone (25 ml) at 0 . The mixture was stirred at 0 for 2 hr, diluted with 8% aqueous sodium bicarbonate solution (30 ml) and extracted with ether (3 x 30 ml). The combined extracts were washed, dried and evaporated to give an oil which was purified by chromatography on silica gel. Elution with ether gave the title compound as an oil (0.245 g) IR (Neat) 3460, 1740, 1710 cm-1.
Analysis Found: C, 68.71; H, 9.67; N, 3.81; C2tH35NO4 requires: C, 69.00; H, 9.65; N, 3.83%
Example 141 [Ia (Z), 2ss]-(#)-7-[[2-N- (phenylmethyl) amino] 5- oxo - 3 - cyclopentenyl] -5 - heptenoic acid, methyl ester
The title compound (0.73 g) was prepared from the
product of Example 32 (1.0 g) by the method
described for Examples 123-137 (Table 11). (Method
A). Chromatography on silica using ether as eluent
gave the title compound as a colourless oil. I.R.
(CHBr3) 1723, 1700 cm-1 Analysis Found: C, 74.0; H, 7.75; N, 4.1;
C21 H27NO3 requires: C, 73.9; H, 8.0; N, 4.1%
Example 142 [1α(Z), 2ss, 5α]-(#)-7-[-(4-Morpholinyl)-3-oxo- 5- (phenylmethoxy) cyclopentyl - 5- heptenoic acid
To a cold (0 ) solution of the product of Example 30 (3.3 g) in acetone (150 ml) was added Jones reagent (4.0 ml, 3.0 molar) and the mixture stirred for 121 h.
Isopropanol (15 ml) was added and the stirring maintained for 30 min. The suspension was filtered, the filtrate neutralised with 8% sodium bicarbonate solution and evaporated. The residue was diluted with water (20 ml) and the pH adjusted to 7.0 by adding 2N hydrochloric acid. The suspension was extracted with dichloromethane (4 x 50 ml). The combined organic extracts were dried (MgSO4), filtered and evaporated to yield an oil (2.8 g) which was subjected to short path column chromatography on silica gel (Merck 7731,90 g). Eluting with ether gave the title compound (2.14 g) I.R. (CHBr3) 3500, 1740, 1703 cm-1. T.l.c. (Silica) Rf 0.39 (ether).
Example 143 [1α(Z), 2ss, 5α]-(#)-7-[5-[[(1,1'-Biphenyl)-4-yl] methoxy]-2- (4 - morpholinyl) - 3 - oxo - cyclopentyl] - 5- heptenoic acid
To a cold (0 ) stirred solution of the product of
Example 77 (2.0 g) in analar acetone 50 ml) was added Jones reagent (2.34 ml) (3M solution). After4 hr isopropanol (25 ml) was added and stirring maintained for a further 30 min. The suspension was neutralised (pH 7) with 8% sodium bicarbonate solution, poured into saturated ammonium chloride solution (200 ml) and extracted with dichloromethane (6 x 70 ml). The combined extracts were dried (MgSO4) and evaporated, and the residue was purified by chromatography on silica. Eluting with ether/petrol 9:1 gave the title compound as a colourless oil (0.71 g) which solidified on cooling m.p.
68-70".
Analysis Found: C, 72.6; H, 7.5; N, 2.9; C29H3sNOs requires: C, 72.9; H, 7.4; N, 2.9%
Example 144 [1 a (Z), 2ss, 5α] - (t) - 7- [S - (4 - Cyclohexy/phenyl- methoxy - 2 - (4- morphollnyl) -3- oxo - cyclopentyl] - 5- heptenoic acid To a stirred cold (0 ) solution of the product of
Example 80 (1.6 g) in analaracetone (50 ml) was added dropwise Jones reagent (1.8 ml). After 3 h isopropanol (10 ml) was added and stirring maintained for a further 30 min. The green suspension was neutralised (pH 7) by 8% sodium bicarbonate solution then poured into saturated ammonium chloride solution (200 ml) and extracted with dichloromethane (5 x 75 ml). The combined extracts were dried (MgSO4) and evaporated to afford a dark brown oil (1.51 g). The product was purified by chromatography on silica. Eluting with ether gave the title compound (0.735 g) as a straw coloured viscous oil. I.R. (CHBr3) 3480, 1740, 1705 cm-1.
Analysis Found: C, 72.4; H, 8.2; N, 2.9;
C29H41NO5 requires: C, 72.0; H, 8.6; N, 2.9%
Example 145 (1α, 2ss, 3α, 5α)-(#)-5-[[(1,1'-Biphenyl)-4-yl] methoxy - 3 - hydroxy - 2 - 64 - morpholinyl) cyclopentane heptanoic acid, methyl ester
A solution of the product of Example 76 (2 g) in ethyl acetate (50 mls) was hydrogenated over prereduced palladium oxide on charcoal (0.5 g) in ethyl acetate (25 mls). Hydrogen uptake ceased after 2 hrs.
(hydrogen uptake 95 mls, theoretical 91 mls). The mixture was filtered (hyflo) and evaporated to afford the title compound as a viscous oil (2.16 g).
T.L.C. SiO2 3% methanol in ether, Rf. 0.30, I.R. (Neat) 3450, 1738 cm-' Example 146 (1α, 2ss, 3α, 5α)-(#)-5-[[(1,1'-Biphenyl)-4-yl] methoxy] - 3 - hydroxy - 2 - (4 - morpholinyl) cyclopentane heptanoic acid
A mixture of the product of Example 145 (2.0 g) and potassium hydroxide (0.45 g) in methanol (10 mls) and water (10 mls) was stirred for 4 1/2 hrs. The suspension was then evaporated under reduced pressure, the residue dissolved in water (30 mls), acidified (pH 6.5) with 2M sodium hydrogen sulphate and extracted into dichloromethane (3 x 50 mls). The combined extracts were dried (MgSO4), filtered and evaporated to afford the title compound as a foam (1.7 g). I.R. (CHBr3) 3500, 1740, 1710 cm-1.
Analysis Found: C, 72.2; H, 8.05; N, 2.8; C29H39NOs requires: C, 72.3; H, 8.2; N, 2.9%
Example 147 (1α, 2ss, 5α)-(#)-5-[[(1,1'-Biphenyl)-4-yl] meth ox V] -2- (4 - morph olin yl) -3- oxocyclopentane heptanoic acid
A cold (0 ) solution ofthe product of Example 146 (1.6g) in acetone (50 mls) was treated with Jones reagent (1.5 mls) and left standing for 30 mins. lsop- ropanol (10 mls0 was added and stirring maintained for a further 15 mins. The mixture was brought to pH 6.5 with 8% sodium bicarbonate solution; poured into ammonium chloride solution (150 mls) and extracted into dichloromethane (3 x 100mls).The combined extracts were dried (MgSO4), filtered and evaporated to afford a green solid (1.46 g).
Chromatography on silica with ether as eluent gave the title compound as white crystalline solid (0.904g). m.p. 111.5-112.5 .
Analysis Found: C, 72.7; H, 7.9; N, 2.9;
C2,H37NO, requires: C, 72.6; H, 7.8; N, 2.9%
Examples 148-170 7 - (2,5 - Disubstituted -3- oxocyclopentyl) heptanoic acid, methyl esters
Table 12 summarises the preparation of the title compounds by the following method: To a stirred solution of the appropriate alcohol and dicyclohexyl carbodiimide in dry dimethyl sulphoxide at room temperature was added pyridinium trifluoroacetate. After the time specified the mixture was poured into water and extracted with dichloromethane or ether. The remaining work-up is as described in Method A, Table 11.
Table 12 (i)
Starting Material Chromatography DMSO DCC Py. TFA Time System Yield I.R. (CHBr3) Tlc (Silica) Ex. Wt. Vol. (ml) Wt. (g) Wt. (g) (h) ether- cm-1 Rf (Solvent) No. Z R (g) petroleum ether 148 # -CH2Ph 2.4 50 4.74 1.68 1 7:3 1.81 1738 0.28 (7:3 ether petroleum ether) 149 # # 0.87 15 1.6 0.48 1 7:3 0.61 1738 0.59 (ether) 150 # -CH2Ph 0.56 10 1.25 0.35 20 ether 0.31 1740 0.25 (ether) 151 # # 0.77 15 1.28 0.45 0.75 7:3 0.5 1735 0.44 (ether) 152 # # 0.72 15 1.38 0.48 1 7:3 0.54 1738 0.54 (ether) 153 # -CH2OCH3 0.4 14 0.89 0.42 3 9::1 0.19 1735 0.36 (ether) 154 # -CH2O(CH2)OMe 0.7 10 1.41 0.5 1 ether 0.34 1736 0.37 (ether) Table 12 (ii)
Starting Material Chromatography DMSO DCC Py. TFA Time System Yield I.R. (CHBr3) Tlc (Silica) Ex. Wt. Vol. (ml) Wt. (g) Wt. (g) (h) ether-petroleum cm-1 Rf (Solvent) No. Z R (g) ether 155 # # 0.88 15 1.65 0.58 1 ether 0.55 2270, 1738 0.37(ether) 156 # -Si Me2tu 1.32 20 2.47 0.87 1 55:45 0.83 1735 0.66 (ether) 157 # -CHPh2 2.0 20 3.34 1.2 2 3:1 1.4 1735 0.5 (ether) 158 # -CH2CH2Ph 1.5 20 2.87 1.34 1 6:4 1.1 1735 m.p. 32.5-33.5 from ether petroleum ether 159 # -CHMe2 2.0 30 4.5 2.1 1 4:1 1.67 1733 0.35 (4:1 ether petroleum ether) 160 # # 0.6 7 0.94 0.34 1 4:1 0.4 1735 0.31 (4:1 ether) petroleum ether) 161 # # 0.9 10 1.66 0.6 1 4:1 0.7 1738 0.44 (4:1 ether petroleum ether) 162 # # 0.4 7 0.67 0.24 2 3:2 0.2 1738 0.38 (7::3 ether petroleum ether) Table 12 (iii)
Starting Material Chromatography DMSO DCC Py. TFA Time System Yield I.R. (CHBr3) Tlc (Silica) Ex. Wt. Vol. (ml) Wt. (g) Wt. (g) (h) ether-petroleum cm-1 Rf (Solvent) No. Z R (g) ether 163 # # 1.2 10 2.03 0.73 1 4:1 0.86 1735 0.35 (4:1 ether petroleum ether) 164 # -CH2Ph 0.5 5 0.96 0.34 0.5 ether 0.25 1738 0.59 195:5 ether-methanol) 165 # -CH2CH=CH2 1.15 10 2.56 0.93 1 7:3 0.86 1740 0.29 (3:2 ether~ petroleum ether) 166 # -C5H11 0.9 10 1.93 0.69 1 7:3 0.62 1735 0.31 (3:2 ether petroleum ether) 167 # CH2Ph 1.4 35 2.52 1.18 1 2:3 0.48 1730 0.48 (2: :3 ether petroleum ether) 168 # # 1.0 15 1.67 0.59 0.75 4:1 0.47 1735 8-81 from ether-petrolem ether 169 # -CH2(Me)Ph 1.3 10 2.49 0.89 2 3:2 1.12 1738 0.39 (7:3 ether petroleum ether) 170 # # 0.7 10 1.3 0.46 0.5 4:1 0.62 1735 0.38 (4::1 ether petroleum ether) Example 171 [1α(E), 2/3,501- (+) - 7 - [2 - (4 - Morpholinyl) - 3 - Oxo - 5-(phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
To a cold (5 ) stirred solution of the product from
Example 21 (1.05 g) and dicyclohexyl carbodimide (2.59 g) in dimethylsulphoxide (7 ml) and dry dimethoxyethane (3 ml) was added pyridinium trifluoroacetate (0.73 g). After 15 mins, the cooling bath was removed and stirring continued for 2 hr at room temperature. The resulting suspension was worked up according to the method of Example 148 to afford an oil (0.81 g) which crystallised on cooling.After recrystal lisation from ether-petroleum ether the title compound had m.p. 51-2 IR (CHBr3) 1735,970 cm-1.
Analysis Found: C, 69.6; H, 8.1; N, 3.7;
C24H33NO5 requires: C, 69.4; H, 8.0; N, 3.4%
Example 172 [1 a(E), 2ss, 5α] - (H - 7- [3 - Oxo - 5- (phenylmethoxy) - 2 - (1 -piperidinyl) cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (0.365 g) was prepared from the product of Example 44 (0.57 g) by the method of
Examples 148-170, Table 12.Chromatography in silica eluting with ether-petroleum ether 2:3 gave the title compound as an orange oil. l.R. (CHBr3) 1730 cm Analysis Found: C, 72.2; H, 8.7; N, 3.4;
C25H35NO4 requires: C, 72.6; H, 8.5; N, 3.4%
Example 173 (1', 2ss) - (i) - 7 - [- (4 - Morpholinyl) - 3 - oxocyclopent - 4 - en - 1- yl] heptanoic acid, methyl ester
Pyridinium trifluoroacetate (803 mg) was added to the product of Example 110 (1.023 g) and dicyc
lohexyl carbodiimide (.71 g) in dimethyl sulphoxide (15 ml) and the mixture stirred for 2 hr. The suspension was poured into water (100 ml) and extracted into ether (4 x 50 ml). The combined organic phases were filtered to remove dicyclohexyl urea.The filtrate was washed with water (100 ml) followed by brine, dried (MgSO4) and evaporated under reduced
pressure to afford an oil (1.25 g). The residue was dissolved in pyridine (20 ml) and left at room temperature for 48 hr. Excess pyridine was removed
under high vacuum (1 mm) to afford a semi-solid.
The residue was subjected to short path column chromatography on silica gel (100 g). Elution with diethyl ether gave the title compound as an oil (0.552
g). I.R. (CHBr3) 1725, 1705 cm-1
Analysis Found: C, 65.5; H, 9.1; N, 4.4;
C17H27NO4 requires: C, 66.0; H, 8.8; N, 4.5%
Example 174 [7a/ZI, 2P]-(±)-7-[2-(4- MorpholinylJ-5- oxo -3- cyclopenten - 1- yl] - 5- heptenoic acid, methyl ester
To a solution of the product of Preparation 113 (0.89.) in drytetrahydrofuran (15 ml) was added tet
rabutyl ammonium fluoride (1.56 g). The solution
was allowed to stand at room temperature for 30
mon, then poured into brine (50 ml) and extracted
into ether (3 x 50 ml). The combined ethereal layers
were dried (MgSO4) and evaporated.The residual oil was purified twice by short path column chromatog
raphy, initially using ethyl acetate and then 95.5
ether-methanol as eluents. The title compound was
obtained as an oil (0.21 g). l.R. (CHBr3) 1728, 1704 cm
Analysis Found: C, 66.3; H, 8.7; N, 4.6; C,7H2sNO4 requires: C, 66.4; H, 8.2; N, 4.6%
Example 175 [1α(Z), 2ss, 5α]-(#)-7-[1,1'-Biphenyl-4-yl] methoxy]-2- (4 - morpholinyl) - 3 - oxo - cyclopentyl] - 5- heptenoic acid, methyl ester
To the product of Example 76 (1g) and dicyclohex ylcarbodiimide (1.67 g) in dry dimethylsulphoxide (15 ml) was added pyridinium trifluoroacetate (0.6 g). The mixture was stirred for 1 hr., poured into water (100 ml) and extracted with ether (4 x 75 ml).
The combined organic extracts were filtered (to remove d icyclohexyl urea), washed successively with water (100 ml) and brine (100 ml), dried (over
MgSO4) and evaporated to afford a semi-solid (2.65 g). The residue was triturated with ether/petroleum ether (1 :1) (50 ml), filtered and the filtrate evaporated. The resulting oil was purified by chromatography on silica, eluting with ether/petroleum ether (7:3) to give the title compound as a colourless oil (0.7 g) I.R. (CHBr3) 1735 cm-'.
Analysis Found: C, 73.8; H, 7.9; N, 3.3
C30H37NO5 requires: C, 73.3; H, 7.6; N, 2.9%
Example 176 [1α(Z), 2ss, 5α]-(#)-7-[5-Cyclohexylphenyl- methoxy) - 2- (4 -morpholinyl)-3- oxocyclopentyig - 5- heptenoic acid, methyl ester
To the product of Example 78 (0.8 g) and dicyc lohexylcarbodiimide (1.32 g) in dimethyl sulphoxide (10 ml) was added pyridinium trifluoroacetate (474 mg). The mixture was stirred at room temperature for 1 hr then poured into water (50 ml) and extracted with ether (4 x 50 ml). The combined extracts were filtered (to remove dicyclohexyl urea), washed with water (50 ml) and brine (50 ml), dried (MgSO4) and evaporated.The residual semi-solid was triturated with ether/petroleum ether (1 :1) (20 ml), filtered and the filtrate evaporated. The residue was purified by chromatography on silica, eluting with ether/petroleum ether (4:1) gave a title compound (0.62 g) as a straw coloured oil. l.R. (CHBr3) 1735 cm-1
Analysis Found: C, 72.3; H, 9.0; N, 3.0 C30H43NO5 requires: C, 72.4; H, 8.7; N, 2.8%
Example 177 [1α(Z), 2ss, 5α]-(#)-7-[5-[4-Dimethylamino (phenylmethoxy)] -2- (4- morpholinyl) -3- oxocyclopentyl] - 5- heptenoic acid, methyl ester
To the product of Example 81 (0.51 g) and dicyc
lohexyl carbodiimide (915 mg) in dry dimethyl sul
phoxide (10 ml) was added pyridinium trifluoroacetate (546 mg.). The mixture was stirred for 1 hrthen
poured into water (100 ml) and extracted with ether
(4 x 50 ml). The combined extracts were filtered (to
remove dicyclohexyl urea), washed with water (2 x
50 ml), followed by brine (50 ml), dried (MgSO4) and
evaporated. The residual semi-solid was triturated
with ether: petroleum ether (1 :1) (10 ml), filtered and
the filtrate evaporated.The product was purified by
chromatography on silica, eluting with ether:pet
roleum ether (4:1) gave the title compound (282 mg)
as a colourless oil. l.R. (CHBr,) 1733 cm-1
Analysis Found: C, 67.8; H, 8.5; N, 6.1; C26H40N2Os requires: C, 68.1; H, 8.4; N, 6.1%
Example 178 [1α(Z), 2ss, 5α]-(#)-7-[5-[4-Azido(phenyl- meth ox V)] -2- (4 - morpholinyl) - 3 - oxocyclopentylg - 5- heptenoic acid, methyl ester
To a cold (ca. 10 ) solution of the product of Example 82 (2.68 g) and dicyclohexylcarbodiimide (4.70 g) in dimethylsulphoxide (20 ml) was added pryidinium trifluoroacetate (1.65 g).The reaction was stirred for 30 min at room temperature then poured into water (100 ml) and extracted with dichloromethane (3 x 100 ml). The combined organic layers were filtered, washed with water (200 ml) and brine (200 ml), dried (MgSO4) and the solvent evaporated. The residual oil was treated with ether to remove suspended dicyclohexylurea giving a yellow oil (4.1 g) which was chromatographed on silica. Elution with ether gave the title compound as a yellow oil (1.94g).
I.R. (Neat) 2110, 1740 cm-1
Analysis Found C,63.15; H,7.1; N, 12.9 C24H32N4Os requires C, 63.1; H, 7.0; N, 12.3%
Example 179 [1α(Z), 2ss, 5α]-(#)-7-[5-[4-Amino (phenyl meth ox V)] -2- (4 - morphollnyl) -3- oxocyclopentyl] - 5- heptenoic acid, methyl ester
Freshly activated zinc powder (1.4 g) was added to a mixture of the product of Example 178 (1.0 g), tetrahydrofuran (10 ml) and potassium dihydrogen phosphate solution (1M, 10 ml) at 0'. The reaction mixture was stirred at room temperature for 2 hr., poured into sodium bicarbonate solution (30 ml) and filtered, Extraction of the filtrate with ether (3 x 30 ml) yielded an oil (936 mg) which was chromatographed on silica (Merck 7729,30 g).Elution with ether gave the title compound as a yellow oil (450 mg). l.R. (CHBr3) 3450,3370, 1735 cm-1
Analysis Found: C, 66.7; H, 8.1; N, 6.6;
C27H34N2O5 requires C, 67.0; H, 7.9; N, 6.5%
Example 180 [1α(Z), 2ss, 5α]-(#)-7-[2-[4-morpholinyl)-3-oxo - 5- phenoxycyclopentylg - 5- heptenoic acid, methyl ester
To the product of Example 84 (0.2g) and dicyclohexylcarbodiimide (409 mg) in dry dimethylsulphoxide (3 mls) was added pyridinium trifluoroacetate (147 mgs). After 1 hrthe mixture was poured into water (30 mls) and extracted with dichloromethane (5 x 30 mls), The combined extracts were dried (over
MgSO4) and evaporated to give a semi-solid (650 mgs). The residue was triturated with ether/petroleum ether (7:3) (10 mls), filtered and the filtrate evaporated.The crude product was subjected to chromatography on silica, eluting with ether/petroleum ether (7:3) gave the title compound (136 mg) as a colourless solid which was purified from ether petroleumt ether m.p. 78-79 . I.R. (CHBr30 1740cm-1
Example 181 [1α(Z), 2ss, Sai - (t)- 7-[3-Oxo-2-(4-methyl- 1piperazinyl) - 5- (phenylmethoxy) - cyclopentyl]-5- heptenoic acid, methyl ester, maleate, (1:1)
A solution of the product of Example 3 Table 5 (364 mg) and dicyclohexylcarbodiimide (0.70 g) in dimethylsulphoxide (5 ml) was treated with trifluoroacetic acid (0.163 ml) with water bath cooling.
After 2 hr. triethylamine (0.53 ml) was added with vigorous stirring followed by addition of water (10
ml) and extraction into ether (3 x 15 ml). The com
bined organic layers were filtered, washed with water and brine, dried (MgSO4) and the solvent evaporated. The residual oil was treated with ether/petroleum ether and filtered to remove the suspended dicyclohexylurea. The filtrate was evaporated to give an oil (414 mg) which was chromatographed on silica eluting with glacial acetic acid/methanol/ether 1:50:50. Foilowing elution of the remaining dicyclohexylurea the eluent polarity was increased to glacial acetic acid/methanol/ether 1:75:25. The fractions containing the acetate salt of the ketone were combined and the solvent evaporated. Sodium bicarbonate solution (15 ml) was added and the ketone extracted into ether (3 x 15 ml).
The combined organic portions were washed with water and brine, dried (MgSO4) and evaporated to give an oil (162 mg). A saturated solution of maleic acid in ether was added to a solution of the oil in ether (3 ml) until precipitation of the maleate salt ceased. The mixture was filtered and the solid (186 mg) was purified from ethyl acetate/etherto give the title compound as a white solid (136 mg) m.p. 102-3 .
Analysis Found: C, 63.6; H, 7.1; N, 5.2; C25H3eN2O4.C4H4O4 requires C, 64.0; H, 7.35; N, 5.2%
Example 182 (1og, 2ss, 5e) - (+) - 3 - Oxo - 5- (phenylmethoxy) - 2 - (4 - thiomorpholinyl) cyclopentane heptanoic acid, methyl ester, S-dioxide
A solution of the product of Example 118 (1.8 g) and dicyclohexylcarbodiimide (4 g) in dry dimethylsulphoxide (30 ml) was stirred at room temperature whilst pyridinium trifluoroacetate (1.12 g) was added in one portion. The reaction was stirred at room temperature for 5 days. The reaction mixture was poured into water (300 ml) and ether (100 ml) and stirred for 10 min. The precipitated urea was filtered off and the layers were separated. The aqueous layer was extracted with ether (x3).The combined organic layers were washed with water, dried and evaporated to give an oil which was purified by chromatography on silica. Elution with ether gave a solid (1.4 g) which was purified from ethyl acetatepetrol (40-60 , 1:1) to give the title compound as white prisms (0.96 g) m.p. 81-3 .
Analysis Found: C, 62.0; H, 8.0; N, 3.05; C24H3sSNO6 requires: C, 61.9; H, 7.6; N, 3.0%
Example 183 [104 2ss, 5aj - (t) -2- [N - (2 - Chloroacetyloxyethyl) - N-methyl-amino]-3-oxo-5-(phenylmethoxy) cyclopentane heptanoic acid, methyl ester
Pyridinium trifluoroacetate (1.07 g) was added to a
mixture of the product of Example 122(1.78 g) and
dicyclohexylcarbodiimide (3.03 g) in dry dimethyl sulphoxide (25 ml). After stirring for 30 min. the mixture was poured into water (150 ml) and extracted
into ether (3 x 100 ml). The combined extracts were
dried (MgSO4), filtered and evaporated to afford a
viscous oil (2.6 g). Column chromatography on silica
gel with 1:3 petroleum ether/ether as eluent gave the
title compound (1.12 g) as a yellow oil. l.R. (CHBr3)
1730 cm-1
Analysis Found: C, 61.8; H, 7.7; N, 3.1 C2sH36CINO6 requires: C, 62.3; H, 7.5; N, 2.9%
Example 184 [1α 2ss, 5α]-(#)-2-[N-[2-Hydroxyethyl)-N methylamino] - 3 - oxo - S - (phenylmethoxy) cyclopentane heptanoic acid, methyl ester
Potassium bicarbonate (0.265 g) was added to a solution of the product of Example 183 (0.85 g) in aqueous methanol (10 ml). After stirring for 6 hr. the mixture was poured into a saturated solution of ammonium chloride (75 ml) and extracted into ether (3 x 50 ml).The combined extracts were dried (MgSO4), filtered and evaporated to afford an oil (0.73 g). Column chromatography on silica gel with 10% methanol in ether as eluent gave the title compound (0.64 g) as a yellow oil. l.R. (CHBr3) 3560,3440 (br), 1738 cm-1
Analysis Found: C, 68.4; H, 8.9; N, 3.4; C23H3sNOs requires C, 68.1; H, 8.7; N, 3.4%
Examples 185-198 7 - (2,5 - Disubstituted -3- oxocyclopentyl) heptanoic acid, methyl esters
Table 13 summarises the preparation of the title compounds by the following method: To a cold (-60") solution of acetyl bromide in dry dichloromethane under nitrogen was added dimethylsulphoxide in dichloromethane. After 10 min. a solution of the appropriate alcohol in dichloromethane was added to the activated complex.
The mixture was stirred for approximately half the specified time whereupon triethylamine was added.
The mixture was allowed to reach ambienttemperature when stirring was continued for the remaining time specified. The solution was poured into water, the phases separated, and the aqueous phase extracted with dichloromethane. The remaining work-up is as described in Method A, Table 11. Table 13 (i)
Starting Material DMSO CH3COBr CH2Cl2 Et3N Time Chromatography Yield I.R. (CHBr3) Tlc (Silica) Ex. Vol. Vol. Total Vol hr System (g) Rf (Solvent)* No. Z R Wt (g) (ml) (ml) (ml) Vol. ether- cm-1 ( ml) petroleum ether 185 # # 0.4 0.23 0.213 10 1.2 2.5 9:1 ether- 0.19 3530, 3410, 0.53 methanol 1740, 1678 186 # # 0.51 0.37 0.39 25 1.5 1.25 1:1 ether- 0.23 1740 0.35 methanol 0.14 (m.p.
187 # # 0.9 0.46 0.41 28 3.9 1 3:2 0.64 1738 47.5-48.5 from ether petroleum ether) 188 # # 0.5 0.35 0.36 25 1.45 1.5 4:1 0.39 1740 0.39 189 # -CH2Ph 1.5 0.6 0.6 25 4.6 2.25 7:3 0.7 1730 0.32 190 # -(CH2)3Ph 0.68 0.41 0.34 25 3.2 1.25 3:2 0.4 1737 0.24 Table 3 (ii)
Starting Material Et3N Chromatography DMSO CH3COBr CH2Cl2 Vol. Time System Yield I.R. (CHBr3) Tlc (Silica) Ex. Vol. Vol. Total Vol (ml) hr ether- (g) Rf (Solvent)* No. Z R Wt (g) (ml) (ml) (ml) petroleum ether cm-1 191 # # 1.0 0.7 0.72 35 2.9 1.5 4:1 0.74 1738 0.32 192 # # 0.9 0.6 0.63 35 2.5 1.5 4:1 0.59 1738 0.35 193 # -CH2Ph 1.2 0.67 0.6 41 5.6 1.5 1:3 0.53 1735 0.46 (ether) 194 # # 0.9 0.6 0.63 35 2.5 1.5 4:1 0.46 1735 0.38 195 # # 0.75 0.51 0.53 35 2.1 1.5 4::1 0.63 1735 0.39 196 # -CH2Ph 0.17 0.093 0.083 6 0.78 1.5 1:3 0.13 1735 0.61 (95:5 ether-methanol) 197 # -CH(Me)2 0.65 0.31 0.31 68 2.5 1.5 1:4 0.37 1730 0.14 198 # -CH2CH2Ph 0.65 0.26 0.26 60 2.1 1.5 3:7 0.24 1735 0.27 * Solvent is as described for column chromatography.
Example 199 [1a(Z), 2/3, 5a] - (#)- 7- [5- [4 (1,1 -Dimethylethyl) phenylmethoxy]-2-(4-morpholinyl)-3-oxocyclopentyl] - 5- heptenoic acid, methyl ester
Dry dimethylsulphoxide (0.92 ml) in dry dich
loromethane (10 ml) was added under nitrogen to a
cold (-60 ) solution of acetyl bromide (0.96 ml) in
dry dichloromethane (5 ml). The resultant yellow
activated complex was stirred for 10 min. where
upon the product of Example 83 (1.3 g) in dry dich
loromethane (10 ml) was slowly introduced. After 40
min. triethylamine (3.8 ml) in dry dichloromethane
(10 ml) was added.The solution was stirred at room temperature for a further 45 min. then poured into water (200 ml) and extracted into dichloromethane (3 x 100 ml). The combined extracts were dried
(MgSO4), filtered and evaporated to afford an oil (1.6 g). Chromatography on silica with 20% petroleum ether in ether as the eluent gave the title compound as an orange oil (0.575 g).
I.R. (CHBr3) 1737 cm-t Analysis Found: C, 71.1; H, 9.0; N, 3.0; C2eH41 NO2 requires: C, 71.3; H, 8.8; N, 3.00/0.
Example 200 [ 104 2ss (2i), Sa] - (j) - 2 - [N- (2 - Chloroacetylox yheptyl) - N - methylamino]-3- oxo - S - (phenyl- methoxy) cyclopentane heptanoic acid, methyl ester
Dimethylsulphoxide (0.75 ml) in dry dichloromethane (5 ml) was added dropwise to a cold (-70 ) solution of acetyl bromide (0.69 ml) in dry dichloromethane (5 ml) under nitrogen. After 15 min.
the product of Example 121 (2.33 g) in dry dichloromethane (5 ml) was added dropwise to the yellow suspension. After40 min. triethylamine (5.8 ml) in dichloromethane (4 ml) was added and the mixture stirred at room temperature for 1 hr. The suspension was poured into 8% sodium bicarbonate solution (100 ml) and extracted with dichloromethane (3 x 100 ml). The combined organic extracts were washed with brine, dried (MgSO4) and concentrated to afford a dark red oil. The product was purified by chromatography on silica. Elution with petroleum ether in ether 1:1 gave the title compound as a yellow oil (1.47 g).
I.R.(CHBr3) 3600, 3500(br), 1730 cm-1
Analysis Found: C, 65.7; H, 8.6; N, 2.6.
C30H46CINO6 requires: C, 65.3; H, 8.4; N, 2.5%.
Example 201 [1α 2ss (2#1)]-(#)-2[N-(2-Hydroxyhetyl)-N- methylamino] -3- oxo - cyclopent-4 4- ene heptanoic acid, methyl ester
Potassium bicarbonate (0.34 g) was added to a cold (0 ) solution of the product of Example 200 (0.61 g) in methanol (5 ml) and water (0.5 ml). The mixture was stirred rapidly at room temperature for 38 hr., poured into saturated ammonium chloride solution (50 ml) and extracted into dichloromethane (3 x 100 ml). The combined organic extracts were washed with brine, dried (MgSO4) and concentrated. The product was combined with material from three further reactions (780 mg) and subjected to short
path column chromatography on silica gel. Eluting
with 3% methanol in dichloromethane gave the title compound (340 mg).The title compound was further
purified by a column chromatography on silica using 15% petroleum ether (40-60 ) in ether as eluent and obtained as a yellow oil (182 mg).
I.R. (Neat) 3440 (br), 1740, 1710 cm-1
Analysis Found: C, 68.2; H, 10.4; N, 3.8; C2.H37NO4 requires: C, 68.6; H, 10.2; N, 3.8%
Example 202 [1α, 2ss (2#), 5α]-(#)-2-[N-(2-Hydroxyheptyl)-N - methylamino] - 3 - oxo - 5- tphenylmethoxy) cyclopentane heptanoic acid, methyl ester
The title compound (110 mg) was obtained from the experiment described in Example 201 byfurther elution of the short path silica column with 3% methanol in dichloromethane.
I.R. (Neat) 3450, 1740 cm-1
Analysis Found: C, 70.2; H, 9.8; N, 3.1; C26H45NOs requires: C, 70.7; H, 9.5; N, 3.00/0 Examples 203-207 (1α,2ss,5α)-(#)-2,5-Disubstituted-3- oxocyclopentane heptanoic acid, methyl esters
Table 14 summarises the preparation of the title compounds by the following method: A solution of the appropriate alkene in ethyl acetate or methanol was hydrogenated over prereduced 10% palladium on charcoal at atmospheric pressure. When the hydrogen uptake ceased after the time specified, the mixture was filtered through hyflo and evaporated. The residue when necessary was chromatographed on silica gel with the solvent specified to give the title compound.
Table 14
Starting Material Product PdO EtoAc MeOH Time Chromatography Yield I.R. (CHBr3) Tlc (Silica) Wt. (g) Vol. Vol. hr System (g) cm-1 Rf (Ether) Ex. (ml) (ml) No. R Wt R (g) 203 -CH2Ph 0.5 -CH2Ph 0.1 - 25 3 - 0.43 1735 0.6 204 -CH2Ph 0.565 -CH(Ph)2 0.1 - 50 0.5 4:1 Ether- 0.37 1732 0.51 petroleum ether 0.5 205 -CH2CH2Ph 0.82 -CH2CH2Ph 0.1 - 70 0.5 3:2 Ether- 0.59 1735 (m.p. 39-40 petroleum ether 206 -CH(Me)2 0.2 -CH(Me)2 0.05 15 - 0.5 Ether 0.195 1730 0.48 207 # 0.86 # 0.43 15 0 0.25 Ether 0.5 3450, 3380, 1738 0.2 Example 208 [1α, 2ss, 5α[-(#)-5-[[(1,1'-Biphenyl)-4-yl] methoxy] - 2- (4- morpholinyl) -3- oxocyclopentane heptanoic acid, methyl ester
A solution of the product of Example 175 (0.5 g) in ethyl acetate (15 ml) was hydrogenated over prereduced 10 palladium oxide on charcoal (200 mg) in ethyl acetate (5 ml). Uptake of hydrogen was complete after 1 hr. (21.5 ml, cf. theoretical 26.9 ml). The mixture was filtered and the ethyl acetate evaporated in vacuo.The resulting solid (500 mg) was chromatographed on silica, eluting with ether to give the title compound as a white solid (0.4 g) m.p. 56-7'.
Analysis Found: C, 73.4; H, 8.15; N, 3.0; C3DH39NOs requires: C, 73.0; H, 7.9; N, 2.8%
Example 209 (1α, 2ss, 5α)-(#)-[2-(2,6-cis-Dimethyl-4- morpholinyl)-3- oxo - S - (phenyl - methoxy) cyclopentane heptanoic acid, methyl ester
A solution of the product of Example 193 Table 13 (0.55 g) in ethanol (39 ml) was treated according to the method of Examples 203-207, Table 14.
Chromatography on silica eluting with etherpetroleum ether 1:4 gave the title compound as an oil (0.17 g).
I.R.(CHBr3) 1735 cm-1.
Analysis Found: C, 69.7; H, 9.15; N, 3.15; C2eH3tNO, requires: C, 70.1; H, 8.8; N, 3.15% Example 210 [1α(Z), 2ss, 5α]-(#)-7-[5-[4-Formyl(phenyl- methoxy]-2-(4-morpholinyl)-2-oxo-cyclopen
tyl] - 5- heptenoic acid, methyl ester
The title compound (0.49 g) was prepared from the
product of Example 50 (0.7 g) using the procedure
described for Examples 148-170 Table 12.
Chromatography on silica, eluting with ether, gave
an oil. I.R. (Neat) 1740, 1700cm-1.
Analysis Found: C, 67.5; H, 7.6; N, 3.6.
C2sH33NO6 requires: C, 67.7; H, 7.5; N, 3.2%
Example21 1 [1α(Z), 2ss, 3α, 5α)-(3)-7-[5(2-Azido (phenylmethoxy]-3-hydroxy-2-(4-morpholinyl)cyc lopentylg - 5 - heptenoic acid, methyl ester
The title compound (4.9 g) was prepared from the
product of Preparation 100 (5 g) and - 2 - oxidobenzyl
bromide (14 g) according to Method Al described for
Tables 7-9. Chromatography on silica, eluting with
ether-petroleum ether (3:1), then (1 :1), gave the pro
duct as an oil. I.R. (Neat) 3460, 2140, 1740 cm-1.
T.l.c. (Silica) Rf. 0.47 (4:1, ether-acetone).
Example 212 [1α(Z), 2ss, 5α-(#)-7-[5-[2-Azido(phenyl- methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]
5- heptenoic acid, methyl ester
The title compound (1.19 g) was prepared from the
product of Example 211 (2.4 g) using the procedure
described for Example 185-198, Table 13.
Chromatography on silica, eluting with ether
petroleum ether (1:1), gave the product as an orange
oil. l.R. (Neat) 2115, 1740 cm-'.
T.l.c. (Silica) Rf. 0.59 (Ether-acetone, 2:1).
Example 213 [1α(Z), 2ss, 5α]-(#)-7-[5-[2Amino(phenyl- methoxy]-2-(4-morpholinyl-3-oxocyclopentyl]
5- heptenoic acid, methyl ester
The title compound (0.66 g) was prepared from the product of Example 212 (1.1 g) using the procedure described for Example 179. Chromatography on silica, eluting with ether-petroleum ether(1 :1), gave the product as a yellow oil. l.R. (Neat) 3455,3370, 1738 cm-1.
Analysis Found: C, 66.5; H, 8.2; N, 6.7 C24H34N2Os requires: C, 67.0; H, 7.9; N, 6.5%.
Example 214 [1α(Z), 2ss, 3α, 5α]-(#)-7-[5-[4-Amino (phenylmethoxy]-3-hydroxy-2-(4-morpholinyl)cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (3.95 g) was prepared from the product of Example 82 (4.4 g) using the procedure described for Example 179.
I.R. (Neat) 3450, 3360, 1738 cm-1.
T.l.c. (Silica) Rf. 0.45 (9:1, ether-methanol)
Example 215 [1α(Z), 2ss, 3α, 5α)-(#)-7-[3-Hydroxy-2-(4- morpholinyl) - 5- [4 - pyrrolidinyl (phenyl- methoxy)]cyclopentyl] - 5- heptenoic acid, methyl ester
A mixture of the product of Example 214(1.5 g), 1, 4- dibromobutane (0.99 g) and potassium carbonate (0.72 g) in acetonitrile (20 ml) was heated at 85 when stirring for 24 hr. 8% Sodium bicarbonate solution (100) ml was added and the mixture was extracted with ether. The combined extracts were worked with
brine, dried (MgSO4) and evaporated to give an oil
(1.86 g). Chromatography on silica, eluting with ether-methanol (95:5), gave the title compound as a straw coloured oil (1.2 g).I.R. (Neat) 3450, 1740 cm-1.
Analysis Found: C, 69.1; H, 9.15; N, 5.6.
C28H42N2O5 requires: C, 69.1; H, 8.7; N, 5.8%.
Example 216 [la(ZI, 2ss, so] - (t)- 7- [2- (4-Morphollnyl)-3- oxo -5 - [4 - pyrrolldinyl (phenylmethoxy)]cyclopentyl] - 5 - heptenoic acid, methyl ester
The title compound (0.3 g) was prepared from the
product of Example 215 (0.55 g) using the procedure described for Examples 148-170, Table 12.
Chromatography on silica, eluting with ether
petroleum ether (2:1), afforded the product as an oil.
I.R. (Neat) 1740 cm-'.
Analysis Found: C, 69.05; H, 8.5; N, 5.7.
C28H40N2Os requires: C, 69.4; H, 8.3; N, 5.8%
Example 217 [1α(Z), 2ss, 3α, 5α]-(#)-7-[3-Hydroxy-2-(4- Morpholinyl) - 5- [4 - dipropylamino (phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
A mixture of the product of Example 214, (0.5 g), propanol (0.67 g) and sodium cyanoborohydride
(0.22 g) in acetonitrile (4 ml) and water (1.8 ml) was
cooled at 0 with stirring whilst glacial acetic acid
(0.15 ml) was added overca. 2 minutes. The reaction
mixture was allowed to warm to room temperature
and stirred for a further 2 hr. The reaction mixture
was diluted with ether and washed with 1 N sodium
hydroxide solution and brine. The organic layer was
dried and evaporated to give an oil which was
chromatogaphed on silica. Eluting with ether
methanol (98:2) gave the title compound as a straw
coloured oil (0.29 g).
I.R. (Neat) 3450, 1740 cm-'.
Analysis Found: C, 69.8; H, 9.8; N, 5.45.
C30H48N2Os requires: C, 69.7; H, 9.4; N, 5.4%.
Example 218 [1α(Z), 2ss, 5α]-(#)-7-[2-(4-Morpholinyl)-3-oxo -5-[dipropylamino (phenylmethoxy] cyclopentyl]5- heptenoic acid, methyl ester
The title compound (0.34 g) was prepared from the product of Example 217 (0.52 g) using the procedure described for Examples 148-170 (Table 12).
Chromatography on silica, eluting with etherpetroleum ether (2:1), gave a colourless oil.
I.R. (Neat) 1740 cm-1.
Analysis Found: C, 69.6; H, 9.0; N, 5.5.
C30H46N2Os requires: C, 70.0; H, 9.0; N, 5.4%
Example 219 [1α, 2ss, 5α]-(#)-5-[[(1,1'-Biphenyl)-4- yl]methoxy] -3- oxo - 2 - (1- piperidinyl) cyclopentane heptanoic acid, methyl ester
The title compound (0.04 g) was prepared from the product of Example 137 (0.18 g) using the procedure described for Examples 203-207 (Table 14).
Chromatography on silica, eluting with ether, gave the product as a colourless oil.
I.R. (Neat) 1740 cm-'.
Analysis Found: C, 75.5; H, 8.8; N, 2.8.
C31H41NO4 requires: C, 75.7; H, 8.4; N, 2.85%.
Example 220 [1α(Z), 2ss, 3α, 5α]-(#)-7-[5-[4-Azido(phenyl- methoxy)]-2-(1-piperidinyl)-3-[(tetrahydro-2Hpyran - 2 - yl)oxy]cyclopentyl] - 5- heptenoic acid, methyl ester.
The title compound (2.55 g) was prepared from the product of Preparation 98 (3.3 g) and 4 - azidobenzyl bromide (10.4 g) according to Method B described for Tables 7-9. Chromatography on silica, eluting with ether, gave a dark orange oil.
I.R. (Neat) 2100, 1740cm-1.
T.l.c. (Silica) Rf 0.5 (ether)
Example 221 [1α(Z), 2ss, 3α 5α]-(#)-7-[5-[4-Azido(phenyl- methoxy)]-3-hydroxy-2-(1-piperidinyl)cyclopentyl] - 5- heptenoic acid, methyl ester.
The title compound (1.2 g) was prepared from the product of Example 220 (2.0 g) according to Method
C2 described for Tables 7-9. Chromatography on silica, eluting with ethermethanol (95:5), gave a yellow oil.
I.R. (Neat) 3440,2110,1738cm-1.
Analysis Found: C, 65.5; H, 7.6; N, 12.0 C25H36N4O4 requires: C, 65.8; H, 8.0; N, 12.3%.
Example 222 [1α(Z), 2ss, 5α]-(#)-7-[5-[4-Azido(phenyl- methoxy)]-3- oxo - 2 - (1- piperidinyl)cyclopentyl] 5 - heptenoic acid, methyl ester
The title compound (0.79 g) was prepared from the product of Example 221 (1.21 g) using the procedure described for Examples 148-170 (Table 12).
Chromatography on silica, eluting with etherpetroleum ether (1:2), gave an oil.
I.R. (Neat) 2120, 1740cm-1.
T.l.c. (Silican) Rf. 0.8 (Ether-methanol, 95.5).
Example 223 [1α(Z), 2ss, 5α]-(#)-7-[5-[4-Amino(phenyl- methoxy]-3- oxo - 2 - (1- piperidinyl)cyclopentyl] 5 - heptenoic acid, methyl ester
The title compound (0.25 g) was prepared from the product of Example 222 (0.39 g) using the procedure described for Example 179. Chromatography on silica, eluting with ether, gave the product as an oil.
I.R. (Neat) 2460,2375, 1740 cm-'.
T.l.c. (Silica) Rf. 0.4 (Ether).
Example 224 [1α(Z), 2ss, 3α 5α]-(#)-7-[3-Hydroxy-2-(4- morpholinyl)- 1 - (naphthalenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (1.6 g) was prepared from the product of Preparation 100 (2.06 g), 1-chloromethylnaphthalene (5.3 g) and sodium bromide (3.1 g) according to Method Al described for Tables 7-9. Chromatography on silica, eluting with ether-methanol (97:3), gave the product as an oil.
I.R. (Neat) 3450 (br), 1740 cm-1.
T.l.c. (Silica) Rf. 0.26 (Ether-methanol, 97:3)
Example 225 [1α(Z), 2ss, 5α]-(#)-7-[2-(4-Morpholinyl)-5α(1- naphthalenylmethoxy) - 3 oxocyclopentyl] - S - heptenoic acid, methyl ester.
The title compound (0.5 g) was prepared from the product of Example 224 (0.7 g) using the procedure described for Examples 148-170 Table 12.
Chromatography on silica, eluting with etherpetroleum ether (4:1), gave an oil.
I.R. (Neat) 1740 cm-1.
T.l.c. (Silica) Rf.0.4 (ether-petroleum ether, 4:1).
Example 226 [1α(Z),-(#)-7-[2-[N-methyl-N
[1α(Z), 2ss, 5α]-(#)-7- [2-[N-methyl-N- (phenylmethy/)amino] - 5- (phenylmethoxy) - 3 - cyclopenten - 1- yl] - 5- heptenoic acid, methyl ester
The title compound (0.52 g) was prepared from the
product of Example 32 (0.8 g) according to Method B
described for Tables 7-9. Chromatography on silica,
eluting with ether-petroleum ether (1:3) ether (2:3),
gave an oil. I.R. (Neat) 1740 cm-'.
T.l.c. (Silica) Rf. 0.55 (Ether-petroleum, ether, 3:2).
Example 227 [1α(Z), 2ss, 3α 5α]-(#)-7-[3-Hydroxy-2-[N- methyl - N- [2 - (phenylmethoxy) ethyl] amino] - 5
(phenylmethoxy) cyclopentyl-] 5] heptenoic acid, methyl ester
The title compound (0.55 g) was prepared from the
product of Preparation 116 (1.44 g) according to
Method C2 described for Tables 7-9. Chromatogra
phy on silica, eluting with ether-petroleum ether
(1:1) then ether, gave the product as an oil.
I.R. (CHBr3) 3540, 1730 cm-1.
Analysis Found: C, 72.6; H, 8.55; N, 2.85.
C30H41NO5 requires: C, 72.75; H, 8.3; N, 2.85%.
Example 228 [1α(Z), 2ss, 3α 5α]-(#)-7-[3-Hydroxy-2-[N- methyl N- (4-phenoxybutyl) amino]-5- (phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (0.48 g) was prepared from the product of Preparation 117 (1.37 g) according to
Method C2 described for Tables 7-9. Chromatography on silica, eluting with ether-petroleum ether (1 :1), then (2:1), gave the product as an amber oil.
I.R. (CHBr3) 3540, 1730 cm-'.
T.l.c. (Silica) Rf. 0.57 (ether-methanol, 9:1)
Example 229 [1α(Z), 2ss, 3α 5α]-(#)-7-[3-Hydroxy-2-[N- methyl- N- (5-phenylpentyl) amino] - 5- (phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (0.7 gj was prepared from the
product of Preparation 118 (15 g) according to
Method C2 described for Tables 7-9. Chromatogra
phy on silica, eluting with benzene-ethyl acetate
(3:1), then (1:1), gave the product as a pale-yellow
oil.
I.R. (CMBr3) 3540, 1730 cm-1.
Analysis Found: C, 75.5; H, 9.0; N, 2.8 C32H4sNO4 requires: C, 75.7; H, 8.9; N, 2.8%.
Example 230 [1α(Z), 2ss, 5α]-(#)-7-[2-Methyl-N-[2- (phenyl methoxy) ethyl amino]-3- oxo - 5 (phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester.
The title compound (0.06 g) was prepared from the product of Example 227 (0.43 g) using the procedure described for Examples 185-198 (Table 13). Repeated chromatography on silica, eluting with benzeneethyl acetate (20:1), gave the product as a pale yellow oil.
Analysis Found: C, 72.8; H, 8.2; N, 2.9.
C30H34NO5 requires: C, 73.0; H, 7.9; N, 2.8%.
Example 231 [1α(Z), 2ss, 5α]-(#)-7-[2-[N-Methyl-N-(4- phenoxybutyl) amino] - 3 - oxo - 5- (phenylmethox y)cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (0.046 g) was prepared from the product of Example 228 (0.31 g) using the procedure described for Examples 185-198 (Table 13).
Repeated chromatography on silica, eluting with benzene-ethyl acetate (20:1), gave the product as a colourless oil.
I.R. (Neat) 1740 cm-'.
Analysis Found: C, 72.4; H, 8.1; N, 2.7.
C3H4,NOs requires: C, 73.35; H, 8.1; N, 2.75%.
Example 232 [1a(Z),2/3 2W 50 - 11- 7- [2 -CN-Methyl-N- /5- phenylpentyl)amino]-3-oxo-5-(phenylmethoxy) cyclopentyl] - 5- heptenoic acid, methyl ester
The title compound (0.15 g) was prepared from the product of Preparation 229 (0.59 g) using the procedure described for Examples 148-170 (Table 12).
Chromatography on silica, eluting with benzene ethyl acetate (25.1), gave an oil.
I.R. (Neat) 1740 cm-1.
T.l.c. (Silica) Rf. 0.3 (benzene - ethyl acetate, 5:1).
Example 233 [1α(Z), 2ss, 5α]-(#)-7-[2-(2-Hydroxyheptyl)- N-methylamino]-5-(phenylmethoxy)-3-cyclopenten - 1- yl] - 5- heptenoic acid, methy ester.
The title compound (0.1 g) was prepared from the
product of Preparation 121 (1.4 g) g) according to
Method Al described for Tables 7-9. Chromatogra
phy on silica, eluting with ether-petroleum ether
(3:2), gave the product as an oil.
I.R. (Neat) 3450, 1740 cm-'.
T.l.c. (Silica) Rf. 0.19 (Ether-petroleum ether, 3:2).
Pharmaceutical Examples
Tablets
These may be prepared by direct compression or
wet granulation. The direct compression method is
preferred but may not be suitable in all cases as it is
dependent upon the dose level and physical characteristics of the active ingredient.
A. Direct Compression mg/tablet
Active ingredient 100.00
Microcrystalline Cellulose
B.P.C. 298.00
Magnesium Stearate 2.00
Compression Weight 400.00
The active ingredient is sieved through a 250 m
sieve, blended with the excipients and compressed
using 10.0mm punches. Tablets of other strengths
may be prepared by altering the compression weight
and using punches to suit.
B. Wet Granulation mg/tablet
Active ingredient 100.00
Lactose B.P. 238.00
Starch B.P. 40.00 Pregelatinised Maize
Starch B.P. 20.00
Magnesium Stearate B.P. 2.00
Compressed Weight 400.00
The active ingredient is sieved through a 250,am sieve and blended with the lactose, starch and pregelatinised starch. The mixed powders are moistened with purified water, granules are made, dried, screened and blended with the Magnesium Stearate.
The lubricated granules are compressed into tablets as described for the direct compression formulae.
The tablets may be film coated with suitable film forming materials, e.g. methyl cellulose or hydroxypropyl methyl cellulose using standard techniques.
Alternatively the tablets may be sugar coated.
Capsules mg/capsule
Active ingredient 100.00 *STA-RX 1500 99.00
Magnesium Stearate B.P. 1.00
Fill Weight 200.00 mg * A form of directly compressible starch supplied by
Colorcorn Ltd., Orpington, Kent.
The active ingredient is sieved through a 250 m sieve and blended with the other materials. The mix is filled into No. 2 hard gelatin capsules using a suitable filling machine. Other doses may be prepared by altering the fill weight and if necessary changing the capsule size to suit.
Syrup mg/5ml dose
Active ingredient 100.00
Sucrose B.P. 2750.00
Glycerine B.P. 500.00
Buffer
Flavour
Colour # as required
Preservative
Distilled Water 5.00ml
The active ingredient, buffer, flavour, colour and
preservative are dissolved in some of the water, and
the glycerine is added. The remainder of the water is
heated to 80 C and the sucrose is dissolved in this
and cooled. The two solutions are combined,
adjusted to volume and mixed. The syrup produced is clarified by filtration.
injection for Intravenous Administration % w/v
Active ingredient 0.50
Water for injections B. P. to 100.00
Sodium chloride may be added to adjust the toxicity of the solution and the pH may be adjusted to that of maximum stability and/or to facilitate solution of the active ingredient using either dilute acid or alkali.
The solution is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass. The injection is sterilised by heating in an autoclave using one of the acceptable cycles. Alternatively the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions. The solution may be packed under an inert atmosphere of nitrogen.
Inhalation Cartridges /cartridge
Active ingredient (micronised) 3mg
Lactose B.P. to 25mg
The active ingredient is micronised so that the majority of the particles are between 1,um and 5,um in longest dimension and none are greaterthan 10 m. The active ingredient is then blended with the lactose and the mix is filled into No. 3 hard gelatin capsules using a suitable filling machine.
Claims (13)
1. Prostanoids of the general formula (1)
in which
A represents
Xis cis or trans -CH=CH- or-(CH2)2-;
R1 is straight or branched C17 alkyl bearing as a terminal substituent-COOR10 where R10 is a hydrogen atom, Cie alkyl or C7-10 aralkyl;;
Y represents (i) - NR2R3 where R2 and R3 are the same or different and are each a hydrogen atom, aralkyl having a C17 alkyl portion or C1 -it alkyl, both alkyls being optionally substituted by one or more substituents-OR7 (where R7 is a hydrogen atom, C17 alkyl, aryl or aralkyl having a C,, alkyl portion) or -NR8R9 (where R6 and R9 are the same or different and are each a hydrogen atom or C1-4 alkyl, or where -NR8R9 is a saturated heterocyclic amino group as defined below for Y); any aryl group in R2 or R3 being optionally substituted by one or more C14 alkyl or trifluoromethyl groups; always provided that the total numbers of carbon atoms in the group -NR2R3 does not exceed 15;
or (ii) a saturated heterocyclic amino group which has 5-8 ring members and (a) optionally contains in the ring -0--S-, -SO2-, -NR14- (where R14 is a hydrogen atom, C17 alkyl or aralkyl having a C,, alkyl portion), > C(OH)R6 (where Rs is a hydrogen atom, C17 alkyl, phony, or aralkyl having a C1-4 # alkyl por- tion); and/or (b) is optionally substituted by one or more C1-4 alkyl groups;
R4 is a hydrogen atom, C1-6 alkyl (optionally interrupted by one or two oxygen atoms), C3e alkenyl,
C2-4 alkanoyl, aralkanoyl having a C24 alkanoyl portion, aryl or aralkyl having a C1-3 alkyl portion (the aryl portion being optionally substituted by one or more halogen, hydroxy, C1-6 alkyl, Cie alkoxy, C,, hydroxyalkoxy, trifluoromethyl, cyano, phenyl, aryloxy, Ca-7 cycloalkyl, aralkoxy, dimethylaminomethyl, carboxamido (-CONH2), thiocarboxyamido (-CSNH2), C1-4 alkanoyl or-NR8R9 groups as defined above);
R5 as is defined above for R4, excluding aryl and with the proviso that R5 is not hydrogen when A is the group (h);
and the physiologically acceptable salts thereof; provided that when A is the group (a) in which both
R4 and Ra are hydrogen atoms and Y is the group -NR2R3 in which R2 is a hydrogen atom or C1-4 # alkyl, R3 is not an alkyl group which is only substituted by a hydroxy group.
2. Compounds as claimed in claim 1 wherein A is the group (a), (c) or (g).
3. Compounds as claimed in claim 1 or claim 2 wherein R1 is -(CH2)2 COOR10 where R10 is a hydrogen atom or a C13 alkyl group.
4. Compounds as claimed in any one of the preceding claims wherein Y is a saturated heterocyclic amino group having 5-7 ring members.
5. Compounds as claimed in claim 4 wherein Y is pyrrolideno, piperidino, piperidino substituted by hydroxy, morpholino, thiamorpholino, 1-dioxothiamorpholino, piperazino, hormomorpholino or hexamethyleneimino, said groups being optionally substituted by one or more C,, alkyl groups.
6. Compounds as claimed in any of the preceding claims wherein Y is a morpholino group, which is optionally substituted by one or more methyl groups.
7. Compounds as claimed in any one of the preceding claims wherein A is the group (c).
8. Compounds as claimed in any one of the preceding claims wherein R4 is Cie alkyl, Cie alkyl interrupted by one or two oxygen atoms, benzyl or
phenethyl, said benzyl and phenethyl groups being optionally substituted by one or more halogen atoms or Time alkyl, C1-6 alkoxy, trifluoromethyl, cyano, phenyl, Ca7 cycloalkyl, amino, dialkylamino, carboxamido, thiocarboxamido, dimethylaminomethyl or formyl groups.
9. Compounds as claimed in claim 1, wherein Y is other than a saturated amino group having 8 ring members and R4 is other than aralkyl substituted by dimethylaminomethyl, carboxamido,thiocarboxamido or Ct 4 alkanoyl.
10. Compounds as claimed in claim 1 wherein:
A is the group (c), Xis cis-CH=CH-, R1 is-(CH2)3- COOCH3, Y is morpholino, and R4 is 4 - phenylbenzyl, 4 - dimethylaminobenzyl, 4 - cyclohexylbenzyl, 4 - aminobenzyl or4-t- butylbenzyl;
or wherein A is the group (c), X is cis -(CH=CH)-,
R1 is -(CH2)3COOH, Y is morpholino and R4 is 4 phenylbenzyl, or 4 - cyclohexylbenzyl;
or wherein A is the group (c), X is -(CH2)2-, Y is morpholino, R4 is 4 - phenylbenzyl and R1 is -(CH2)3COOCH3 or-(CH2)3COOH.
11. A pharmaceutical composition comprising a compound as claimed in any one of the preceding claims and one or more pharmaceutical carriers.
12. A process for the preparation of a compound as claimed in claim 1, which process comprises:
(a) in the preparation of a compound of formula (2)
(where R1a is as defined in claim 1 for R1 where R1 bears a terminal -COOH group, and Y and R4 are as defined in claim 1), reacting a lactol of formula (3), or the aldehyde isomer thereof.
(where Y is as defined above and -OR4, is as defined above for -OR4 or is a protected hydroxy group) with a phosphane of formula R113 P=CHRta or a salt thereof (where R1, is as defined above and R11 is Cie alkyl or aryl), followed, where R4 is hydrogen, by removal of the protecting group -R4a; any hydroxy or amino group present in Y being protected during the reaction;
(b) in the preparation of a compound of formula (8)
(where R1, is as defined above, Ya is as defined in claim 1 for Y other than amino, and R5 is as defined in claim 1), reacting a compound of formula (9)
(where Ya is as defined above and -OR5a is as defined in claim 1 for-OR5 or is a protected hydroxy group) with a phosphorane of the formula R113 P=CHR1, (as defined above) or a salt thereof; any hydroxy group present in Y" being protected during the reaction;
(c) in the preparation of a compound of formula (12)
(where R4, R5 and X are as defined in claim 1 and R1, is as defined above), reducing a compound of formula (13))
(d) in the preparation of a compound of formula (17)
(where R1" is as defined above - Y is as defined in claim 1), treating a compound of formula (18)
with a phosphorane of the formula R113P=CHR1a (as defined above) or a salt thereof, any hydroxy or amino group present in Y being protected during the reaction;
(e) in the preparation of a compound in which R is terminally substituted by an esterified carboxy group, esterifying the corresponding carboxylic acid;;
(f) in the preparation of a compound in which R is terminally substituted by a carboxyl group, saponifying a corresponding ester;
(g) in the preparation of a compound in which X is trans -CH=CH-, isomerising the corresponding cis compound;
(h) in the preparation of a compound in which X is -(CH2)2-, catalytically hydrogenating a corresponding compound in which X is-CH=CH-;
(i) in the preparation of a compound in which R4 or R5 is alkyl, alkenyl or aralkyl, etherifying the cor
responding hydroxy compound;
(j) in the preparation of a compound in which R4 or R5 is alkanoyl or aralkanoyl, esterifying the cor
responding hydroxy compound; ;
(k) in the preparation of a compound in which R4
or R5 is a hydrogen atom, removing the protecting
group from a corresponding compound having a
protected hydroxy group from a corresponding
compound having a protected hydroxy group;
(I) in the preparation of a compound having an oxo group at the 9-or 11-position, oxidising the corresponding hydroxy compound;
(m) in the preparation of a compound in which A is the group (d) or (b), eliminating R4aOH or R5aOH from a corresponding compound in which A is the group (c) or (h), R4a and R5" being as defined above;
(n) in the preparation of a compound in which A is the group (e) or (f), catalytically hydrogenating the corresponding compound in which A is the group (d) or(g);;
(o) in the preparation of a compound in which Y is a mono- or disubstituted amino group, modifying a corresponding primary or secondary amine;
(p) in the preparation of a compound in which R4 is aralkyl substituted by amino, reducing the corresponding azide;
(q) in the preparation of a compound in which R4 is aralkyl substituted by-CH2N(CH3)2, reacting the corresponding formyl compound with dimethylamine in the presence of a reducing agent;
(r) in the preparation of a compound in which R4 is aralkyl substituted by-CONH2 or-CSNH2, hydrolysing or hydrosulphiding the corresponding cyano compound; or
(s) in the preparation of a salt, treating a compound as claimed in claim 1 with an acid or treating a compound in which R10 is a hydrogen atom with a base.
13. A compound as claimed in claim 1, said compound being the title compound of any one of the examples.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB7924204A GB2028805B (en) | 1978-07-11 | 1979-07-11 | Prostanoid compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB7829403 | 1978-07-11 | ||
GB7924204A GB2028805B (en) | 1978-07-11 | 1979-07-11 | Prostanoid compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2028805A true GB2028805A (en) | 1980-03-12 |
GB2028805B GB2028805B (en) | 1982-11-03 |
Family
ID=26268169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB7924204A Expired GB2028805B (en) | 1978-07-11 | 1979-07-11 | Prostanoid compounds |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2028805B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2481703A1 (en) * | 1980-04-30 | 1981-11-06 | Glaxo Group Ltd | AMINOCYCLOPENTANE-ALKENOIC ACIDS AND THEIR ESTERS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS |
EP0069447A2 (en) * | 1981-04-29 | 1983-01-12 | Glaxo Group Limited | Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation |
EP0074861A1 (en) * | 1981-09-16 | 1983-03-23 | Glaxo Group Limited | Aminocyclopentane esters and their preparation and pharmaceutical formulation |
EP0078668A1 (en) * | 1981-10-29 | 1983-05-11 | Glaxo Group Limited | Preparation of aminocyclopentanealkenoic acids |
EP0127930A2 (en) * | 1983-03-15 | 1984-12-12 | Glaxo Group Limited | Aminocyclopentane esters and their preparation and pharmaceutical formulation |
FR2551440A1 (en) * | 1983-09-06 | 1985-03-08 | Glaxo Group Ltd | AMINOCYCLOPENTANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
GB2165235A (en) * | 1984-09-05 | 1986-04-09 | Glaxo Group Ltd | Carbocyclic compounds |
GB2165535A (en) * | 1984-09-05 | 1986-04-16 | Glaxo Group Ltd | Carbocyclic compounds |
US4628061A (en) * | 1981-12-23 | 1986-12-09 | National Research Development Corporation | Prostaglandins |
EP0296802A1 (en) * | 1987-06-22 | 1988-12-28 | Glaxo Group Limited | Aminocyclopentyl ethers and their preparation and pharmaceutical formulation |
US8513027B2 (en) | 1997-09-25 | 2013-08-20 | Asterand Uk Acquisition Limited | Method of identifying an inhibitor of the prostanoid EP4 receptor |
-
1979
- 1979-07-11 GB GB7924204A patent/GB2028805B/en not_active Expired
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3117087A1 (en) * | 1980-04-30 | 1982-03-11 | Glaxo Group Ltd., London | "AMINOCYCLOPENTANAL ACID ACIDS AND ESTERS AND THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS" |
US4327092A (en) | 1980-04-30 | 1982-04-27 | Glaxo Group Limited | Aminocyclopentane alkenoic acids and esters and pharmaceutical formulations |
FR2481703A1 (en) * | 1980-04-30 | 1981-11-06 | Glaxo Group Ltd | AMINOCYCLOPENTANE-ALKENOIC ACIDS AND THEIR ESTERS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS |
EP0069447A2 (en) * | 1981-04-29 | 1983-01-12 | Glaxo Group Limited | Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation |
EP0069447A3 (en) * | 1981-04-29 | 1983-03-16 | Glaxo Group Limited | Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation |
EP0074861A1 (en) * | 1981-09-16 | 1983-03-23 | Glaxo Group Limited | Aminocyclopentane esters and their preparation and pharmaceutical formulation |
EP0078668A1 (en) * | 1981-10-29 | 1983-05-11 | Glaxo Group Limited | Preparation of aminocyclopentanealkenoic acids |
US4628061A (en) * | 1981-12-23 | 1986-12-09 | National Research Development Corporation | Prostaglandins |
US5006539A (en) * | 1981-12-23 | 1991-04-09 | National Research Development Corporation | Prostaglandins |
EP0127930A3 (en) * | 1983-03-15 | 1985-03-06 | Glaxo Group Limited | Aminocyclopentane esters and their preparation and pharmaceutical formulation |
EP0127930A2 (en) * | 1983-03-15 | 1984-12-12 | Glaxo Group Limited | Aminocyclopentane esters and their preparation and pharmaceutical formulation |
GB2146023A (en) * | 1983-09-06 | 1985-04-11 | Glaxo Group Ltd | Aminocyclopentanes and their preparation and pharmaceutical formulation |
FR2551440A1 (en) * | 1983-09-06 | 1985-03-08 | Glaxo Group Ltd | AMINOCYCLOPENTANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
GB2165235A (en) * | 1984-09-05 | 1986-04-09 | Glaxo Group Ltd | Carbocyclic compounds |
GB2165535A (en) * | 1984-09-05 | 1986-04-16 | Glaxo Group Ltd | Carbocyclic compounds |
EP0296802A1 (en) * | 1987-06-22 | 1988-12-28 | Glaxo Group Limited | Aminocyclopentyl ethers and their preparation and pharmaceutical formulation |
US8513027B2 (en) | 1997-09-25 | 2013-08-20 | Asterand Uk Acquisition Limited | Method of identifying an inhibitor of the prostanoid EP4 receptor |
Also Published As
Publication number | Publication date |
---|---|
GB2028805B (en) | 1982-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4409213A (en) | Prostanoid compounds and pharmaceutical compositions | |
US4327092A (en) | Aminocyclopentane alkenoic acids and esters and pharmaceutical formulations | |
US3931296A (en) | Trans-Δ2 -prostaglandins | |
GB2028805A (en) | Prostanoid compounds | |
US4033989A (en) | 9-Deoxy-PGF2 Analogs | |
GB2097397A (en) | Aminocyclopentanol acids and esters as prostaglandin analogues and their preparation and pharmaceutical formulation | |
EP0160495B1 (en) | Cyclopentyl ethers and their preparation and pharmaceutical formulation | |
EP0122019B1 (en) | A prostaglandin analogue | |
US4195183A (en) | ω-Nor-aromatic-13,14-dehydro-prostaglandins and process for their preparation | |
HU199411B (en) | Process for producing cyclopentyl ether derivatives and pharmaceutical compositions containing them as active components | |
EP0032432B1 (en) | Prostanoid compounds and their preparation and pharmaceutical formulations | |
GB2169803A (en) | Compositions for treating hormone dependent neoplasias | |
US4052512A (en) | Prostaglandin analogues | |
US4054604A (en) | Amide derivatives of 9-oxo-13-trans-prostenoic acid | |
US3953495A (en) | 16-Methylene PGE2 | |
DE2719901A1 (en) | PGE AND 11-DEOXY-PGE COMPOUNDS WITH A METHYLENE GROUP ON THE C-9 | |
IE51367B1 (en) | Aminocyclopentanone amides and their preparation and pharmaceutical formulation | |
US4438112A (en) | Prostanoid compounds and pharmaceutical formulations | |
EP0069447B1 (en) | Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation | |
EP0074861A1 (en) | Aminocyclopentane esters and their preparation and pharmaceutical formulation | |
US4438111A (en) | Prostanoid compounds and pharmaceutical formulations | |
US4757087A (en) | Carbacyclin derivatives | |
EP0046597B1 (en) | 2,4-diazabicyclo(3.3.0)octane-3-one derivatives, their preparation and their pharmaceutical formulation | |
US4824993A (en) | Cyclopentyl ethers and their preparation and pharmaceutical formulation | |
US4070537A (en) | 17-Oxo-17-phenyl-prostaglandins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |